Scientific Programme

eular berlin 2012 

Scientific Programme 

13:00 – 14:30 Hall 6.2 A 

Satellite Symposium: Abbott 

13:00 – 14:30 Hall 5.2 A 

Satellite Symposium: Pfizer 

13:00 – 14:30 Hall 6.2 B 

Satellite Symposium: UCB Pharma 

13:00 – 14:30 Hall 4.1 

Satellite Symposium: Celgene Corporation 

13:00 – 14:30 Room Dublin 

Satellite Symposium: International Medical Press 

13:00 – 14:30 Room Paris 2 

Satellite Symposium: Menarini 

12:00 – 13:00 Exhibition opening cocktail 

within the exhibition area 

13:30 - 14:30 Room New York 3 

PARE Session 

Pre-conference outlook 

Learning Objectives: 

• The session will give an overview about the congress 

centre and relevant venues for PARE delegates and 

will introduce the PARE and Joint Sessions 

Chairperson(s): 

Neil Betteridge (United Kingdom) 

Maria Batziou (Greece) 

Ursula Faubel (Germany) 13:35 

General information and outlook on EULAR 2012 

Kate Llewelyn Betteridge (United Kingdom) 13:55 

Abstract N° SP0001 

Overview of the PARE programme and joint sessions 

Yolanda Marron (Spain) 14:15 

Standing Committee of PARE meeting and networking 

dinner 

14:30 – 15:00 

Coffee break within the exhibition area 

15:00 - 16:30 Hall 1.2 

What is New (WIN) 

WIN Session 1 

Iain B. McInnes (United Kingdom) 15:05 


Early arthritis 

Alberto Martini (Italy) 15:45 

Paediatric rheumatology 

15:00 - 16:30 Hall 1.1 

Clinical Science Session 

Health economics of RA in 2012: Can we 

afford to treat? Can we afford not to treat? 


Annelies Boonen (Netherlands) 

Hans Severens (Netherlands) 15:05 

Key concepts for understanding the health-economics 

of RA 

Martin Neovius (Sweden) 15:25 


The costs to society of RA - data from the Swedish 

national registries 

Arthur Kavanaugh (USA) 15:45 


The gains to society from RA treatments - data from 

randomized trials 

Bengt Jönsson (Sweden) 16:05 


An economist's long-term perspective on the pricing of 

drugs 

15:00 - 16:30 Hall 6.2 A 


Interstitial lung disease in rheumatic 

disease: an update 


• To better understand the epidemiology genetics/ 

natural history/risk factors for the development of 

ILD in association with rheumatic disease 

• To better understand the histopathology of the ILD 

seen with rheumatic disease and how it 

compares/contrast in our diseases - PSS, RA, SLE- as 

well as with idiopathic ILD 

1 

Wednesday, 6 June 2012 

19


20 


• To provide an understanding of benefits and deficiencies 

of present treatment protocols for ILD and 

potential new therapeutic approaches 


Daniel Furst (USA) 

Oliver Distler (Switzerland) 

Eric Matteson (USA) 15:05 


Epidemiology/genetic predisposition/natural history of 

ILD in rheumatic disease: what do we know? 

Athol Wells (United Kingdom) 15:30 


Histopathology of ILD in rheumatic disease - what clues 

does it provide re pathogenesis and treatment options 

Kevin Brown (USA) 15:55 

ILD in rheumatic disease: present and future management 

L. A. Saketkoo (USA) 16:20 

D. Khanna, D. Huscher, P. Dellaripa, K. Flaherty, 

E. Matteson, C. Oddis, A. Wells, C. Denton, 

O. Distler, O. Kowal-Bielecka, N. Sandorfi, 

R. Christmann, K. Phillips, D. Pittrow, V. Strand, 

K. Brown, J. Seibold 

Abstract N° OP0001 

Developing a disease activity and therapeutic response 

index in connective tissue disease - interstitial lung 

disease (CTD-ILD): results from a delphi exercise: 

consensus on domains 

15:00 - 16:30 Hall 5.2 A 

How to Manage/Treat (HOT) 

How to manage 1 

Tore K. Kvien (Norway) 15:05 

Osteoarthritis 

David M. Reid (United Kingdom) 15:45 


Osteoporosis 

15:00 - 16:30 Hall 5.2 B 

Outcomes Science Session 

Long-term outcomes of modern treatment 


Deborah Symmons (United Kingdom) 

Axel Finchk (Switzerland) 

Johan Askling (Sweden) 15:05 


Mortality 

William G. Dixon (United Kingdom) 15:25 

Cardiovascular morbidity 

Ingemar Petersson (Sweden) 15:45 


Economic outcomes: sick leave and work disability 

L. Gossec (France) 16:05 

C. Gaujoux-Viala, A.-C. Rat, B. Fautrel, A. Saraux, 

F. Guillemin, S. Paternotte, M. Dougados 


Are patient global and fatigue predictive of structural 

outcomes, 3 years later, in patients in remission in early 

arthritis? Results from the French ESPOIR cohort 

M. T. Nurmohamed (Netherlands) 16:15 

Y. Bao, J. Signorovitch, P. M. Mulani, D. E. Furst 


Use of anti-TNF therapy is associated with reduced 

cardiovascular event risk in rheumatoid arthritis 

15:00 - 16:30 Hall 6.2 B 

Challenges in Clinical Practice Session 

Seronegative rheumatoid arthritis 



• Wrong diagnosis may be a reason for poor response 

to anti rheumatic medications. We present seronegative 

cases who were treated as early rheumatoid 

arthritis and were later revealed various diagnoses 

• The objective of this session is to remind of the 

necessity to re-evaluate diagnosis of patients with 

persistent seronegative “RA” 


Diego Kyburz (Switzerland) 

Tuulikki Sokka (Finland) 

Milos Antic (Switzerland) 15:05 


Case 1 presentation: Arthritis with Parvovirus 

Diego Kyburz (Switzerland) 15:10 


Case 1 discussion 

Tuomas Rannio (Finland) 15:25 


Case 2 presentation: Hemachromatosis 

Tuulikki Sokka (Finland) 15:30 



Milos Antic (Switzerland) 15:45 


Case 3 presentation: Whipple's disease 

Diego Kyburz (Switzerland) 15:50 



Tuomas Rannio (Finland) 16:05 


Case 4 presentation: Polycystic lipomembranous 

osteodysplasia (Nasu-Hakola disease) 



Case 4 discussion



15:00 - 16:30 Hall 6.1 

PReS Session 

Transition for teenagers and young adults 

with arthritis: what does it need? 


• Understand how arthritis clinical phenoptypes differ 

in the adolescent age range compared to children 

• Learn some key clinical imperatives of caring for 

young adults who had JIA as a child 

• Hear data about E-health approach to long term data 

and follow up among adolescents with arthritis 


Nico Wulffraat (Netherlands) 

Michael Hofer (Switzerland) 

John Ioannou (United Kingdom) 15:05 


ERA in the adolescent age: one or two diseases 

Helen E. Foster (United Kingdom) 15:30 


Young adults who had JIA - key clinical management 

issues to remember 

Kirsten Minden (Germany) 15:55 


Data collection for adolescents with arthritis: how to 

make it cool 

N. Solari (Italy) 16:20 

E. Palmisani, A. Consolaro, A. Pistorio, S. Lanni, 

S. Dalprà, B. Schiappapietra, G. Bracciolini, 

A. Frisina, A. Martini, A. Ravelli 


Predictors of achievement of inactive disease in children 

with juvenile idiopathic arthritis treated with Etanercept 

15:00 - 16:30 Hall 5.1 

Fellows in Training Session 

Beginning and succeeding as a clinical 

academic researcher 


• To identify the balance between work and private life 

• To identify the balance between different aspects of 

your work: patient care and research 

• To identify key elements on starting clinical research 


Sofia Ramiro (Portugal) 

Axel Hueber (Germany) 

Ronald van Vollenhoven (Sweden) 15:05 

The big balancing act: time management 

E. Roussou (United Kingdom) 15:35 

M. Thapper 


“Rheumaholidays”, “niche” speciality and “women’s 

preference” is how final years medical students view 

rheumatology as a speciality when asked if they would 

consider it as part of fountation years training 

Loreto Carmona (Spain) 15:45 

Tips for becoming a successful clinical researcher 

Sofia Ramiro (Portugal) 16:15 

Panel discussion 

15:00 - 16:30 Room Europa 2 

Basic and Translational Science Session 

Meet the ADAM's family: ADAM, MMP's, 

ADAMTS 


• To understand the role of TIMPs in inflammation 

• To understand the function of ADAM17 and its role 

in inflammation 

• To understand how MMPs contribute to OA 


Carl Blobel (USA) 

Francesco dell’Accio (United Kingdom) 

Kati E. Georgiadis (USA) 15:05 


An aggrecanase-selective inhibitor for the treatment of 

osteoarthritis 

Stefan Rose-John (Germany) 15:25 


ADAM17 orchestrates pro- and anti-inflammatory cytokine 

activities 

Carl Blobel (USA) 15:45 


ADAM17/TACE is a key molecule in immune-complex 

and complement induced 

Amanda Fosang (Australia) 16:05 


Knock-in mice reveal in vivo consequences of MMP 

activity for OA 

15:00 - 16:30 Room Berlin 2 


Talking microparticles 


Carlo Chizzolini (Switzerland) 

Paul Bowness (United Kingdom) 

Jörg H. Distler (Germany) 15:05 


Role of microparticles in inflammation 

Nigel Mackman (USA) 15:30 


Microparticles in haemostasis and thrombosis 

Mauro Perretti (United Kingdom) 15:55 


Neutrophil microparticles - what do they do? 

3 


21


22 


15:00 - 16:30 Room Dublin 

Health Professionals Session 

How to run an osteoarthritis clinic in daily 

practice 


• Describe various organizational models for osteoarthritis 

clinics, in particular the health professionals’ 

role 

• Describe the key elements of the initial assessment to 

be employed in an osteoarthritis clinic 

• Describe the key elements of interventions to be 

included in an osteoarthritis clinic 

• Describe measurement instruments to evaluate the 

effectiveness of an osteoarthritis clinic on the individual 

patient’s and group levels 


Joost Dekker (Netherlands) 

Anne Marie Norén (Sweden) 

Krysia Dziedzic (United Kingdom) 15:05 


An overview of best practices for OA care 

Susan M. Oliver (United Kingdom) 15:25 


A nurse-led osteoarthritis clinic in specialist care 

Sita Bierma-Zeinstra (Netherlands) 15:45 


A stepped care approach towards hip and knee osteoarthritis 

in primary care 

Linda Fernandes (Norway) 16:05 


EULAR recommendations on non-pharmacological 

management of hip and knee OA 

15:00 - 16:30 Room Paris 2 

Practical Skills Session 

Ultrasound basic 1 


Marcin Szkudlarek (Denmark) 

Maria-Antonietta d'Agostino (France) 15:05 

Grading of synovitis in small joints 

Wolfgang Hartung (Germany) 15:25 

Grading of synovitis in large joints 

George W. Bruyn (Netherlands) 15:45 

Defining the ultrasound appearance of tenosynovitis 

Marcin Szkudlarek (Denmark) 16:05 

The practical case 

15:00 - 16:30 Room New York 1 

EULAR Projects in Clinical Affairs 

EULAR criteria - work to improve 

rheumatologic care 



Daniel Aletaha (Austria) 

Maya H. Buch (United Kingdom) 

Daniel Aletaha (Austria) 15:05 

Introduction 

Laure Gossec (France) 15:20 

EULAR recommendations for management of psoriatic 

arthritis 

N. Duru (Netherlands) 15:30 

M. C. van der Goes, J. W. Jacobs, T. Andrews, 

M. Boers, F. Buttgereit, N. Caeyers, M. Cutolo, 

S. Halliday, J. A. Da Silva, J. R. Kirwan, D. Ray, 

J. Rovensky, G. Severijns, R. Westhovens, 

J. W. Bijlsma 


EULAR evidence-based recommendations on the 

management of medium to high dose systemic glucocorticoid 

therapy in rheumatic diseases 

M. H. Buch (United Kingdom) 15:40 

L. Carmona, L. Silva, M. Boers on behalf 

of EULAR Task Force 


Development of EULAR recommendations for the 

reporting of clinical trial extension studies 

Michael T. Nurmohamed (Netherlands) 15:50 

Challenges in implementing EULAR recommendations: 

the CV risk recommendations 

L. Barbosa (Portugal) 16:00 

S. Ramiro, S. Garcês, M. J. Santos, J. Canas da Silva 

on behalf of Portuguese Rheumatology Nurse 

Practitioners Working Group 

Abstract N° OP0008-HPR 

Challenges with the applicability of the EULAR recommendations 

for rheumatology nursing management in 

Portugal 

Maxime Dougados (France) 16:10 

Conclusion



15:00 - 16:30 Room New York 3 

PARE Session 

Political campaigning 


• How to influence policy makers at national and E.U. 

level by using relevant data and new forms of social 

media to maximise the impact of key messages 


Marios Kouloumas (Cyprus) 

Josef S. Smolen (Austria) 

Jona Hölderle (Germany) 15:05 

Using social media to foster community and mobilise 

supporters 

Till Uhlig (Norway) 15:25 


How to use the new data from EUMUSC.NET to 

support national political campaigning 

Dragan Chichikj (Macedonia, 15:45 

The former Yugoslav Republic of) 


How to use the EULAR Brussels declaration 2010 in 

support of national campaigning 

L. M. Thomsen (Denmark) 16:05 

Abstract N° OP0009-PARE 

Easy-to-open packaging - a practical tool developed by 

involving people with arthritis 

I. Põldemaa (Estonia) 16:15 

K. Mustkivi, E. Adler 


"Life with a secret" - successful campaign designed by 

young rheumatics 

16:30 – 17:00 Coffee break 

17:00 - 18:30 Hall 1.1 


Lupus in little and big folks 


• In recent years a number of important clinical trials 

have been conducted in lupus and EULAR has developed 

management recommendations 

• This session seeks to deepen their understanding and 

facilitate their implementation 


Dimitrios Boumpas (Greece) 

Alberto Martini (Italy) 

David Jayne (United Kingdom) 17:05 


Adult lupus nephritis 

Alberto Martini (Italy) 17:25 

Paediatric lupus nephritis 

Caroline Gordon (United Kingdom) 17:45 


Adult neuropsychiatric lupus 

Tadej Avcin (Slovenia) 18:05 


Paediatric neurochiatric lupus 

17:00 - 18:30 Hall 6.2 A 


"RADAR" - RAre Diseases Associated 

with Rheumatology 


• EULAR strategic objective #1: to strengthen activities 

in areas that are currently less prioritized, such as 

non-inflammatory and orphan diseases 


Rolando Cimaz (Italy) 

Bernhard Manger (Germany) 

Julien Haroche (France) 17:05 


Erdheim-Chester disease - a multisystem disease with 

rheumatologic manifestations 

Christina Lampe (Germany) 17:30 


Mucopolysaccharidoses - what should the rheumatologist 

know? 

Jochen Zwerina (Austria) 17:55 


Stickler´s syndrome and other hereditary collagen disorders 

17:00 - 18:30 Hall 5.2 A 



Loic Guillevin (France) 17:05 


Vasculitis 

Yannick Allanore (France) 17:45 


Raynaud's phenomenon and systemic sclerosis 


23


24 


17:00 - 18:30 Hall 5.2 B 


Equitable or equal? To what or to whom? 

Equity issues in rheumatology 


• By attending this session, one will learn basic 

concepts of health equity in rheumatic diseases, such 

as disparities, inequalities and inequities 

• You will also learn how equity is studied and 

approached 

• Examples of inequities in rheumatology will be presented 


Annelies Boonen (Netherlands) 

Estibaliz Loza (Spain) 

Francis Guillemin (France) 17:05 

Some variability may be good; other may lead to inequities 

Cory Borkhoff (Canada) 17:30 


Disparities in access and in quality of care in rheumatology 

Sherine E. Gabriel (USA) 17:55 

How could we reduce inequities? 

P. Putrik (Netherlands) 18:20 

S. Ramiro, T. Kvien, T. Uhlig , A. Boonen on behalf 

of Working Group Equity in Clinical Eligibility 

Criteria for RA Treatment 


Inequalities across 46 European countries in clinical 

eligibility criteria for the start of a first (reimbursed) 

biologic in patients with rheumatoid arthritis 

17:00 - 18:30 Hall 6.2 B 


Two difficult SLE patient cases 


• To understand the differential diagnosis of kidney 

problems in patients with APS 

• To understand the differential diagnosis of thrombocytopenia 

in patients with SLE 


Johannes W.J. Bijlsma (Netherlands) 

Nurten Duzu (Netherlands) 

Ruth Fritsch-Stork (Netherlands) 17:05 


Case 1 presentation: Kidney problems in patients 

with APS 

Ronald Derksen (Netherlands) 17:15 



Remco Luijten (Netherlands) 17:45 


Case 2 presentation: Thrombocytopenia in patients 

with SLE 

Ronald Derksen (Netherlands) 17:55 



17:00 - 18:30 Hall 6.1 

PReS Session 

Aseptic bone inflammation 


Julien Wipff (France) 

Hermann Girschick (Germany) 

Hermann Girschick (Germany) 17:05 


Chronic osteomyelitis in children 

Gilles Hayem (France) 17:30 

SAPHO syndrome, the perspective from the adult rheumatologist 

Christian M. Hedrich (USA) 17:55 


Immunological and genetic basis of CRMO 

A. Z. Bech (Denmark) 18:20 

T. Herlin, O. R. Hansen, C. Heuck, B. Fiirgaard 


Chronic recurrent non-bacterial osteomyelitis in Danish 

children 

17:00 - 18:30 Hall 5.1 



From bench to bedside and vice versa 

in paeditaric rheumatology 


• Show the new developments in translational 

research in pediatric rheumatology and stimulate interactions 

and exchanges between young researchers 


Lucy Wedderburn (United Kingdom) 

Klaus Tenbrock (Germany) 

Ellen Wehrens (Netherlands) 17:05 

T effector cells out of control in JIA 

Kiran Nistala (United Kingdom) 17:25 

Balancing TH17 cells in arthritis 

Dirk Holzinger (Germany) 17:45 

MRP's: immune modulators and biomarkers in autoinflammation 

Elisabetta Traggiai (Italy) 18:05 

Purinergic control of B cell response and relevance for 

autoimmunity



17:00 - 18:30 Room Europa 2 


From joint development to osteoarthritis 


• To gain insight into novel models that are useful for 

the study of osteoarthritis 

• To understand the contribution of abnormal joint and 

skeletal development to OA 


Francis Berenbaum (France) 

Amanda Fosang (Australia) 

Stefan Schulte-Merker (Netherlands) 17:05 


Zebrafish: a remarkable model to study skeletal development 

and disease 

Petra Seemann (Germany) 17:25 


Joint development and disease: the chick limb mode 

Harrie Weinans (Netherlands) 17:45 


Joint shape modeling and osteoarthritis 

M. van den Bosch (Netherlands) 18:05 

A. Blom, P. van Lent, H. van Beuningen, 

F. van de Loo, E. Blaney Davidson, 

P. van der Kraan, W. van den Berg 


Synovial overexpression of WNTS and WISP1 induces 

cartilage damage by skewing of TGF-beta signaling and 

reduction of the anti-hypertrophic factor SOX9 

P. Van Lent (Netherlands) 18:15 

M. ter Huurne, A. Blom, L. Casteilla, R. Blattes, 

C. Jorgensen, W. van den Berg 


Intra-articular injection of adipose-derived stem cells 

(ADSCS) inhibits synovial activation and protects 

against cartilage damage and osteophyte formation in 

murine experimental osteoarthritis 

17:00 - 18:30 Room Berlin 2 


Fibroblasts transforming rheumatology 


Steffen Gay (Switzerland) 

Andrew Filer (United Kingdom) 

Elena Neumann (Germany) 17:05 


Pluripotent fibroblasts in RA 

Christopher P. Denton (United Kingdom) 17:25 


Role of fibroblasts in scleroderma 

Rik Lories (Belgium) 17:45 


Spondylarthropathy - a fibroblast driven disease? 

C. Beyer (Germany) 18:05 

N. Reich, S. C. Schindler, A. Distler, C. Dees, 

M. Tomcik, C. Hirth-Dietrich, G. von Degenfeld, 

P. Sandner, O. Distler, G. Schett, J. H. Distler 


Stimulation of soluble guanylate cyclase reduces experimental 

dermal fibrosis 

M. Tomcik (Czech Republic) 18:15 

K. Palumbo-Zerr, J. Avouac, A. Horn, 

A. Khodzighorova, P. Zerr, C. Dees, A. Distler, 

C. Beyer, R. Becvar, L. Senolt, O. Distler, G. Schett, 

J. H. Distler 


Tribbles homolog 3 mediates the stimulatory effects of 

TGF-beta on fibroblast activation and dermal fibrosis in 

systemic sclerosis 

17:00 - 18:30 Room Dublin 


Crossing boundaries of primary 

to secondary care 



• How to meet the future demands for cooperation 

between specialised care and primary care? 


Mari Klokkerud (Norway) 

Alison Hammond (United Kingdom) 

Stefan Bergman (Sweden) 17:05 

Opportunities and challenges in a future primary health 

care for people with rheumatic diseases 

Nina Østerås (Norway) 17:25 


Collaboration across health service levels - an example 

of a Norwegian joint projection programme between 

primary care and specialist care 

Connie R. Ziegler (Denmark) 17:45 


Hopes and real life experiences of communication 

between specialist health care and primary health 

Birgit Prodinger (Canada) 18:05 


Future challenges for health professionals; communication 

across health care levels 


25


26 


17:00 - 18:30 Room Paris 2 


Crystals in synovial fluid 1 


• The most common obstacles encountered by those 

interested in starting the crystal analysis process are: 

– the idea that crystal analysis is not possible 

without a fully equipped compensated polarized 

microscope 

– that it is time consuming 

– that it is difficult to differentiate urate from 

pyrophosphate crystals and 

– that learning will be a difficult process 

• These will be discussed, and the keys for starting with 

the generally available instruments - the ordinary 

microscope - will be given 


Eliseo Pascual Gomez (Spain) 

Thomas Bardin (France) 

Tutors: 

Jose Pimentao (Portugal) 

Francesca Oliviero (Italy) 

Mariano Andrés (Spain) 

17:00 - 18:30 Room Berlin 1 


MRI Workshop basic 1 


Kay-Geert Hermann (Germany) 

Mikkel Østergaard (Denmark) 

Espen A. Haavardsholm (Norway) 17:05 

Basic MRI technical issues and how to interpret and use 

the different MR image types in peripheral arthritis 

Mikaël Boesen (Denmark) 17:20 

MRI in rheumatoid arthritis 

Mikkel Østergaard (Denmark) 17:35 


MRI in psoriatic arthritis - update on the current state 

Kay-Geert Hermann (Germany) 17:50 

MRI of gout update on the current state 


Recognizing common MRI pathologies in arthritis. 

Interactive assessment of MR images on PC projector 

17:00 - 18:30 Room New York 3 


PARE Session 

Less well-known but just as important: 

some 'other' rare musculoskeletal diseases 


• To raise awareness of the issues faced by people living 

with less well known RMDs e.g. access to effective 

treatments, stigma and social participation 


Kim Fligelstone (United Kingdom) 

Nele Caeyers (Belgium) 

Alan Tyndall (Switzerland) 17:05 


Treating the lesser-known RMDs 

Kirsten Lerstroem (United Kingdom) 17:25 


Accessing spealist care for rare and complex RMDs 

Ann T. Kennedy (Ireland) 17:45 


Taking action against stigmatization 

Cor van Drogen (Netherlands) 18:05 


Working to participate equally 

18:45 - 20:00 Hall 1.2 

EULAR 2012 Opening Plenary Session



08:15 – 09:45 Hall 1.2 

Satellite Symposium: Roche 

08:15 – 09:45 Hall 1.1 


08:15 – 09:45 Hall 6.1 

Satellite Symposium: AstraZeneca 

08:15 – 09:45 Hall 4.1 

Satellite Symposium: Lilly 

08:15 – 09:45 Room Dublin 

Satellite Symposium: Ibsa - Laboratoires Genèvrier 

08:15 – 09:45 Room Paris 2 

Satellite Symposium: medac 

08:15 – 09:45 Room New York 1 

Satellite Symposium: Savient Pharmaceuticals 

08:15 - 09:45 Room Europa 2 


MicroRNA - macro effect 


Ingo Tarner (Germany) 

Astrid Jüngel (Switzerland) 08:20 

Abstract N° SP0054F 

MicroRNA in rheumatoid arthritis epigenetics 

Gabor Illei (USA) 08:40 


MicroRNA in connective tissue disease 

Hans-Martin Jäck (Germany) 09:00 


Potential therapeutic use of microRNAs in rheumatology 

M. Trenkmann (Switzerland) 09:20 

M. Brock, R. E. Gay, R. Speich, B. A. Michel, 

S. Gay, L. C. Huber 


The TNF-alpha-induced miR-18A activates rheumatoid 

arthritis synovial fibroblast through a positive feedback 

loop in NF-kappa B signalling 

S. Vettori (Italy) 09:30 

M. Brock, N. Iwamoto, B. Maurer, A. Jungel, 

R. E. Gay, M. Calcagni, G. Valentini, J. J. Distler, 

S. Gay, O. Distler 


MicroRNA-145 down-regulation in systemic sclerosis is 

limited to skin fibroblasts and influenced by epigenetic 

modifications and negative feedback loop by TGF-ß 

08:15 - 09:45 Room Berlin 2 


New developments in the pre-clinical 

phases of rheumatoid arthritis 


• Learn about new autoantibodies other than ACPAs in 

very early RA 

• Update on how the joint stroma might be the key 

driver in early disease 

• Appreciate the emerging data relating to lymph 

nodes in early RA development 

Thursday, 7 June 2012 

27


28 



Diane van der Woude (Netherlands) 

Lars Klareskog (Sweden) 

Rene Toes (Netherlands) 08:20 

New antibodies in early RA 

Andrew Filer (United Kingdom) 08:40 


Leucocyte - stromal interactions in preclinical RA 

Lisa van Baarsen (Netherlands) 09:00 


Where does RA start - the joint or lymphoid tissues? 

U. Harre (Germany) 09:20 

D. Georgess, R. Axmann, H. Bang, 

R. Toes, H. U. Scherer, A. Catrina, L. Klareskog, 

P. Jurdic, G. Schett 


Anti-citrullinated protein antibodies directly induce 

bone loss in rheumatoid arthritis 

J. Lubbers (Netherlands) 09:30 

M. Brink, L. A. van de Stadt, S. Vosslamber, 

J. G. Wesseling, D. van Schaardenburg, 

S. M. Rantapaa-Dahlqvist, C. L. Verweij 


Validation of gene signatures to predict rheumatoid 

arthritis development 

10:15 - 11:45 Hall 1.2 


WIN Session 2 

Francis Berenbaum (France) 10:20 

Osteoarthritis 



Clinical implications of imaging advances 

10:15 - 11:45 Hall 1.1 

Abstract Session 

Abstract Session: Update on non anti-TNF 

biologics 


Maya H. Buch (United Kingdom) 

Stanley Cohen (USA) 

P.-Y. Berclaz (USA) 10:20 

M. Genovese, M. Greenwald, C.-S. Cho, 

A. Berman, L. Jin, G. Cameron, L. Wang, 

L. Xie, D. Braun, S. Banerjee 


A phase 2 study of multiple subcutaneous doses of 

LY2439821, an anti-IL-17 monoclonal antibody, in 

patients with rheumatoid arthritis in two populations: 

naïve to biologic therapy or inadequate responders to 

tumor necrosis factor alpha inhibitors 


M. Schiff (USA) 10:30 

R. Fleischmann, M. Weinblatt, R. Valente, 

D. van der Heijde, G. Citera, C. Zhao, 

M. Maldonado 


Abatacept SC versus Adalimumab on background 

Methotrexate in RA: one year results from the AMPLE 

study 

T. W. Huizinga (Netherlands) 10:40 

A. J. Kivitz, M. Rell-Bakalarska, 

R. M. Fleischmann, M. Jasson, A. R. Radin, 

M. C. Genovese 


Sarilumab for the treatment of moderate-to-severe 

rheumatoid arthritis: results of a phase 2, randomized, 

double-blind, placebo-controlled, international study 

N. Damjanov (Serbia) 10:50 

M. Tlustochowicz, J. Aelion, A. Dimic, 

M. Greenwald, A. Diehl, I. Bhattacharya, 

S. Menon, I. Gourley 


Safety and efficacy of SBI-087 in subjects with active 

rheumatoid arthritis in a phase 2 randomized, doubleblind, 

placebo-controlled study 

B. Hsu (USA) 11:00 

S. Sheng, M. E. Weinblatt, J. S. Smolen 


Results from a multicenter, international, randomized, 

double-blind, placebo-controlled, phase 2 study of 

sirukumab, a human anti-IL-6 monoclonal antibody, in 

patients with active rheumatoid arthritis despite Methotrexate 

therapy 

I. Ancuta (Romania) 11:10 

C. Codreanu, R. Ionescu, M. Parvu, M. Bojinca 


Sustained and cumulated response over time in RA 

patients treated with Rituximab after initial failure of 

anti-TNF agents 

S. Drynda (Germany) 11:20 

M. Gloetzner, D. Leesch, J. Kekow 


A single nucleotide polymorphism in the MED29 gene 

is associated with the clinical outcome of a TNF-blocker 

and B cell directed therapy in RA patients 

K. Chatzidionysiou (Sweden) 11:30 

E. Lie, E. Nasonov, G. Lukina, M. Hetland, U. Tarp, 

I. Ancuta, K. Pavelka, D. Nordström, C. Gabay, 

H. Canhao, M. Tomsic, P. van Riel, J. Gomez-Reino, 

T. Kvien, R. van Vollenhoven 


Efficacy of different doses of Rituximab for the treatment 

of RA: data from the CERERRA collaboration



10:15 - 11:45 Hall 6.2 A 


Abstract Session: Osteoarthritis 


Philip G. Conaghan (United Kingdom) 

Ali Guermazi (USA) 

A. Guermazi (USA) 10:20 

M. Jarraya, D. T. Felson, D. Hayashi, F. W. Roemer, 

Y. Zhang, J. Niu, M. Crema, M. Englund, 

J. A. Lynch, M. C. Nevitt, J. Torner, C. E. Lewis 


Medial meniscal root tears are associated with medial 

meniscal extrusion and medial tibiofemoral cartilage 

damage - the MOST study 

P. M. Welsing (Netherlands) 10:30 

M. B. Kinds, A. Marijnissen, M. Viergever, 

P. J. Emans, F. P. Lafeber 


Identifying radiographic phenotypes of early knee 

osteoarthritis using separate quantitative features might 

improve patient selection for more targeted treatment 

J. Wesseling (Netherlands) 10:40 

S. M. Bierma-Zeinstra, M. Kloppenburg, 

J. W. Bijlsma 


Comparison between CHECK study (Cohort Hip& 

Cohort Knee) and osteoartritis initiative; development 

of pain and function in 3 years of follow-up 

F. Birrell (United Kingdom) 10:50 

A. Abraham, K. D. Mann, M. S. Pearce, R. M. Francis 


Ultrasound features of osteophytes and cartilage thickness 

at the knee are associated with pain and functional 

impairment: the Newcastle thousand families study 

R. Wittoek (Belgium) 11:00 

D. Elewaut, G. Verbruggen 


Radiographical follow-up data of a one-year open-label 

extension study of treatment with Adalimumab in 

erosive osteoarthritis of the IP joints 

M. Englund (Sweden) 11:10 

I. K. Haugen, A. Guermazi, F. W. Roemer, J. Niu, 

T. Neogi, P. Aliabadi, M. Clancy, D. T. Felson 


The association between radiographic hand osteoarthritis 

and meniscal damage on MRI in the general 

population 

J.-D. Laredo (France) 11:20 

A. Wyler, C. Alvarez, M. Aout, M. Lequesne, 

E. Vicaut 


Value of bilateral standing oblique radiographs («faux 

profil de Lequesne») in the diagnosis of hip osteoarthritis 

S. Lee (Korea, Republic Of) 11:30 

T.-N. Kim, S.-H. Kim 


Sarcopenic obesity is more closely associated with 

radiographic knee osteoarthritis than non-sarcopenic 

obesity: a cross-sectional study using data from the fifth 

Korean national health and nutrition examination 

survey (KNHANES V-1) 

10:15 - 11:45 Hall 5.2 A 



Jürgen Braun (Germany) 10:20 


Spondyloarthritis/ankylosing spondylitis drug therapy 

Filip van den Bosch (Belgium) 11:00 


Psoriatic arthritis 

10:15 - 11:45 Hall 5.2 B 


Abstract Session: Osteoporosis 


Gyula Poor (Hungary) 

Kenneth Saag (USA) 

O. Törring (Sweden) 10:20 

J. Brown, J.-E. B. Jensen, N. Gilchrist, C. Recknor, 

C. Roux, M. Austin, A. Wang, A. Grauer, P.-R. Ho, 

R. Wagman 


Denosumab discontinuation and associated fracture 

incidence: analysis from the FREEDOM trial 

I. Ghozlani (Morocco) 10:30 

A. Rezqi, A. Mounach, L. Achemlal, A. Bezza, 

A. El Maghraoui 


Vertebral fractures prevalence and abdominal aortic 

calcification in men 

A. Dhainaut (Norway) 10:40 

M. Hoff, U. Syversen, G. Haugeberg 


Increased porosity in hand bones is strongly associated 

with distal radius fracture in elderly women 

J. Kikuta (Japan) 10:50 

M. Ishii 


Dynamic in vivo imaging of TH17-mediated control of 

osteoclast function in live bones by using intravital 

multiphoton microscopy 


29


30 


D. Umlauf (Germany) 11:00 

H. Hidding, L. O. Lindemann, S. Frank, B. Dankbar, 

C. Cromme, M. Rupp, R. Stange, R. P. Marshall, 

M. Amling, A. Dietrich, M. Steiner, U. Kornak, 

A. Schwab, T. Pap, J. Bertrand 


Essential role for TRPC1 channels in osteoclast fusion 

and in osteoporotic bone loss 

H. Z. Ke (USA) 11:10 

M. S. Ominsky, Q.-T. Niu 


Increased modeling-based bone formation and decreased 

bone resorption on endocortical surfaces in male 

cynomolgus monkeys treated with sclerostin antibody 

A. Sehgal (USA) 11:20 

A. Mannalithra, A. Mithal, G. Singh, 

G. Triadafilopoulos 


Hip fracture in the extreme elderly: the last frontier of a 

growing public health problem 

D. Padhi (USA) 11:30 

M. Allison, A. J. Kivitz, M. J. Gutierrez, 

B. Stouch, C. Wang, G. Jang 


The effects of multiple doses of sclerostin antibody 

AMG 785 in healthy men and postmenopausal women 

with low bone mass 

10:15 - 11:45 Hall 6.2 B 


Abstract Session: RA prognosis, predictors, 

outcomes 


Günter Steiner (Austria) 

Carlo Salvarini (Italy) 

N. Soroka (Belarus) 10:20 

V. Yagur, N. Dostanko 


Genetic markers of sulphasalazine adverse reactions in 

rheumatoid arthritis patients 

M. Lahiri (Singapore) 10:30 

C. Morgan, R. N. Luben, D. K. Bunn, M. Lunt, 

S. M. Verstappen, D. P. Symmons, K.-T. Khaw, 

N. J. Wareham, I. N. Bruce 


A risk score to identify individuals at higher risk of 

inflammatory polyarthritis: results from the European 

prospective investigation of cancer (NORFOLK) and 

the NORFOLK arthritis register (the EPIC-2-NOAR 

study) 


J. Listing (Germany) 10:40 

D. Pattloch, J. Kekow, J. Kaufmann, 

G.-R. Burmester, A. Zink, A. Strangfeld 


Successful control of disease activity and treatment with 

biologics increase the life expectancy in rheumatoid 

arthritis patients 

E. Nikiphorou (United Kingdom) 10:50 

L. Carpenter, D. James, P. Kiely, D. Walsh, 

R. Williams, A. Young on behalf of Early 

Rheumatoid Arthritis Study (ERAS), Early 

Rheumatoid Arthritis Network (ERAN) 


Orthopaedic interventions for RA have changed over 

the period 1986-2011. An evaluation of joint surgery 

rates and DMARD/anti-TNF treatment patterns in two 

UK inception cohorts 

L. Aguilar-Lozano (Mexico) 11:00 

J. Padilla-Ibarra, C. Sandoval-Castro, 

J. D. Castillo-Ortiz, J. Morales-Torres, 

C. Hernandez, R. Burgos-Vargas, C. Pacheco-Tena, 

C. Ramos-Remus 


The lenght of remission and rate of relapse after 

Tocilizumab withdrawal in rheumatoid arthritis patients 

A. Ruyssen-Witrand (France) 11:10 

P.-A. Gourraud, D. Nigon, C. Lukas, 

C. Miceli-Richard, B. Jamard, A. Cantagrel, 

A. Cambon-Thomsen, P. Dieudé, A. Constantin 


Evolution of the alternative classification of HLA-DRB1 

alleles in rheumatoid arthritis: impact on the production 

of the anti-citrullinated protein antibodies and structural 

progression, data from the ESPOIR cohort 

S. Lillegraven (USA) 11:20 

N. A. Shadick, Z. Jabbar-Lopez, A. Potapov, 

M. L. Frits, C. K. Iannaccone, E. A. Haavardsholm, 

T. K. Kvien, M. E. Weinblatt, D. H. Solomon 


Joint damage progression in established rheumatoid 

arthritis: common and strongly associated with seropositivity 

A. Filer (United Kingdom) 11:30 

M. Z. Cader, A. Abhishek, G. Allen, C. Buckley, 

P. de Pablo, K. Raza 


Use of ultrasound to predict persistence in patients with 

very early synovitis



10:15 - 11:45 Hall 6.1 


PReS Abstract Session: Basic Science 

in paediatric rheumatology 


Nico Wulffraat (Netherlands) 

Martina Prelog (Germany) 

Nico Wulffraat (Netherlands) 10:20 

Introduction 

K. Tenbrock (Germany) 10:30 

K. Ohl, T. Rauen 


CREMalpha destabilizes Foxp3 expression in regulatory 

T cells 

A. Avau (Belgium) 10:40 

T. Mitera, K. Put, S. Put, T. Tousseyn, A. D. Billiau, 

C. Wouters, P. Matthys 


Complete Freund’s adjuvant induces, in interferongamma-deficient 

mice, a chronic inflammatory disease 

reminiscent of systemic juvenile idiopathic arthritis 

W. De Jager (Netherlands) 10:50 

S. J. Vastert, B. J. Noordman, B. J. Prakken, 

N. M. Wulffraat 


IL-1 receptor antagonist restores IL-18 NK cell axis in 

systemic JIA 

Y. Fleischer (Germany) 11:00 

K. Barczyk, L. Klotz, H. Wiendl, J. Roth 


12/15-lipoxygenase mediates GC-induced anti-inflammatory 

mechanisms in monocytes 

L. Watson (United Kingdom) 11:10 

A. Midgley, L. Ballantine, C. A. Jones, 

R. C. Holt, S. D. Marks, C. Pilkington, K. Tullus, 

M. W. Beresford 


Monocyte chemoattractant protein 1 is expressed from 

kidney epithelial cells in response to activated macrophages 

in juvenile-onset systemic lupus erythematosus 

(JSLE) 

K. N. Sustal (Germany) 11:20 

G. Almanzar, R. Trippen, K. Höfner, M. Prelog 


CCR6+ T cells in children with juvenile idiopathic 

arthritis 

Martina Prelog (Germany) 11:30 

Conclusion 

10:15 - 11:45 Hall 5.1 


Abstract Session: Lupus and Sjögren's: 

basics - diagnosis - treatment 


Jane E. Salmon (USA) 

Athanasios G. Tzioufas (Greece) 

T. Kaneko (Japan) 10:20 

Y. Saito, T. Kotani, H. Ohnishi, Y. Murata, 

Y. Yonemoto, K. Okamura, T. Matozaki, 

K. Takagishi 


Importance of the protein tyrosine phosphatase shp1 in 

dendritic cells for prevention of TH1 cell differentiation 

and autoimmunity: a potential target for the therapy 

P. L. Meroni (Italy) 10:30 

E. Raschi, C. Chighizola, C. Grossi, N. Ronda, 

R. Gatti, M. O. Borghi 


Beta2GPI and TLR4 interaction on endothelial cells: a 

bridge between innate and adaptive immunity in APS 

J. G. Hanly (Canada) 10:40 

On behalf of the Systemic Lupus International 

Collaborating Clinics (SLICC) 


Seizures in systemic lupus erythematosus: a prospective 

study of predictors and outcomes in a large, international, 

disease inception cohort 

K. Rao (USA) 10:50 

F. Ferrario, T. Cook, I. Bajema, J. A. Bruijn, 

L.-H. Noel, R. Maciuca, P. Brunetta, S. Shahdad 


Lupus nephritis histopathology interobserver agreement 

between local pathologists and an expert panel of 

nephropathologists in belong 

M. O'Toole (USA) 11:00 

A. Seyhan, Y. Zhang, F. W. Immermann, 

A. Hill, P. Reddy, J. Masferrer, T. Zhou, W. Mounts, 

M. Whitley, T. Walker, S. Kamp, J. James, 

S. Sridharan, J. T. Merrill, M. Honczarenko 


Impact of baseline interferon pathway activation on 

widespread gene expression changes with disease flare 

in lupus patients: interim report from the BOLD (biomarkers 

of lupus disease) study 

G. Bertsias (Greece) 11:10 

M. Tektonidou, Z. Amoura, M. Aringer, I. Bajema, 

J. Berden, J. Boletis, R. Cervera, T. Dörner, 

A. Doria, F. Ferrario, J. Flöge, F. Houssiau, 

J. P. Ioannidis, D. Isenberg, C. G. Kallenberg, 

L. Lightstone, S. Marks, A. Martini, G. Moroni, 

I. Neumann, P. Niaudet, M. Praga, M. Schneider, 

V. Tesar, C. Vasconcelos, R. van Vollenhoven, 

E. Zakharova, M. Haubitz, C. Gordon, D. Jayne, 

D. Boumpas 


Joint EULAR/ERA-EDTA recommendations for the 

management of adult and paediatric lupus nephritis 


31


32 


V. Devauchelle-Pensec (France) 11:20 

X. Mariette, S. Jousse-Joulin, J.-M. Berthelot, 

A. Perdriger, E. Hachulla, X. Puéchal, V. Le Guern, 

J. Sibilia, J.-E. Gottenberg, L. Chiche, V. Goeb, 

G. Hayem, J. Morel, C. Zarnitsky, J.-J. Dubost, 

J.-O. Pers, E. Nowak, A. Saraux on behalf of the 

TEARS study group (Institutional grant support 

from the French Health ministry PHRC 2007) 


Tolerance and efficacy of Rituximab in primary Sjögren 

syndrome (tears): results of a randomized controlled trial 

G. Cinquetti (France) 11:30 

C. Larroche, B. Combe, E. Hachulla, O. Meyer, 

E. Pertuiset, G. Kaplanski, X. Mariette, 

J.-E. Gottenberg on behalf of Club Rhumatismes et 

Inflammations 


Efficacy of Rituximab in systemic manifestations of 

patients with primary Sjögren’s syndrome: results from 

the AIR registry 

10:15 - 11:45 Hall 4.1 


Abstract Session: Regional pain and 

fibromyalgia: understanding mechanisms 

and effective management 


Serge Perrot (France) 

Mark Porcheret (United Kingdom) 

E. Docampo (Spain) 10:20 

G. Escaramis, R. Rabionet, J. Carbonell, J. Rivera, 

J. Alegre, J. Vidal, X. Estivill, A. Collado 


Cluster analysis of clinical data identifies fibromyalgia 

subgroups 

D. Bohn (Germany) 10:30 

H. Kühn-Becker, G. Schmutzer, W. Häuser 


Mediation of childhood/adolescence maltreatment and 

adult fibromyalgia syndrome by depression - a case 

control study 

E. Bossema (Netherlands) 10:40 

H. Van Middendorp, J. W. Jacobs, J. W. Bijlsma, 

R. Geenen 


The influence of weather on daily pain and fatigue in 

female patients with fibromyalgia 

W. Häuser (Germany) 10:50 

I. Kopp 


Update of the German evidence-based guideline on the 

management of fibromyalgia syndrome 


H. G. Predel (Germany) 11:00 

B. Giannetti, I. Burnett, A. M. Hug 


Efficacy and safety of diclofenac diethylamine 1.16% gel 

in the treatment of acute neck pain: a randomized, 

double-blind, placebo-controlled study 

T. Krogh (Denmark) 11:10 

E. M. Bartels, T. Ellingsen, K. Stengaard-Pedersen, 

R. Buchbinder, U. Fredberg, H. Bliddal, 

R. Christensen 


Comparative effectiveness of injection therapies in 

lateral epicondylitis: a systematic review and network 

meta-analysis of randomized controlled trials 

L. Grøvle (Norway) 11:20 

J. I. Brox, A. J. Haugen, A. Keller, B. Natvig, 

M. Grotle 


Prognostic factors for return to work in patients with 

sciatica 

N. T. Baerlecken (Germany) 11:30 

M. Stoll, T. Witte, R. E. Schmidt, D. Meyer-Olson 


Clinical study: frequency and manifestations of joint 

disease in HIV-infected patients 

10:15 - 11:45 Room Europa 2 


Abstract Session: Early pathogenic 

mechanisms; clues for targeted therapies 

in arthritis 


Frances Humby (United Kingdom) 

Ruth Fritsch-Stork (Netherlands) 

L. Yeo (United Kingdom) 10:20 

A. D. Filer, C. D. Buckley, D. Scheel-Toellner, 

K. Raza 


Comparison of synovial tissue cytokine mRNA profiles 

in very early arthritis patients with divergent outcomes 

C. Turesson (Sweden) 10:30 

M. Hansson, U. Bergström, L. T. Jacobsson, 

L. Mathsson, L. Klareskog, P.-J. Jakobsson, 

R. Holmdahl, J. Rönnelid 


Patterns of circulating antibodies in the pre-clinical 

phase of rheumatoid arthritis suggest epitope spreading 

in the immune reaction against citrullinated peptides 

M. Brink (Sweden) 10:40 

M. Hansson, L. Mathsson, L. Nogueira, G. Serre, 

P.-J. Jakobsson, R. Holmdahl, J. Rönnelid, 

L. Klareskog, S. Rantapää Dahlqvist 


Multiplex analysis of antibodies against citrullinated 

peptides in individuals prior to development of rheumatoid 

arthritis



P. Hoff (Germany) 10:50 

C. M. Spies, T. Gaber, J. Mazuch, B. Maier, M. Hahne, 

C. Strehl, C. L. Tran, N. Soboleva, A. Stoehr, 

M. Wagegg, M. Fangradt, M. Jakstadt, D. Huscher, 

G.-R. Burmester, J. Detert, A. Kramer, F. Buttgereit 


Alterations of immune cellular circadian rhythms in 

rheumatoid arthritis 

N. Y. Lin (Germany) 11:00 


Autophagy contributes to TNFα-mediated joint destruction 

D. De Rooy (Netherlands) 11:10 

N. Yeremenko, R. Knevel, E. Brouwer, G. Wilson, 

E. Lindqvist, T. Saxne, A. Krabben, M. Leijsma, 

R. Tsonaka, N. Daha, S. Zhernakova, J. Houwing- 

Duistermaat, T. Huizinga, D. Baeten, R. Toes, 

A. Van der Helm-van Mil 


Genetic studies on Dickkopf-1, sclerostin and the severity 

of joint destruction in rheumatoid arthritis 

W. de Munter (Netherlands) 11:20 

B. Walgreen, M. M. Helsen, A. W. Sloetjes, 

W. B. van den Berg, P. L. van Lent 


LDL receptor deficiency results in osteophyte formation 

during experimental osteoarthritis which is increased 

under high cholesterol conditions 

10:15 - 11:45 Room Berlin 2 


Abstract Session: Spondyloarthritis - 

translational science 


Paul Bowness (United Kingdom) 

Peggy Jacques (Belgium) 

D. Poddubnyy (Germany) 10:20 

K. Conrad, G. Ruiz-Heiland, U. Syrbe, H. Haibel, 

H. Appel, M. Rudwaleit, G. Schett, J. Sieper 


Prediction of radiographic spinal progression using 

biomarkers in patients with ankylosing spondylitis who 

are at high risk for progression 

U. Syrbe (Germany) 10:30 

R. Scheer, P. Wu, J. Sieper 


Differential systemic and synovial TH1 cell reactivity 

towards escherichia coli antigens in patients with 

ankylosing spondylitis and rheumatoid arthritis 

L. M. Van Duivenvoorde (Netherlands) 10:40 

C. A. Ambarus, H. Masdar, T. K. van Melsen, 

M. N. van Tok, P. P. Tak, N. G. Yeremenko, 

D. L. Baeten 


Relative overexpression of transmembrane versus soluble 

TNF in human and experimental spondyloarthritis 

G. Nocturne (France) 10:50 

S. Pavy, P. Goupille, M. Dougados, C. Roux, 

X. Mariette, C. Miceli-Richard 


Dkk1 serum level is increased in recent spondyloarthritis 

and is associated with higher prevalence of 

syndesmophytes. Data from the DESIR cohort 

M. Uddin (Canada) 11:00 

D. D. O'Reilly, R. D. Inman, W. P. Maksymowych, 

D. D. Gladman, S. Hamilton, R. Yazdani, 

P. Rahman 


Customized CNV microarray identified UGT2B17 as a 

novel susceptibility gene associated with familial ankylosing 

spondylitis 

A. Finckh (Switzerland) 11:10 

A. Ciurea, A. Scherer, U. Weber, M. Nissen, P. Exer, 

J. Bernhard, G. Tamborrini, R. Mueller, B. Weiss, 

R. Kissling, B. A. Michel on behalf of the 

Rheumatologists of SCQM 


Tobacco smoking is associated with increased disease 

activity in HLA-B27 positive axial spondyloarthritis patients, 

but does not alter the course of disease activity 

D. Poddubnyy (Germany) 11:20 

H. Haibel, J. Listing, E. Märker-Hermann, 

H. Zeidler, J. Braun, M. Rudwaleit, J. Sieper 


Cigarette smoking predicts radiographic progression in 

the spine in patients with axial spondyloarthritis in a 

dose-dependent manner 

K. Mchugh (United Kingdom) 11:30 

J. Shaw, S. Kollnberger, L. Utriainen, D. Firmin, 

S. Milling, C. Renner, P. Bowness 


The detection of a potentially pathogenic subset of 

HLA-B27 conformers at the cell surface in a rat model 

of SpA 


33


34 


10:15 - 11:45 Room Dublin 


HPR Abstract Session: Progress in 

rehabilitation - the future is bright 


Linda Fernandes (Norway) 

Karin Niedermann (Switzerland) 

M. J. Stukstette (Netherlands) 10:20 

J. Dekker, A. A. den Broeder, W. Noort van der 

Laan, J. W. Bijlsma, C. H. van den Ende 


A multidisciplinary and multidimensional program for 

hand osteoarthritis is not effective: results of a randomised 

controlled study 

M. Hermann (Norway) 10:30 

T. Nilsen, C. Støyva Eriksen, I. Haugen, 

B. S. Christensen, I. Kjeken 


Effects of a soft thumb base splint in persons with carpometacarpal 

osteoarthritis: a randomised controlled 

trial 

W. F. Peter (Netherlands) 10:40 

P. H. van der Wees, J. Verhoef, Z. de Jong, 

L. van Bodegom-Vos, W. K. Hilberdink, M. Fiocco, 

T. P. VlietVlieland 


The effect of an interactive workshop on the adherence 

with the Dutch physical therapy practice guideline for 

hip and knee osteoarthritis: a randomised controlled 

trial 

I. Kjeken (Norway) 10:50 

I. Bø, A. Rønningen, C. Spada, P. Mowinckel, 

K. B. Hagen, H. Dagfinrud 


A three week rehabilitation program had positive long 

term effects in patients with ankylosing spondylitis: 

results from a randomised controlled trial 

B. Hamnes (Norway) 11:00 

I. Kjeken, P. Mowinckel, K. B. Hagen 


Effects of a one week multidisciplinary inpatient selfmanagement 

programme for patients with fibromyalgia: 

a randomised controlled trial 

F. Jennings (Brazil) 11:10 

M. Cardoso, V. G. Cruz, H. A. Oliveira, J. Natour 


Aerobic training in patients with ankylosing spondylitis: 

a randomized controlled trial 

J. Meesters (Netherlands) 11:20 

W. Pont, L. Beaart-van de Voorde, T. Stamm, 

T. Vliet Vlieland 


Concepts important to patients with rheumatoid arthritis 

in rehabilitation and their coverage by rehabilitation 

tools 


G. Haugeberg (Norway) 11:30 

S. G. Eppeland, A. Diamantopoulos, D. M. Soldal 


Short term effect of 2-weeks rehabilitation on disease 

activity and health status in patients with ankylosing 

spondylitis 

10:15 - 11:45 Room Paris 2 


Abstract Session: Don't forget 

the "orphans" 


Duncan Porter (United Kingdom) 

Maurizio Cutolo (Italy) 

Duncan Porter (United Kingdom) 10:20 

Introduction: Keep up the interest on orphan conditions 

H. J. Lachmann (United Kingdom) 10:30 

I. Touitou, L. Obici, P. Woo, A. Naselli, R. Berendes, 

J. Anton, C. Modesto, P. Quartier, R. Merino, 

S. Ozen, R. Cimaz, A. Meini, N. Ruperto, 

M. Gattorno on behalf of PRINTO, Eurotraps and 

Eurofever Projects 


Clinical features at presentation in a series of 86 patients 

with genetically confirmed TRAPS and 33 patients with 

inflammatory symptoms and the R92Q variant from the 

Eurofevers/Eurotraps registry 

S. Colafrancesco (Italy) 10:40 

G. Picarelli, A. Gattamelata, R. Priori, G. Valesini 


Clinical and laboratory findings in a cohort of Italian 

patients with Adult Onset Still’s disease 

S. Bilge (Turkey) 10:50 

T. Kasifoglu, E. Gonullu, F. Bekdemir, C. Korkmaz 


Evaluation of potential risk factors of amyloidosis in 

familial Mediterranean fever 

J. Danjo (Japan) 11:00 

H. Dobashi, T. Kameda, K. Susaki, Y. Yamamoto, 

S. Nakashima, H. Shimada, M. Izumikawa, 

Y. Nishiyama, T. Matsunaga 


The utility of fluorodeoxyglucose-positron emission 

tomography for IgG4-related disease diagnosed according 

to comprehensive diagnostic criteria 

C. M. Feced Olmos (Spain) 11:10 

M. Fernández Matilla, J. J. Alegre Sancho, 

D. Ybáñez García, M. A. Martínez Ferrer, 

E. Valls Pascual, M. Robustillo Villarino, 

I. de la Morena Barrio 


Arthritis secondary to Epstein-Barr virus: an infrequent 

reality



A. Jawad (United Kingdom) 11:20 

A. Pákozdi, D. Watson, L. Kuitert 


Cystic fibrosis related arthritis in adults in south east 

England 

I. J. W. Hansen (Norway) 11:30 

S. Noraas, T. Skarpaas, V. Kjelland, G. Haugeberg 


Lyme arthritis in southern Norway - an endemic area for 

Lyme Borreliosis 

10:15 - 11:45 Room Berlin 1 


Abstract Session: Metabolic and crystal 

diseases of joints and bone 



Jochen Zwerina (Austria) 

D. Holzinger (Germany) 10:20 

N. Nippe, K. Marketon, N. Dalbeth, T. Merriman, 

D. Baeten, N. Busso, T. Vogl, D. Foell, C. Gabay, 

J. Roth 


Toll-like receptor 4 agonists MRP 8 and MRP 14 act as 

endogenous enhancers of MSU-crystal induced IL-1 

secretion in vitro and reflect disease activity in gout 

patients in vivo 

P. Primatesta (Switzerland) 10:30 

D. Rothenbacher, A. Kleiner, W. Koenig, 

L. P. Breitling, H. Brenner 


Gout in patients with stable coronary heart disease and 

the impact of serum uric acid levels on adverse cardiovascular 

outcomes: a long-term follow-up study 

M. Wolfson (USA) 10:40 

R. A. Yood, F. D. Ottery, W. Irish 


Effect of chronic kidney disease status on pegloticase 

treatment response 

F. Perez-Ruiz (Spain) 10:50 

L. Martinez-Indart, J. I. Pijoan, A. M. Herrero- 

Beites, E. Krisnan, L. Carmona 


Presence of tophi and high level hyperuricemia are 

associated with increased risk of mortality in patients 

with gout 

C.-F. Kuo (United Kingdom) 11:00 

K.-H. Yu, S.-F. Luo, L.-C. See 


Risk of end-stage renal disease associated with gout: a 

nationwide population study 

M. Andres (Spain) 11:10 

V. Pardo, J. M. Caturla, E. Pascual 


Hypouricemia due to high urate renal excretion in septic 

systemic inflammatory response syndrome 

P. Hoff (Germany) 11:20 

T. Gaber, M. Hahne, C. Strehl, M. Fangradt, 

K. Schmidt-Bleek, G. R. Burmester, 

G. Schmidmaier, G. N. Duda, C. Perka, F. Buttgereit 


Accumulation of CD34+ hematopoietic stem cells in the 

initial inflammatory human fracture hematoma is driven 

by RANTES and eotaxin 

S. Bantia (USA) 11:30 

C. Parker, L. Harman, D. Papac, A. Hollister 


Effect of BCX4208 add-on therapy to allopurinol 300 mg 

on plasma hypoxanthine and xanthine concentrations 

in gout patients 

10:15 - 11:45 Room New York 1 


Abstract Session: Epidemiololgy 

and health services 


Loreto Carmona (Spain) 


J. A. B. Van Nies (Netherlands) 10:20 

E. Brouwer, T. W. J. Huizinga, M. D. Posthumus, 

A. H. M. van der Helm-van Mil 


Improving early recognition of arthritis: evaluation of 

the first year results on two early arthritis recognition 

clinics 

J. Primdahl (Denmark) 10:30 

H. C. Horn, R. Petersen, K. Hørslev-Petersen 


Clinical and radiological outcome in outpatients with 

rheumatoid arthritis followed by medical, nursing or 

shared care - a two year randomised controlled trial 

W. Kievit (Netherlands) 10:40 

M. Vermeer, I. Kuper, A. Braakman-Jansen, 

H. Bernelot Moens, T. Zijlstra, A. den Broeder, 

P. van Riel, J. Fransen, M. van de Laar 


Cost-effectiveness and cost-utility analysis of treat-totarget 

versus usual care in early rheumatoid arthritis: 

results of the DREAM registry 

T. Gati (Hungary) 10:50 

C. Morgan, R. N. Luben, M. Lahiri, S. M. 

Verstappen, D. K. Bunn, M. Lunt, D. P. Symmons, 

N. J. Wareham, K.-T. Khaw, I. N. Bruce 


HDL-C and HbA1c predict the development of inflammatory 

polyarthritis: results from the European prospective 

investigation of cancer (NORFOLK) and the 

NORFOLK arthritis register (EPIC-2-NOAR study) 

3 


35


36 


A. Z. Alhusain (United Kingdom) 11:00 

S. M. Verstappen, M. Lunt, H. Mirjafari, D. Bunn, 

T. Marshall, V. Charlton-Menys, P. Durrington, 

D. Symmons, I. N. Bruce 


Predictors of overall/cardiovascular mortality in patients 

with early inflammatory polyarthritis; the lipid-paradox? 

G. Singh (USA) 11:10 

A. Mannalithara, A. Mithal, G. Triadafilopoulos 


Great progress but much more needed: hospitalizations 

due to complicated gastric and duodenal ulcers in the 

US (1990-2009) 

A. J. Svendsen (Denmark) 11:20 

J. V. Hjelmborg, A. Skytthe, G. Houen, K. Kyvik, 

P. Junker 


The incidence of rheumatoid arthritis and the impact of 

smoking 

J. Eriksson (Sweden) 11:30 

J. Askling, M. Neovius 


Combined and specific costs for hospitalisations, drugs, 

and lost work days in prevalent contemporary RA: a 

nationwide cohort study 

10:15 - 11:45 Room New York 3 

PARE Session 

How to get a job and how to keep it 


• How better two-way communication between 

employers and employees can create a positive and 

supportive work environment for people with RMD 

and also maximise productivity 


Maria Batziou (Greece) 

Frane Grubisic (Croatia) 

Christina Flourentzou-Kakouri (Cyprus) 10:20 


How legislative initiatives can support disabled people 

in securing employment and ensuring social inclusion 

Tim Trengenza (United Kingdom) 10:40 

Promoting healthy workplaces for people with rheumatic 

and musculoskeletal diseases 

Olaf Tscharnezki (Germany) 11:00 

The role of employers and employees in promoting 

communication to create a positive and supportive work 

environment 

L. Willumsen (Denmark) 11:20 

H. Jeppesen 


Pauseboogie - campaign to raise awareness of the 

Danish rheumatism association 


T. Jasinski (Estonia) 11:30 

H. Lemetti, I. Käppa 


Local government services for disabled people in Tartu 

and the role of Tartu rheumatism association in 

mediating the services 

11:45 – 13:30 Poster viewing and lunch 

12:00 - 13:15 Hall 4.1 

Primary Care Session 

Hot topics for primary care: What's new? 


• To learn about management objectives 

• To understand the role of primary care 


Tore K. Kvien (Norway) 

Ana Maria Nielsen Bentsen (Spain) 

Cyrus Cooper (United Kingdom) 12:05 


State of the Art Plenary Lecture: Osteoporosis implications 

for primary care 

Robert B.M. Landewé (Netherlands) 12:35 


Spondyloarthritis: what's new for primary care? 

Wolfgang L. Gross (Germany) 12:55 

Polymyalgia Rheumatica: key issues for primary care 

diagnosis and management 

12:15 - 13:15 Poster Area 

Guided Poster Tours 

Please note that you need to register to participate in a 

guided Poster Tour.The number of participants is limited 

to 20 per Poster Tour. Registrations can be made at the 

Posters & Workshops Desk, located at the Registration 

Area (Hall 2.1) based on a “First-Come-First-Served” 

basis.” 

Detailed information on the Poster Tours is provided on 

pages 47 to 51. 

Poster Tour T01: (Epi)-Genetics and 

genomics 1: where are we? 


Rene Toes (Netherlands) 

Marthe Maehlen (Netherlands) 

Poster Tour T02: Novel aspects of joint 

homeostasis and pathology 


Dennis McGonagle (United Kingdom) 

Shea Carter (Belgium) 

Poster Tour T03: B cells and beyond 


Paul Emery (United Kingdom) 

Maya H. Buch (United Kingdom)



Poster Tour T04: RA small molecules - 

old and new 


Daniel Aletaha (Austria) 

Pedro Machado (Portugal) 

Poster Tour T05: SLE, APS, Sjögren's 



Cristina Pamfil (Greece) 

Poster Tour T06: Clinical scleroderma 1 

and inflammatory myopathy 



Britta Maurer (Switzerland) 

Poster Tour T07: Spondyloarthritis 

treatment 


Rik Lories (Belgium) 

Barbara Neerinckx (Belgium) 

Poster Tour T08: PReS - basic research in 

paediatric rheumatology 


Berent J. Prakken (Netherlands) 

Dirk Holzinger (Germany) 

Poster Tour T09: Orphan diseases and 

infectious arthritis 


Maurizio Cutolo (Italy) 

Alberto Sulli (Italy) 

Poster Tour T10: Health Professionals: 

Clinical aspects of care 


Patricia Cornell (United Kingdom) 

Mwidimi Ndosi (United Kingdom) 

13:30 - 15:00 Hall 1.2 


WIN Session 3 

Paul Emery (United Kingdom) 13:35 

Clinical aspects of rheumatoid arthritis 

Josef S. Smolen (Austria) 14:15 

Biological therapy of rheumatoid arthritis 

13:30 - 15:00 Hall 1.1 


Vasculitis: new therapies changing 

outcomes 


• Update participants in current clinical developments 

in the classification, diagnosis and outcomes of 

systemic vasculitis 


Alfred Mahr (France) 

Julia Holle (Germany) 

Niels Rasmussen (Denmark) 13:35 


Vasculitis definition: the revised Chapel Hill definitions 

Raashid Luqmani (United Kingdom) 13:55 


Classification and diagnosis of vasculitis 

Kerstin Westman (Sweden) 14:15 


Long term outcomes in systemic vasculitis 

N. Basu (United Kingdom) 14:35 

A. McClean, R. Luqmani, L. Harper, O. Flossmann, 

D. Jayne, M. Little, E. N. Amft, N. Dhaun, 

J. McLaren, V. Kumar, L. Erwig, G. Jones, D. Reid, 

G. Macfarlane 


Contextualising quality of life in ANCA- Associated 

Vasculitis (AAV) 

A. Mahr (France) 14:45 

L. B. Luong Nguyen, N. G. Bonitsis, A. Altenburg, 

C. C. Zouboulis 


Gender-specific differences in Adamantiades-Behçet’s 

disease presentation: meta-analyses of combined data 

from the German registry for Adamantiades-Behçet’s 

disease and from a systematic literature review 

13:30 - 15:00 Hall 6.2 A 


Molecular targets for therapy in fibrotic 

diseases 


• To understand common and distinct pathways in 

different fibrotic disorders 

• To identify molecular targets for therapies in different 

fibrotic disorders 

• To appreciate the challenges of proof of concept 

studies in fibrotic diseases 



Serena Guiducci (Italy) 

Raghu Kalluri (USA) 13:35 

Origins of fibroblasts in fibrotic diseases 

David Brenner (USA) 13:55 


Molecular targets for therapy in liver fibrosis 

Jörg H. Distler (Germany) 14:15 


Molecular targets for therapy in systemic sclerosis 

Dinesh Khanna (USA) 14:35 

Challenges in study design for proof of concept trials in 

fibrosis 


37


38 


13:30 - 15:00 Hall 5.2 A 



Serge Perrot (France) 13:35 


Management of pain 

Ernest Choy (United Kingdom) 14:15 


Fibromyalgia 

13:30 - 15:00 Hall 5.2 B 


Soft predictors of hard outcomes 


Patrick Verschueren (Belgium) 

Maarten Boers (Netherlands) 

Gareth T. Jones (United Kingdom) 13:35 


Markers of premature mortality: chronic symptoms 



Markers of premature mortality: poor physical fitness 

and performance 

Maria Suarez-Almazor (USA) 14:25 


Changing health behaviours with social marketing 

C. A. Scire' (United Kingdom) 14:50 

M. Lunt, D. P. Symmons, S. M. Verstappen 


Early and sustained remission is associated with 

improved survival in patients with inflammatory 

polyarthritis: results from the NORFOLK arthritis 

register 

13:30 - 15:00 Hall 6.2 B 


Myositis 


Eugen Feist (Germany) 

Jiri Vencovsky (Czech Republic) 

Udo Schneider (Germany) 13:35 

Case 1 presentation: Myositis and Alveolitis 

Eugen Feist (Germany) 13:45 

Case 1 discussion: Myositis and Alveolitis- a challenging 

treatment constellation 

Hermann Mann (Czech Republic) 14:05 

Case 2 presentation: Phenotype defined by autoantibodies 

in inflammatory myopathies 

Jiri Vencovsky (Czech Republic) 14:15 

Case 2 discussion: Phenotype defined by autoantibodies 

in inflammatory myopathies 

13:30 - 15:00 Hall 6.1 

Joint PReS/EULAR Session 

Autoinflammation 1: Linking 

autoinflammation to autoimmunity 



• Understand the complex interactions between 

autoinflammation (innate immune driven disease) 

and autoimmunity 

• Insights that the autoinflammation concept brings to 

disease classification 

• How the innate immune system can drive inflammation 

against itself 

• How the innate immune system activates adaptive 

immunity at the molecular level 


Tilmann Kallinich (Germany) 

Florence Apparailly (France) 

Michael F. McDermott (United Kingdom) 13:35 


Autoimmunity and autoinflammation- oppositive sides 

of the same coin 

Polly Ferguson (USA) 13:55 


Emerging genetics and molecular aspects of autoinflammatory 

bone disease 

Johannes Roth (Germany) 14:15 

How danger associated molecular patterns (DAMPs) 

may initiate and sustain autoimmune disease 

Fabio Martinon (Switzerland) 14:35 


Inflammasomes - powerhouses of intracellular innate 

immune responses 

13:30 - 15:00 Hall 5.1 


EULAR Scientific Training Bursaries - 

an opportunity to win 



Georg Schett (Germany) 

Mary Conolly (Ireland) 13:35 

Investigation of miR-323, a novel microRNA in Rheumatoid 

Arthritis on disease pathogenesis 

Penelope Palominos (Brazil) 13:45 

Impact of psoriatic arthritis: is the patient's perspective 

correctly captured by existing questionnaires? 

Domenico Capocotta (Italy) 13:55 

The experience of a young Italian physician, right after 

his graduation at the Viennese center of excellence in 

rheumatology



Maria Stoenoiu (Belgium) 14:05 

Tendon friction rubs in systemic sclerosis: a possible 

explanation. An ultrasound and magnetic resonance 

imaging study 

Tünde Minier (Hungary) 14:15 

Systemic autoimmune diseases 

Tamas Gati (Hungary) 14:25 

Various clinical experiences in infirmary 

Anna Moltó Revilla (Spain) 14:35 

Clinical differences in rheumatoid arthritis in black 

individuals and Caucasians 

13:30 - 15:00 Hall 4.1 


Supporting self management in OA: 

the role of primary care 


• Awareness of evidence for self management in OA 

• Understanding the role of the primary care team 


Ingemar Petersson (Sweden) 

Jurgen Damen (Netherlands) 

Francis Berenbaum (France) 13:35 


Self management in OA: what is the evidence? 

Mark Porcheret (United Kingdom) 13:55 


Self management for OA: the role of the GP 

Krysia Dziedzic (United Kingdom) 14:15 


Self management in OA: evidence for the role of the 

multidisciplinary team 

Beryl Svanberg (Sweden) 14:35 

The patient’s perspective on self management 

13:30 - 15:00 Room Europa 2 


EULAR-EFIS Session: B regulatory cells 


• Immunology for clinicians 


Catherine Sautes-Fridman (France) 

Claudia Mauri (United Kingdom) 

Thomas F. Tedder (USA) 13:35 


B10 cells and regulatory B cells during inflammation, 

autoimmunity and cancer 

Claudia Mauri (United Kingdom) 14:00 


Regulation of autoimmunity by B regulatory cells 

Simon Fillatreau (Germany) 14:25 

Function of B regulatory cells during bacterial infections 

13:30 - 15:00 Room Berlin 2 


Collateral damage in muscles 


• To learn how various inflammatory states including 

severe systemic insults can lead to severe secondary 

muscle damage 

• To understand the genetic basis for statin myopathy 

and its implications 

• Recognise that emerging different immunopathologic 

patterns of necrotising myopathy 


Pedro Machado (Portugal) 

David Isenberg (United Kingdom) 

Russell Lane (United Kingdom) 13:35 


Immune driven muscle disease: from the thymus to 

myocytes 

Robert Cooper (United Kingdom) 13:55 


The genetics of myositis - recent insights from autoimmune 

diseases and statins 

Oliver Boyer (France) 14:15 


Necrotising myopathy - the new kid on the block that 

the old kids need to recognise 

Ingrid E. Lundberg (Sweden) 14:35 


Steroid myopathy - do molecular mechanism bring us 

closer to novel treatment strategies? 

13:30 - 15:00 Room Dublin 

Joint Clinical/HPR/PARE Session 

Patient involvement in research. Past, 

present and future 


• To get an overview of "best practices" on how to 

capture the patient perspective in MSD research 


Christina Opava (Sweden) 

Dieter Wiek (Germany) 

John R Kirwan (United Kingdom) 13:35 


Fifteen years of experience with patient involvement in 

research. What has been achieved? 


39


40 


Maarten de Wit (Netherlands) 13:55 


Ten golden rules for researchers - how to capture the 

patient perspective in your research project? 

Ingvild Kjeken (Norway) 14:15 


What does it mean to involve patients successfully in 

research? The health professionals perspective 

Laure Gossec (France) 14:35 


Patient involvement in research on the international 

arena 

13:30 - 15:00 Room Paris 2 


Crystals in synovial fluid 2 


• The most common obstacles encountered by those 

interested in starting the crystal analysis process are: 

– The idea that crystal analysis is not possible 

without a fully equipped compensated polarized 

microscope 

– That it is time consuming 

– That it is difficult to differentiate urate from pyrophosphate 

crystals 

– That learning will be a difficult process 

• These will be discussed, and the keys for starting with 

the generally available instruments - the ordinary 

microscope - will be given 



Eliseo Pascual Gomez (Spain) 

Tutors: 

Jose Pimentao (Portugal) 

Francesca Oliviero (Italy) 

Mariano Andrés (Spain) 

13:30 - 15:00 Room Berlin 1 


MRI Workshop advanced 1 




Robert G. Lambert (Canada) 13:35 


MRI in spondyloarthritides - update on the current state 

Iris Eshed (Israel) 13:55 

Non-inflammatory findings in hand MRI 

Claudia Schueller-Weidekamm (Austria) 14:15 

MRI of the cervical spine with a focus on rheumatoid 

arthritis 


Interactive MRI case interpretations 

13:30 - 15:00 Room New York 1 


EULAR Projects in Paediatric Rheumatology 

Working Parties 2.0: vision on the future 


• Learn about activities and vision in different fields of 

paediatric rheumatology presented by working 

parties 


Joost F. Swart (Netherlands) 

Michael Beresford (United Kingdom) 

Annet van Royen (Netherlands) 13:35 

Update on the juvenile dernatomyositis working party 

Tadej Avcin (Slovenia) 14:00 

Update on the SLE working party 

Joost Frenkel (Netherlands) 14:25 

Update on the periodic fever working party 

13:30 - 15:00 Room New York 3 

PARE Session 

What's new: latest advances in treatment 

and management 


• Latest advances in the treatment and management of 

connective tissue disorders and inflammatory 

diseases 


Iain B. McInnes (United Kingdom) 

Ursula Faubel (Germany) 

Simon Bowman (United Kingdom) 13:35 


Latest advances in connective tissue disorders 

Loreto Carmona (Spain) 14:10 

Latest advances in inflammatory diseases 

13:30 - 15:00 Room New York 2 

PReS Session 

ENCA Session: Rheumatic diseases in 

childhood: making the transition to adult 

health care easier 


Claudia Grave (Germany) 

Helle Rasmussen (Denmark) 

Delila Singh (United Kingdom) 13:35 

Experiences in transition from the view of a young 

woman with rheumatism 

Deborah Hilderson (Belgium) 14:15 

Paediatric rheumatology: the bridge between paediatrics 

and adult medicine - the Leuven project



13:30 - 15:00 Room London 3 

PReS AHP Sesssion 

Thieves Market: sharing difficult cases and 

best practices in taking care of children 

with rheumatic diseases 


• Difficult cases and best practices will be presented by 

the participants and an expert panel and discussed in 

the plenary 

Tutors: 

Janjaap van der Net (Netherlands) 

Susan Maillard (United Kingdom) 

Angelo Ravelli (Italy) 

15:00 – 15:30 Coffee break 

15:30 - 17:00 Hall 1.2 


WIN Session 4 

Dimitrios Boumpas (Greece) 15:35 

SLE 

Xavier Mariette (France) 16:15 

Sjögren's syndrome 

15:30 - 17:00 Hall 1.1 


Personalised medicine 


• To understand the definition of a biomarker 

• To appreciate current challenges applying biomarkers 

for diagnostic and prognostic purposes in clinical 

practice 


Pierre Miossec (France) 


William Robinson (USA) 15:35 

Personalised diagnosis: are biomarkers helpful? 

Gerd Rüdiger Burmester (Germany) 15:55 

Predictors of treatment response: a critical view on 

biomarkers 

Josef S. Smolen (Austria) 16:15 

Tayloring patient management beyond drugs 

A. C. Bay-Jensen (Denmark) 16:35 

I. Byrjalsen, A. Kenwright, A. Platt, M. A. Karsdal 


Identification of serological biomarker profiles associated 

with early response to Tocilizumab in rheumatoid 

arthritis 

S. R. Kapoor (United Kingdom) 16:45 

A. Filer, M. Fitzpatrick, B. A. Fisher, P. C. Taylor, 

C. Buckley, I. McInnes, K. Raza, S. P. Young 


Metabolic profiling of urine samples predicts response 

to anti-TNF therapy in patients with rheumatoid 

arthritis 

15:30 - 17:00 Hall 6.2 A 


New insights in osteoarthritis 


• To precise the new insights in OA 


Tim McAlindon (USA) 

Pascal Richette (France) 

Philip G. Conaghan (United Kingdom) 15:35 


Role of imaging in osteoarthritis: biomarker, prognosis 

factor, outcome measure in RCT? 

David Walsh (United Kingdom) 15:55 


Links between angiogenesis, inflammation and pain in 

OA 

Stefan Lohmander (Sweden) 16:15 


Are we close to use biomarkers in daily practice in 

osteoarthritis? 

A. Abou-Raya (Egypt) 16:35 

S. Abou-Raya, M. Helmii, T. Khadrawi 


Effect of low dose oral prednisolone on symptoms and 

systemic inflammation in older adults with moderate to 

severe knee osteoarthritis: a randomized placebocontrolled 

trial 

H. J. Kerkhof (Netherlands) 16:45 

S. Bierma-Zeinstra, B. Hofman, F. Rivadeneira, 

A. Uitterlinden, C. Janssens, J. van Meurs 


Prediction model for knee osteoarthritis including 

clinical, genetic and biochemical risk factors 

15:30 - 17:00 Hall 5.2 A 



Michael Doherty (United Kingdom) 15:35 


Gout and other crystal diseases 



Comorbidity in rheumatic diseases 


41


42 


15:30 - 17:00 Hall 5.2 B 


Update on ACR/EULAR RA classification 

criteria: what have we learned? 


• Recently, ACR and EULAR proposed new classification 

criteria for rheumatoid arthritis 

• This session will give an overview of the validation of 

these criteria, of the changes these criteria have made 

already, and of what we can expect in the future 


Loreto Carmona (Spain) 

Alan J. Silman (United Kingdom) 

Daniel Aletaha (Austria) 15:35 

The new ACR/EULAR criteria: can they replace the 1987 

criteria? Validation 2 years later 

Désirée van der Heijde (Netherlands) 15:55 


What is erosive disease in the criteria? 

J. Humphreys (United Kingdom) 16:15 

S. Verstappen, M. Lunt, K. Hyrich, T. Marshall, 

D. Symmons 


Incidence of rheumatoid arthritis in the UK using the 

2010 ACR/EULAR classification criteria for RA; and 

comparison with estimates using the 1987 ACR criteria 

J. Nicolau (France) 16:25 

P. Boumier, A. Daragon, O. Mejjad, J.-F. Ménard, 

S. Pouplin, O. Vittecoq, P. Fardellone, X. Le Loët 


Validation of the 2010 ACR/EULAR classification criteria 

for rheumatoid arthritis in the very early arthritis 

community-based (VERA) cohort: slight improvement 

after excluding erosion criterion 

D. Nakagomi (Japan) 16:35 

K. Ikeda, A. Okubo, T. Iwamoto, Y. Sanayama, 

K. Takahashi, M. Yamagata, H. Takatori, K. Suzuki, 

K. Takabayashi, H. Nakajima 


Ultrasonographic assessment of synovitis improves the 

accuracy of 2010 American college of rheumatology/ 

European league against rheumatism classification 

criteria for rheumatoid arthritis to predict development 

of a Methotrexate-requiring disease 

A. Krabben (Netherlands) 16:45 

A. Abhishek, K. Britsemmer, A. Filer, 

T. W. J. Huizinga, K. Raza, D. van Schaardenburg, 

A. H. M. van der Helm-van Mil 


Risk stratification in patients with undifferentiated 

arthritis according to the 2010 ACR/EULAR criteria 

15:30 - 17:00 Hall 6.2 B 



Underrecognized and challenging 

manifestations in systemic sclerosis 


• To understand the limitations in diagnosing, classifying 

and treating myopathies in connective tissue 

diseases such as systemic sclerosis 

• To be able to identify calcinosis cutis as a possible 

cause of ulcers in systemic sclerosis and to be updated 

on treatment options for calcinosis cutis 


Marco Matucci-Cerinic (Italy) 

Serena Vettori (Italy) 

Britta Maurer (Switzerland) 15:35 


Case 1 presentation: Myopathy in SSc 

Ulrich Walker (Switzerland) 15:45 


Case 1 discussion: Myopathy in SSc 

Niamh Quillinan (United Kingdom) 16:15 

Case 2 presentation: Calcinosis cutis 

Christopher P. Denton (United Kingdom) 16:25 


Case 2 discussion: Calcinosis cutis 

15:30 - 17:00 Hall 6.1 

PReS Session 

Macrophage activation syndrome 


• To understand MAS and HLH and their pathogenesis 

and treatment 


Pierre Quartier (France) 

Alberto Martini (Italy) 

Angelo Ravelli (Italy) 15:35 


Diagnostic criteria 

Jan-Inge Henter (Sweden) 15:55 


Treatment of hemophagocytic lymphohistiocytosis 

Alexei Grom (USA) 16:15 

The pathogenesis of MAS 

S. Davì (Italy) 16:35 

B. Lattanzi, E. Demirkaya, S. Rosina, A. Novelli , 

N. Ruperto, A. Martini, R. Q. Cron, A. Ravelli on 

behalf of International Investigator Consortium 

for MAS Diagnostic Criteria




Clinical and therapeutic features of 270 patients with 

macrophage activation syndrome enrolled in a multinational 

survey 

Nicola Ruperto (Italy) 16:45 

Canakinumab in systemic juvenile idiopathic arthritis 

with active systemic features 

15:30 - 17:00 Hall 5.1 


Dealing with journalists 


Leo van de Putte (Netherlands) 

Laure Gossec (France) 

Johannes W.J. Bijlsma (Netherlands) 15:35 

The value of media engagement - best practice and 

personal experience 

Jeff Smith (United Kingdom) 15:45 

The what and why of media activity 

Candice Debleu (United Kingdom) 16:00 

The audience - key messages - interview skills 

Leo van de Putte (Netherlands) 16:15 

Open floor Q&A 

15:30 - 17:00 Hall 4.1 


Work and workability in rheumatic 

diseases: what does it mean for primary care 


• Awareness of importance of musculosketal problems 

in work absence 

• Awareness of how to recognise patients at risk of 

work absence presenting to GPs 

• Understanding the role of the primary care team in 

supporting people to stay at work 


Fernando León Vázquez (Spain) 

Elaine Hay (United Kingdom) 

Ingemar Petersson (Sweden) 15:35 

What we know about work absence in MSK disorders 

from disease registers 

Steven J. Linton (Sweden) 15:55 


How to spot those at risk of work absence NEW: how to 

identify those at risk of developing work disability 

Hendrik J. Bieleman (Netherlands) 16:15 

Keeping people in work: what works in primary care? 

F. Buttgereit (Germany) 16:35 

R. Tuominen 


Impact of morning stiffness on work performance in 

people with rheumatoid arthritis 

D. Pattloch (Germany) 16:45 

P. Herzer, S. Zinke, A. Gräßler, A. Zink, 

A. Strangfeld 

Abstract N° OP0137-PC 

Decreasing incidence of disability pensions in patients 

with rheumatoid arthritis in Germany 

15:30 - 17:00 Room Europa 2 


Immunological memory 


• Immunological memory is pivotal to combat infection 

and thereby to the survival of the host. However, 

in case directed against the bodies own molecules, it 

is can cause chronic inflammation. The latest insights 

of this “pathological memory”will be discussed 


Hans-Ulrich Scherer (Netherlands) 

Andrew Cope (United Kingdom) 

Andreas Radbruch (Germany) 15:35 


Twisting pathogenic T cell memory 

Vivi Malström (Sweden) 15:55 


CD28null T cells in myositis 

Antonio Lanzavecchia (Switzerland) 16:15 

Immunological memory in humans 

A. Magnani (Italy) 16:35 

A. Meloni, M. Gattorno, A. Martini, E. Traggiai 


B cell subsets phenotype in autoimmunity with immunodeficiency: 

analysis of a large cohort of patients with 

APECED syndrome 

H. E. Mei (Germany) 16:45 

I. Wirries, C. Giesecke, D. Frölich, M. Brisslert, 

S. Schmidt, R. Engelmann, C. Perka, A. Radbruch, 

T. Dörner 


A distinct subset of CD19-negative plasma cells resides 

in the human bone marrow 


43


44 


15:30 - 17:00 Room Berlin 2 


Innate lymphoid cells: straddling innate 

and adaptive immunity 


• Recent observations have shown a close developmental 

link between lymphoid cells involved in lymphoid 

tissue formation (LTi), their inflammatory 

counterparts (TH17) and NK cells 

• The implications of these findings will be discussed 

and in particular the therapeutic implications in a 

range of immune mediated inflammatory diseases 


Francesca Barone (United Kingdom) 

Caroline Ospelt (Switzerland) 

Tom Cupedo (Netherlands) 15:35 


What are innate lympoid cells and what do they do 

David Withers (United Kingdom) 15:55 


Role of innate lymphoid cells in immunological memory 

Mark Coles (United Kingdom) 16:15 


Innate lymphoid cells in the formation of lymphoid 

tissue 

Sanjiv A. Luther (Switzerland) 16:35 


Innate lympoid cells and their interaction with stroma in 

tertiary lymphoid tissue formation 

15:30 - 17:00 Room Dublin 


Promotion of physical activity in 

rheumatology targeting patients, providers 

and the public 


• Define motivational interviewing and self-regulation 

• Describe the use of motivational interviewing and 

self-regulation to increase physical activity in rheumatoid 

arthritis 

• Describe outcomes of interventions using motivational 

interviewing and self-regulation to promote 

physical activity in rheumatoid arthritis 

• Describe education, monitoring and outcome in 

providers to increase physical activity in rheumatoid 

arthritis 

• Describe the key elements and effects of a health 

communications campaign promoting physical 

activity in arthritis 


Patricia Cornell (United Kingdom) 

Christina Opava (Sweden) 

Linda Ehrlich-Jones (USA) 15:35 


Motivational interviewing from the patient’s perspective 

to increase physical activity in arthritis 

Emalie Hurkmans (Netherlands) 15:55 


Motivational interviewing and self-regulation to 

increase physical activity in patients with rheumatoid 

arthritis 

Ingrid Demmelmaier (Sweden) 16:15 


Education, monitoring and outcome in providers of a 

self-regulation program to increase physical activity in 

rheumatoid arthritis 

Teresa J. Brady (USA) 16:35 


Promoting physical activity through mass media: the US 

centers for disease control and prevention´s health 

communications campaign targeting physical activity 

among people with arthritis 

15:30 - 17:00 Room Paris 2 


Ultrasound advanced 1 



Nemanja Damjanov (Serbia) 

Wolfgang A. Schmidt (Germany) 

Stephanie Finzel (Germany) 15:35 

What does high-resolution CT tell us about the 

sonographic appearance of erosions? 

Wolfgang A. Schmidt (Germany) 15:55 

What does dual energy CT tell us for the sonographic 

diagnosis of gout? 

Emilio Filippucci (Italy) 16:15 

Fusion imaging - can we use it in clinical practice? 

Nemanja Damjanov (Serbia) 16:35 

The practical case



15:30 - 17:00 Room Berlin 1 


MRI Workshop basic 2 





Basic MRI technical issues and how to interpret and use 

the different MR image types in peripheral arthritis 


MRI in psoriatic arthritis - update on the current state 


MRI in gout - update on the current state 


Recognizing common MRI pathologies in arthritis. 

Interactive assessment of MR images on PC projector 

15:30 - 17:00 Room New York 3 

PARE Session 

Comorbidity 


• To highlight the impact and associated risks faced by 

people living with at least one other significant condition 

caused by, or linked to, their RMD 


Kirsten Lerstroem (United Kingdom) 

David Magnusson (Sweden) 

Chris Naylor (United Kingdom) 15:35 


The link between longterm conditions and mental 

health 

Borgi Winkler-Rohlfing (Germany) 16:00 


Improving the prevention of comorbidity of lupus 

patients - a project of the German lupus patient organisation 

Michael T. Nurmohamed (Netherlands) 16:25 


RMDs and cardiovascular risk factors 

J. Cumming (United Kingdom) 16:50 

R. G. Hull 


The complexity of living with rheumatic and musculoskeletal 

diseases and other health problems 

17:45 – 19:00 Hall 1.1 


17:45 – 19:00 Hall 5.2 A 

Satellite Symposium: MSD 

17:45 – 19:00 Hall 5.2 B 

Satellite Symposium: Pfizer 

17:45 – 19:00 Hall 6.2 B 

Satellite Symposium: Grünenthal 

17:45 – 19:00 Hall 4.1 

Satellite Symposium: Bristol-Myers Squibb 

17:45 – 19:00 Room Dublin 

Satellite Symposium: UCB Pharma 

17:45 – 19:00 Room Paris 2 

Satellite Symposium: Fidia 


45


Guided Poster Tours 

Guided Poster Tours 12:15 - 13:15 

Please note that you need to register to participate in guided a Poster Tour. The number of participants is limited to 20 

per Poster Tour. Registrations can be made at the Poster & Workshop Desk, located in the Registration area Hall 2.1 

based on a “First-Come-First-Served”basis. 

Poster Tour T01: (Epi)-Genetics and genomics 1: where are we? Hall 2.2 

Chairperson(s): Rene Toes (Netherlands), Marthe Maehlen (Netherlands) 

THU0001 VARIATION IN GRANZYME-B IS ASSOCIATED WITH PROGRESSION OF JOINT DESTRUCTION IN RHEUMATOID 

ARTHRITIS / R. Knevel* - A. Krabben - G. Wilson - E. Brouwer - E. Lindqvist - D. de Rooy - N. Daha - M. van der Linden - 

R. Tsonaka - S. Zhernakova - H.-J. Westra - L. Franke - J. Houwing-Duistermaat - R. Toes - T. Huizinga - T. Saxne - A. van der 

Helm-van Mil 

THU0002 FINE MAPPING AND EXPRESSION STUDIES OF THE 12Q13-14 LOCUS ASSOCIATED WITH RHEUMATOID ARTHRITIS / 

A.Yarwood* - A. Barton - J. Bowes - P. Martin - J. Worthington - S. Eyre on behalf of RACI 

THU0003 FINE-MAPPING OF AUTOIMMUNE SUSCEPTIBILITY LOCI USING IMMUNOCHIP IDENTIFIES NOVEL SUSCEPTIBILITY 

LOCI FOR PSORIATIC ARTHRITIS / J. Bowes* - P. Ho - E. Korendowych - N. McHugh - J. Packham - I. N. Bruce - A. Barton 

THU0004 CAMP RESPONSIVE ELEMENT MODULATOR (CREM) ALPHA CONTRIBUTES TO DECREASED NOTCH-1 EXPRESSION IN 

T CELLS FROM PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) / T. Rauen* - A. Grammatikos - C. M. Hedrich - 

V. C. Kyttaris - K. Tenbrock - U. Raffetseder - J. Floege - G. C. Tsokos 

THU0005 AN IMMUNOCHIP BASED INTERROGATION OF SCLERODERMA SUSCEPTIBILITY VARIANTS / J. Charlesworth - 

J. Stankovich - P. Lewis - J. Byron - W. Stevens - J. Sahhar - S. Proudman - J. Roddy - P. Nash - K. Tymms - M. Brown - J. Zochling 

THU0006 COMBINATORIAL CONTROL OF TH1 AND TH17 CELL FUNCTIONS BY SINGLE-NUCLEOTIDE POLYMORPHISMS AT 

GENES ASSOCIATED WITH THE IL-23 SIGNALING PATHWAY IN SPONDYLOARTHRITIS / L. Rogge* - M. Coffre - M. Roumier 

- M. Rybczynska - E. Sechet - H. Law - L. Gossec - M. Dougados - E. Bianchi 

THU0007 ANALYSIS OF PROTEIN ACETYLATION AND HISTONE DEACETYLASE EXPRESSION IN THE SYNOVIAL TISSUE REVEALS 

COMPLEX RELATIONSHIPS BETWEEN EPIGENETIC REGULATORY MECHANISMS AND INFLAMMATION IN RHEUMA- 

TOID ARTHRITIS / A. M. Grabiec* - C. Ospelt - L. G. M. van Baarsen - I. E. van Es - S. Gay - P. P. Tak - K. A. Reedquist 

THU0008 META-ANALYSIS OF THE ASSOCIATION OF SMOKING AND PTPN22 R620W GENOTYPE ON AUTOANTIBODY STATUS 

AND RADIOLOGICAL EROSIONS IN RHEUMATOID ARTHRITIS / L. H.Taylor* - S.Twigg - J. J.Worthington - P. Emery - A.W. Morgan 

- A. G. Wilson - M. D. Teare on behalf of UKRAGG 

THU0009 DIFFERENTIAL EXPRESSION OF DKK1 IN SYNOVIAL FIBROBLASTS FROM RESOLVING AND EARLY RHEUMATOID 

ARTHRITIS / M. Juarez* - D. Scheel Toellner - L.Yeo - K. Howlett - R. Bayley - B. de Paz - R. Hardy - K. Raza - M. Cooper - 

C. Buckley - A. Filer 

Poster Tour T02: Novel aspects of joint homeostasis and pathology Hall 2.2 

Chairperson(s): Dennis McGonagle (United Kingdom), Shea Carter (Belgium) 

THU0020 SERUM PYRIDINOLINE LEVELS PREDICT THE SEVERITY OF FUTURE JOINT DESTRUCTION IN RHEUMATOID ARTHRITIS 

/ A. Krabben* - R. Knevel - T. W. J. Huizinga - G. Cavet - A. H. M. van der Helm-van Mil 

THU0021 CARTILAGE ZONE SPECIFIC PROTEINS: A QUANTITATIVE PROTEOMIC ANALYSIS / P. Fernández-Puente - L. Lourido - 

V. Calamia - J. Mateos - C. Ruiz-Romero - M. Lotz - F. J. Blanco* 

THU0022 ENHANCED EXPRESSION OF SUPPRESSOR OF CYTOKINE SIGNALING 3 IN ARTHRITIC CARTILAGE DYSREGULATES 

HUMAN CHONDROCYTE FUNCTION / F.Van De Loo* - B. van den Brand - S.Veenbergen - M. Bennink - E. Blaney-Davidson 

- H. van Beuningen - P. van der Kraan - W. van den Berg 

THU0023 A NOVEL ROLE FOR ELR+ CXC CHEMOKINE SIGNALING IN CARTILAGE HOMEOSTASIS / J. Sherwood* - G. Nalesso - 

J. Bertrand - P. Achan - L. Brandolini - T. Pap - C. Pitzalis - F. Dell'Accio 

THU0024 DIFFERENCES BETWEEN HEALTHY AND OSTEOARTHRITIS PROTEOMIC PROFILES OF BONE MARROW 

MESENCHYMAL STEM CELLS UNDERGOING CHONDROGENESIS / B. Rocha - V. Calamia - J. Mateos - P. Fernández-Puente 

- L. Lourido - C. Fernández-Costa - C. Fernández-López - N. Oreiro - C. Ruiz-Romero - F. J. Blanco* 

THU0025 EXPRESSION OF INTERLEUKIN-20 AND ITS RECEPTORS IN OSTEOBLASTS AND OSTEOCLASTS IN BONE TISSUE FROM 

PATIENTS WITH RHEUMATOID ARTHRITIS / J. Rømer* - P. A. Usher - M. N. Nielsen - J. Mandelbaum - M. Jackerott 

* Presenting author 


47


48 

Poster Tour T03: B cells and beyond Hall 2.2 

Chairperson(s): Paul Emery (United Kingdom), Maya H. Buch (United Kingdom) 

THU0086 SEROPOSITIVITY AND RESPONSE TO RTX: DATA FROM THE CERERRA COLLABORATION / K. Chatzidionysiou* - E. Lie - 

E. Nasonov - G. Lukina - M. Hetland - U. Tarp - I. Ancuta - K. Pavelka - D. Nordström - C. Gabay - H. Canhao - M. Tomsic - 

P. van Riel - J. Gomez-Reino - T. Kvien - R. van Vollenhoven 

THU0087 ONE SINGLE INFUSION OF RITUXIMAB 1G MIGHT BE SUFFICIENT IN THE LONG-TERM MANAGEMENT OF RHEUMA- 

TOID ARTHRITIS PATIENTS RESPONDING TO A FIRST CYCLE OF RITUXIMAB (2 X 1G): RESULTS OF A 2-YEAR MULTI- 

CENTER RANDOMIZED CONTROLLED TRIAL / M. Dougados* - B. Combe - X. Le Loët - J. Tebib - J. Sibilia - S. Rouanet - 

R. Jourdan - X. Mariette 

THU0088 ABNORMAL MEMORY B-CELL RECONSTITUTION FOLLOWING ANTI-CD20 THERAPY FOR AUTOIMMUNE DISEASES 

PREDICTS CLINICAL RELAPSE / G. Arumugakani* - A. Rawstron - R. Tooze - A. Cherukuri - A. Varghese - E. Vital - P. Emery - 

D. McGonagle 

THU0089 RESPONSE TO ABATACEPT AND TOCILIZUMAB IN PATIENTS WHO HAD FAILED RITUXIMAB- INITIAL SINGLE CENTRE 

EXPERIENCE / S. Das* - S. Horton - E.Vital - D. Bryer - P. Emery - M. Buch 

THU0090 SAFETY AND EFFICACY OF ATACICEPT IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RHEUMATOID 

ARTHRITIS: RESULTS FROM THE ATACICEPT FOR REDUCTION OF SIGNS AND SYMPTOMS IN RHEUMATOID ARTHRITIS 

TRIAL (III) / R. F. van Vollenhoven* - S. Wax - S. Copt - P. P. Tak 

THU0091 COMPARISON OF THE CLINICAL UTILITY OF ANTI-IL-6 RECEPTOR ANTIBODY THERAPY AND ANTI-TNF THERAPY IN 

AA AMYLOIDOSIS IN RHEUMATIC DISEASE / Y. Okuda* - M. Ohnishi - K. Takasugi 

THU0092 THE ADVANTAGE OF EARLY INTERVENTION BY TOCILIZUMAB FOR RHEUMATOID ARTHRITIS - FULL ANALYSIS OF 

ALL-CASE POSTMARKETING SURVEILLANCE IN 7,901 PATIENTS IN JAPAN / H. Yamanaka* - M. Harigai - S. Inokuma - 

N. Ishiguro - J. Ryu - S. Takei - T. Takeuchi - Y. Tanaka - Y. Sano - T. Koike 

THU0093 CLINICAL, RADIOGRAPHIC, AND IMMUNOGENIC EFFECTS AFTER 1 YEAR OF TOCILIZUMAB (TCZ)-BASED TREATMENT 

STRATEGY WITH AND WITHOUT METHOTREXATE (MTX) IN RA: THE ACT-RAY STUDY / M. Dougados* - K. Kissel - P. G. 

Conaghan - E. Martin-Mola - G. Schett - H. Amital - R. M. Xavier - O. Troum - C. Bernasconi - T. W. J. Huizinga 

THU0094 DIRECT COMPARISON OF FOUR BIOLOGICAL AGENTS IN BIO-NAÏVE RHEUMATOID ARTHRITIS PATIENTS / Y.Yonemoto* 

- K. Okamura - K. Takeuchi - M. Matsushita - T. Kaneko - T. Kobayashi - T. Aramaki - K. Takagishi 

THU0095 EARLY RESPONSE TO ABATACEPT PLUS MTX IN MTX-IR RA PATIENTS USING POWER DOPPLER ULTRASONOGRAPHY: 

AN OPEN-LABEL STUDY / M. D’Agostino* - R. Wakefield - H. Berner Hammer - O.Vittecoq - M. Galeazzi - P. Balint - E. Fillipucci 

- I. Moller - A. Iagnocco - E. Naredo - M. Ostergaard - C. Gaillez - W. Kerselaers - K. Van Holder - M. Le Bars on behalf of 

OMERACT-US Task Force 

THU0096 MAVRILIMUMAB IN RHEUMATOID ARTHRITIS: RESULTS OF A PHASE 2 DOUBLE-BLIND, PLACEBO CONTROLLED 

STUDY / G. Burmester* - M. Weinblatt - I. McInnes - O. Barbarash - E. Esfandieri - M. Sleeman - A. Godwood - F. Magrini on 

behalf of EARTH Study group 

THU0097 SYSTEMATIC REVIEW OF THE SAFETY OF PROTEIN KINASE INHIBITORS IN CLINICAL TRIALS IN RHEUMATOID 

ARTHRITIS / E. Salgado* - J. R. Maneiro - L. Carmona - J. J. Gomez-Reino 

Poster Tour T04: RA small molecules - old and new 

Chairperson(s): Daniel Aletaha (Austria), Pedro Machado (Portugal) 



THU0127 FUNCTIONAL ACTIVITY OF MEMBRANE-BOUND GLUCOCORTICOID RECEPTORS / C. Strehl* - T. Gaber - M. Jakstadt - 

M. Hahne - P. Hoff - G.-R. Burmester - F. Buttgereit 

THU0128 THE EXTRA-LOW-DOSE METHOTREXATE TREATMENT FACILITATES THE INTRACELLULAR ACCUMULATION OF 

LONGER CHAIN SUBGROUPS OF METHOTREXATE POLYGLUTAMATES / Y. Koyama* - K. Hase - D. Hidaka - S. Nagano - T. 

Ota - A. Uchino - J. Nakagawa 

THU0129 SELECTIVE ELIMINATION OF PATHOGENIC TH17 CELLS FROM PERIPHERAL BLOOD OF RHEUMATOID ARTHRITIS 

PATIENTS BY A PURIFIED FUNGAL POLYSACCHARIDE / A. Alunno* - E. Pericolini - E. Gabrielli - O. Bistoni - S. Caterbi - 

E. Bartoloni - S.-K. Chow - A. Casadevall - A.Vecchiarelli - R. Gerli 

THU0130 ASSESSMENT OF TRANSAMINASITIS WITH DAILY METHOTREXATE THERAPY IN PATIENTS WITH INFLAMMATORY 

RHEUMATIC DISEASES. A LONG-TERM FOLLOW-UP COHORT STUDY / M. U. Martinez Martinez* - A. Sánchez-Arriaga - C. 

Abud-Mendoza 

THU0131 TOFACITINIB (CP-690,550), AN ORAL JANUS KINASE INHIBITOR: ANALYSIS OF MALIGNANCIES ACROSS THE RHEUMA- 

TOID ARTHRITIS CLINICAL PROGRAMME / X. Mariette* - J. R. Curtis - E. B. Lee - R. Riese - I. Kaplan - R. Chew - J. Geier - 

L. Wang - J. D. Bradley 

THU0132 COMPARISON OF DOSE ESCALATION OF INFLIXIMAB AND THE ADDITION OF TACROLIMUS IN RHEUMATOID 

ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO INFLIXIMAB AND METHOTREXATE COMBINATION 

THERAPY / Y.Yonemoto* - K. Okamura - T. Kaneko - T. Kobayashi - K. Takagishi 

THU0133 INTRA-ARTICULAR METHOTREXATE: CLINICAL AND POWER DOPPLER ULTRASONOGRAPHY STUDY OF SYNOVITIS 

IN MEDIUM SEIZED JOINTS OF RHEUMATOID ARTHRITIS PATIENTS / M. Mortada* - A. SOLYMAN 

THU0134 BIOMARKERS OF METOTHREXATE ADVERSE REACTIONS IN RHEUMATOID ARTHRITIS PATIENTS / N. Dostanko* - 

V.Yagur - N. Soroka 

* Presenting author



Poster Tour T05: SLE, APS, Sjögren's Hall 2.2 

Chairperson(s): Dimitrios Boumpas (Greece), Cristina Pamfil (Greece) 

THU0158 SIX YEAR FOLLOW-UP STUDY OF BONE MINERAL DENSITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / 

J. Jacobs* - L.-A. Korswagen - A. Schilder - L. van Tuyl - B. Dijkmans - W. Lems - A.Voskuyl - I. Bultink 

THU0159 INCIDENCE AND PREVALENCE OF MAJOR CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN SYSTEMIC LUPUS 

ERYTHEMATOSUS (SLE): A 3 YEAR PROSPECTIVE EVALUATION AND CLINICAL CORRELATIONS IN 370 

PATIENTS / E. I. Kampylafka* - H. Alexopoulos - M. L. Kosmidis - D. B. Panagiotakos - P. G.Vlachoyiannopoulos - M. C. Dalakas 

- H. M. Moutsopoulos - A. G. Tzioufas 

THU0160 WHITE MATTER LESIONS ARE PREDOMINANTLY DEMYELINATING IN SYSTEMIC LUPUS ERYTHEMATOSUS. AN 

SUPPORT VECTOR MACHINES CLASSIFICATION OF TEXTURE PARAMETERS / A. T. Lapa - M. P. Bento - L. Rittner - 

H. H. Ruocco - G. Castellano - B. D. Damasceno - L. T. L. Costallat - S. Appenzeller* - R. Lotufo - F. Cendes 

THU0161 NEUROPSYCHIATRIC INVOLVEMENT AND SLE: PERFORMANCE OF A NEW ALGORITHM FOR ATTRIBUTION OF NP 

EVENTS TESTED ON AN ITALIAN MULTICENTER COHORT / A. Bortoluzzi* - S. Bombardieri - C. Casu - F. Conti - S. De Vita 

- A. Doria - I. Farina - G. Ferraccioli - E. Gremese - E. Mansutti - M. Mosca - M. Padovan - M. Piga - A. Tincani - P. Tomietto - 

C. Tani - G.Valesini - M. Zen - A. Mathieu - M. Govoni on behalf of on behalf of the Italian Study Group for the Neuropsychiatric 

Involvement in Systemic Lupus Erythematosus 

THU0162 THROMBOTIC MICROANGIOPATHY IN RENAL BIOPSIES FROM PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / 

J. Gerhardsson - A. Zickert - B. Sundelin - E. Svenungsson - I. Gunnarsson* 

THU0163 PREDICTORS OF METABOLIC SYNDROME AT ENROLMENT INTO A MULTICENTRE INTERNATIONAL INCEPTION 

COHORT OF PATIENTS WITH SLE / B. Parker* - M. B. Urowitz - M. Lunt - I. N. Bruce on behalf of SLICC Registry for 

Atherosclerosis 

THU0164 RISK OF SERIOUS INFECTIONS IN RHEUMATOID ARTHRITIS AND OTHER CHRONIC INFLAMMATORY IMMUNE- 

MEDIATED DISEASES TREATED WITH TNF ANTAGONISTS OR RITUXIMAB / T. Cobo-Ibáñez* - M. A. Descalzo - S. Muñoz- 

Fernández - E. Loza - L. Carmona - J. J. Gómez-Reino on behalf of on behalf of the BIOBADASER 2.0 Study Group 

THU0165 HIGH RATE OF CARDIOVASCULAR EVENTS IN LUPUS PATIENTS AT 5 YEAR FOLLOW UP AND ASSOCIATION OF 

CLASSICAL AND LUPUS RELATED RISK FACTORS / S. Skeoch* - S. Haque - B. Parker - Y. Ahmad - L. S. Teh - I. Bruce 

THU0166 REBAMIPIDE IN THE TREATMENT OF XEROSTOMIA IN SJÖGREN’S SYNDROME: RANDOMIZED PLACEBO- 

CONTROLLED STUDY / A. Abou-Raya* - S. Abou-Raya - N. Sallam - M. Helmii 

Poster Tour T06: Clinical scleroderma 1 and inflammatory myopathy Hall 2.2 

Chairperson(s): Oliver Distler (Switzerland), Britta Maurer (Switzerland) 

THU0231 THE EFFICACY OF TACROLIMUS IN PATIENTS WITH INTERSTITIAL LUNG DISEASES COMPLICATED WITH 

POLYMYOSITIS OR DERMATOMYOSITIS / T. Kurita* - S.Yasuda - K. Oba - K. Otomo - H. Shida - T. Watanabe - Y. Kanetsuka - 

M. Kono - T. Odani - Y. Fujieda - Y. Kon - T. Horita - N. Sato - T. Atsumi 

THU0232 PREGNANCY OUTCOME IN IDIOPATHIC INFLAMMATORY MYOPATHY PATIENTS IN A MULTICENTER STUDY / M.Vincze* 

- A.Váncsa - K. Dankó - L. Plestilova - J.Vencovsky - K. Gheorghe - I. Lundberg - P. Charles - H. Balsam - E. Wegier-Szewczyk 

THU0233 MYOPATHY IS A POOR PROGNOSTIC FEATURE IN SYSTEMIC SCLEROSIS. RESULTS FROM THE CANADIAN SCLERO- 

DERMA RESEARCH GROUP (CSRG) COHORT / M. Jung* - M. Baron - M. Hudson - A. Bonner - J. E. Pope on behalf of Canadian 

Scleroderma Research Group 

THU0234 SYSTEMATIC LITERATURE REVIEW: EFICACY OF RAYNAUD PHENOMENON PHARMACOLOGYCAL TREATMENT IN 

SYSTEMIC SCLEROSIS PATIENTS / P. Garcia De La Peña Lefebvre* - M. B. Nishishinya - C. A. PEREDA - J. ROMAN IVORRA - 

P. CARREIRA - E. LOZA - I. Rúa-Figueroa - S. Muñoz-Fernández 

THU0235 IDENTIFYING AND QUANTIFYING PROGNOSTIC FACTORS IN SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG 

DISEASE USING A TIME-VARYING COVARIATE SURVIVAL MODEL / O. A. Moore* - N. Goh - T. Corte - H. Rouse - 

O. Hennessy - V. Thakkar - J. Byron - J. Sahhar - J. Roddy - P.Youssef - P. Nash - J. Zochling - S. M. Proudman - W. Stevens - 

M. Nikpour on behalf of Australian Scleroderma Interest Group 

THU0236 LOW GRADE EROSIVE ARTHRITIS IS A GENUINE AND FREQUENT DISEASE MANIFESTATION OF SYSTEMIC SCLEROSIS 

/ E. Akbayrak - I. H. Tarner - U. Müller-Ladner - R. Dinser* 

THU0237 IMPACT OF RECURRENT ISCHEMIC DIGITAL ULCERS ON HAND DISABILITY IN SYSTEMIC SCLEROSIS / L. Mouthon* - 

P. Carpentier - A. Khau Van Kien - P. Clerson - H. Maillard - E. Hachulla - C. Frances - E. Diot - C. Lok - E. Puzenat - A. Sparsa - 

A. Bérezné - V. Gressin - M.-A. Richard 

THU0238 LONG-TERM FOLLOW-UP OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE 

SYSTEMIC SCLEROSIS / H. Tsukamoto* - T. Horiuchi - T. Miyamoto - H. Niiro - Y. Arinobu - Y. Inoue - M. Ayano - A. Tanaka - 

N. Ueda - M. Harada - K. Akashi 

THU0239 CARDIOVASCULAR RISK FACTORS IN ADULTS WITH POLYMYOSITIS AND DERMATOMYOSITIS – A MULTICENTER 

STUDY / L. C. Diederichsen* - A. C. Diederichsen - J. A. Simonsen - P. Junker - K. Søndergaard - I. E. Lundberg - N. Tvede - 

A. F. Christensen - L. Dreyer - L. Ejstrup - S. Jacobsen 

THU0240 ROSUVASTATIN IMPROVES IMPAIRED ENDOTHELIAL FUNCTION AND LOWERS HIGH SENSITIVITY CRP IN PATIENTS 

WITH SYSTEMIC SCLEROSIS – A PROSPECTIVE CASE-SERIES STUDY / O. Timár - Z. Szekanecz - G. Kerekes - J. Végh - 

A. V. Oláh - Z. Csiki - K. Dankó - S. Szamosi - Á. Németh - P. Soltész - G. Szücs* 



49


50 



Poster Tour T07: Spondyloarthritis treatment Hall 4.2 

Chairperson(s): Rik Lories (Belgium), Barbara Neerinckx (Belgium) 

THU0260 CIRCULATING LEVELS OF TNF-LIKE CYTOKINE 1A (TL1A) ARE INCREASED IN PATIENTS WITH ANKYLOSING 

SPONDYLITIS / M. Konsta* - M. Tektonidou - A. Iliopoulos - G. Bamias - P. P. Sfikakis 

THU0261 CONTINUOUS NSAID USE REVERTS THE EFFECTS OF INFLAMMATION ON RADIOGRAPHIC PROGRESSION IN 

PATIENTS WITH ANKYLOSING SPONDYLITIS / F. Kroon* - R. Landewé - M. Dougados - D. van der Heijde 

THU0262 SCLEROSTIN DOES NOT PREDICT RADIOGRAPHIC PROGRESSION IN PATIENTS ON ANTI-TNF THERAPY – NEW 

RESULTS FROM THE EUROPEAN ANKYLOSING SPONDYLITIS (AS) INFLIXIMAB COHORT (EASIC) / X. Baraliakos* - 

F. Heldmann - J. Listing - G. Schett - T. Appelboom - J. Brandt - F. van den Bosch - M. Breban - G. Burmester - M. Dougados - 

P. Emery - H. Gaston - M. Gruenke - I. van der Horst-Bruinsma - R. Landewé - M. Leirisalo-Repo - J. Sieper - K. de Vlam - J. Braun 

on behalf of EASIC 

THU0263 DEVELOPMENT OF CHRONIC INFLAMMATORY CHANGES ON WHOLE BODY MAGNETIC RESONANCE IMAGING IN 

PATIENTS WITH EARLY AXIAL SPONDYLOARTHRITIS AFTER TWO YEARS OF CONTINUOUS TREATMENT WITH ETANER- 

CEPT – 2 YEAR DATA OF THE ESTHER TRIAL / I.-H. Song* - K.-G. Hermann - H. Haibel - C. Althoff - D. Poddubnyy - J. Listing 

- A. Weiss - E. Lange - B. Freundlich - M. Rudwaleit - J. Sieper 

THU0264 ADALIMUMAB SIGNIFICANTLY REDUCES RECURRENCE RATE OF ANTERIOR UVEITIS IN PATIENTS WITH ANKYLOSING 

SPONDYLITIS / C. van Denderen* - I. M.Visman - M. T. Nurmohamed - M. S. Suttorp-Schulten - I. E. van der Horst-Bruinsma 

THU0265 EARLY CHANGE IN BONE RESORPTION PREDICTS DISCONTINUATION OF TUMOR NECROSIS FACTOR-ALPHA 

BLOCKING THERAPY IN PATIENTS WITH ANKYLOSING SPONDYLITIS / S. Arends* - A. Spoorenberg - P. M. Houtman - 

M. K. Leijsma - C. G. M. Kallenberg - E. Brouwer - E. van der Veer 

THU0266 SARCOPENIA REVERSAL IN ANKYLOSING SPONDYLITIS (AS) UNDER ANTI-TNF THERAPY: A 24-MONTH LONGITU- 

DINAL ANALYSIS / M. A. Barros* - C. S. Saad - L. Takayama - J. C. Moraes - A. C. Medeiros - E. Bonfa - R. M. Pereira 

Poster Tour T08: PReS - basic research in paediatric rheumatology Hall 4.2 

Chairperson(s): Berent J. Prakken (Netherlands), Dirk Holzinger (Germany) 

THU0287 GLYCOSYLATION OF VITAMIN D BINDING PROTEIN REDUCED IN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS AT RISK 

OF DISEASE EXTENSION / D. S. Gibson* - S. Finnegan - G. Manning - M. Duncan - S. Pennington - T. Moore - M. Rooney 

THU0288 PROTEOMIC PROFILING OF THE SYNOVIAL MEMBRANE IN EARLY UNTREATED JUVENILE IDIOPATHIC ARTHRITIS / 

S. Finnegan* - D. S. Gibson - M. Rooney 

THU0289 MICRORNA SIGNATURE IN PEDIATRIC LUPUS NEPHRITIS: A PILOT STUDY / P. Costa Reis* - P. A. Russo - K. E. Sullivan 

THU0290 PERIPHERAL MONONUCLEAR CELLS OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS PATIENTS HAVE NO INTRINSIC 

DEFECT IN INTERFERON-GAMMA SIGNALING / K. Put* - A. Avau - T. Mitera - S. Put - B. Bader-Meunier - P. Quartier - 

C. Wouters - P. Matthys 

THU0291 NEUTROPHIL APOPTOSIS IS NOT AFFECTED BY GLUCOCORTICOID OR DMARD TREATMENT IN JUVENILE-ONSET 

SYSTEMIC LUPUS ERYTHEMATOSUS / F. Gohar* - L. Ballantine - M. W. Beresford 

THU0292 STIMULATION OF JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS BLOOD CELLS INDUCES IL-17 PRODUCTION / 

L. Ballantine* - A. Midgley - L. Watson - M. Beresford 

THU0293 JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS (JSLE) AND JUVENILE DERMATOMYOSITIS (JDM) PATIENTS HAVE A 

DISTINCT PROFILE OF SOLUBLE APOPTOSIS MOLECULES / B. L. Liphaus* - M. H. B. Kiss - S. Carrasco - C. A. Silva - 

C. Goldenstein-Schainberg 

THU0294 REGULATORY T CELLS/TH17 BALANCE IN THE PATHOGENESIS OF PEDIATRIC BEHÇET DISEASE / T.-A. Tran* - A. Hubert 

- A. Letierce - B. Terrier - G. Geri - D. Saadoun - I. Kone-Paut - M. Rosenzwajg 

THU0295 ISOTYPE CHARACTERIZATION OF ANTI-INFLIXIMAB ANTIBODIES IN PEDIATRIC PATIENTS WITH RHEUMATIC 

DISEASES TREATED WITH INFLIXIMAB / M. Kosmač* - N. Toplak - G. Simonini - R. Cimaz - V. Čurin Sˇerbec - T. Avčin 

THU0296 MATRIX INTERFERENCE OF IL-6, IL-17, IL-21 AND TNF-ALPHA MEASUREMENT IN JUVENILE-ONSET SYSTEMIC LUPUS 

ERYTHEMATOSUS SERUM AND PLASMA / J. Ong* - D. Harris - G. Jeffers - L. Watson - L. Ballantine - M. Beresford 

* Presenting author



Poster Tour T09: Orphan diseases and infectious arthritis Hall 4.2 

Chairperson(s): Maurizio Cutolo (Italy), Alberto Sulli (Italy) 

THU0379 A 20 YEAR SINGLE CENTRE EXPERIENCE OF AA AMYLOIDOSIS DEMONSTRATING CHANGES IN ITS EPIDEMIOLOGY / 

H. J. Lachmann* - J. D. Gillmore - A. D. Wechalekar - S. D. Gibbs - J. H. Pinney - D. M. Rowczenio - H. Trojer - T. Lane - C. P.Venner 

- S. M. Banypersad - J. A. Gilbertson - F. T. Hunt - D. Gopaul - D. F. Hutt - N. Wassef - M. B. Pepys - P. N. Hawkins 

THU0378 INTERLEUKIN-6 BLOCKING THERAPY BY TOCILIZUMAB IN PATIENTS WITH MULTICENTRIC CASTLEMAN’S DISEASE 

RESULTS IN A SIGNIFICANT DECREASE IN SERUM LEVELS OF IGG4 AND IGE / M. Murakami* - T. Matsutani - C. Aoki - 

H.-M. Lee - Y. Li - N. Nishimoto 

THU0377 EFFICACY, SAFETY AND PHARMACOKINETICS OF THE ANTI-INTERLEUKIN-1 BETA ANTIBODY CANAKINUMAB IN 

PATIENTS WITH SCHNITZLER SYNDROME / H. D. De Koning* - J. Schalkwijk - J. van der Ven-Jongekrijg - M. Stoffels - 

J. W. van der Meer - A. Simon 

THU0376 SERUM LEPTIN, RESISTIN, VISFATIN AND ADIPONECTIN LEVELS IN TUMOR NECROSIS FACTOR RECEPTOR-ASSOCI- 

ATED PERIODIC SYNDROME (TRAPS) / L. Cantarini* - L. Obici - G. Simonini - R. Cimaz - M. R. Bacarelli - G. Merlini - A.Vitale 

- O. M. Lucherini - M. G. Brizi - M. Galeazzi - A. Fioravanti 

THU0375 MALONDIALDEHYDE SERUM LEVELS AND MYCOARDIAL GLOBAL STRAIN IN IDIOPATHIC INFLAMMATORY 

MYOPATHY. / K. Ramirez-Santillan* - M.Vazquez-Zaragoza - A. Camargo-Coronel - E. Gomez - B. Mendoza-Perez - L. Moreno- 

Ruiz - A. Chavez-Negrete - L. Barile-Fabris 

THU0374 ARTICULAR SYMPTOMS IN CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME : A RETROSPECTIVE FRENCH STUDY / 

L. Houx* - X. Guennoc - E. Hachulla - I. Koné-Paut - P. Quartier - G. Grateau - P. Pillet - M. Hamidou - I. Lemelle - A. Pagnier - 

B. Neven - C. Richez - V. Devauchelle-Pensec 

THU0373 CLINICAL PRESENTATION OF ERDHEIM-CHESTER DISEASE: DATA FROM A COHORT OF 10 PATIENTS AND REVIEW OF 

THE LITERATURE / G. Cavalli* - B. Guglielmi - C. Campochiaro - A. Berti - M. G. Sabbadini - L. Dagna 

THU0372 MRI QUANTIFICATION OF FAT INFILTRATION IN SKELETAL MUSCLE OF PATIENTS WITH CAMPTOCORMIA / S. Guis* - 

J. P. Mattei - Y. Le Fur - N. Cuge - E. Soulier - P. Cozzone - D. Bendahan 

THU0371 INCREASED EXPRESSION OF INFLAMMATORY CYTOKINES AND CHEMOKINES IN AN AUTOINFLAMMATORY 

DISORDER, NAKAJO-NISHIMURA SYNDROME. / K. Arima* - N. Kanazawa - F. Furukawa - H. Ida - K.Yoshiura 

THU0370 RISK INFECTION ASSESSMENT IN RHEUMATOID ARTHRITIS PATIENTS FROM THE PORTUGUESE BIOREPORTAR AND 

REGISTAR DATABASES / I. Silva* - F. Araújo - M. Mateus - J. C. Branco 

THU0369 SEPTIC ARTHRITIS: CHANGING TRENDS IN EPIDEMIOLOGY OVER TWO DECADES / R. Kalagate - A. Rivera - C. H. Pritchard 

- L. H. Brent* 

THU0368 RISK OF HERPES VIRUSES INFECTIONS (HSV,VZV) DURING ANTI-TNF THERAPY IN PATIENTS WITH INFLAMMATORY 

RHEUMATIC DISEASES. SYSTEMATIC REVIEW AND META-ANALYSIS / H. Che - J. Morel - B. Combe - C. Lukas* 

Poster Tour T10: Health Professionals Clinical aspects of care Hall 4.2 

Chairperson(s): Patricia Cornell (United Kingdom), Mwidimi Ndosi (United Kingdom) 

THU0466-HPR MAINTENANCE OF PHYSICAL ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS: A QUALITATIVE INTERVIEW 

STUDY / K. Loeppenthin* - B. A. Esbensen - T. Thomsen - J. Midtgaard 

THU0467-HPR A STANDARDIZED EDUCATIONAL PROGRAM DIRECTED TO PATIENTS FOR SELF-CARE PROMOTION CAN BE EQUALLY 

EFFECTIVE IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA), SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), 

ANKYLOSING SPONDYLITIS (AS) / L. Cano-García* - R. Navas-Fernández - F. G. Jiménez-Nuñez - I. Ureña - S. Manrique - 

C. M. Romero-Barco - V. Rodríguez-García - L. Nieves-Martín - M. Á. Belmonte-López - V. Coret - M. C. Ordóñez - M.V. Irigoyen 

- A. Fernández-Nebro 

THU0468-HPR MENTAL FUNCTIONING IN PATIENTS WITH RHEUMATOID ARTHRITIS OVER AN ELEVEN YEARS FOLLOW-UP PERIOD: 

THE ROLE OF COMORBIDITY / J. Van Den Hoek* - L. D. Roorda - H. Boshuizen - G. A. van den Bos - J. van Hees - I. Rupp - 

G. Tijhuis - J. Dekker 

THU0469-HPR SEXUAL PERCEPTION AND SEXUAL PROBLEMS IN PATIENTS WITH ANKYLOSING SPONDYLITIS / K. Hansen Berg* - 

A. Prøven - E. Almås - E. E. P. Benestad - M. Østensen - G. Haugeberg 

THU0470-HPR WILL I WASTE YOUR TIME? DELAYS IN HELP-SEEKING FOR RA FLARES / C. A. Flurey* - M. Morris - J. Pollock - R. Hughes 

- P. Richards - S. Hewlett 

THU0471-HPR CRYING WITHOUT TEARS: DIMENSIONS OF CRYING AND RELATIONS WITH OCULAR DRYNESS IN PATIENTS WITH 

SJÖGREN’S SYNDROME / N.Van Leeuwen* - E. R. Bossema - R. R.Vermeer - A. A. Kruize - H. Bootsma - J. W. Bijlsma - R. Geen 

THU0472-HPR CALIBRATION OF A MULTIDIMENSIONAL ITEM BANK TO MEASURE FATIGUE IN RHEUMATOID ARTHRITIS PATIENTS / 

S. Nikolaus* - C. Bode - E. Taal - C. Glas - M. van de Laar 

THU0481-HPR LESSONS FROM PATIENT REPORTED OUTCOMES OF BIOLOGIC TREATMENT: IMPROVEMENTS IN QUALITY OF LIFE 

AND HEALTH STATUS ARE STABLE OVER TIME DESPITE DECLINING PHYSICAL FUNCTION / T. Harrison* - C. Barnabe - 

L. Martin - S. G. Barr 

THU0482-HPR COMPARISON OF AGREEMENT AND RESPONSIVENESS TO TREATMENT EFFECTS OF 100MM VISUAL ANALOG SCALE 

AND 11 POINT NUMERICAL RATING SCALE TO ASSESS WRIST PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS / 

E. Taal* - M. M.Veehof - M. A. van de Laar 



51


52 

Genomics, genetics and epigenetics of rheumatic diseases 


Scientific Poster Session 1 11:45 - 13:30 

Scientific Poster Session 1 

THU0001 VARIATION IN GRANZYME-B IS ASSOCIATED WITH PROGRESSION OF JOINT DESTRUCTION IN RHEUMATOID 

ARTHRITIS / R. Knevel* - A. Krabben - G. Wilson - E. Brouwer - E. Lindqvist - D. de Rooy - N. Daha - M. van der Linden - 

R. Tsonaka - S. Zhernakova - H.-J. Westra - L. Franke - J. Houwing-Duistermaat - R. Toes - T. Huizinga - T. Saxne - A. van der 

Helm-van Mil 

THU0002 FINE MAPPING AND EXPRESSION STUDIES OF THE 12Q13-14 LOCUS ASSOCIATED WITH RHEUMATOID ARTHRITIS / 

A.Yarwood* - A. Barton - J. Bowes - P. Martin - J. Worthington - S. Eyre on behalf of RACI 

THU0003 FINE-MAPPING OF AUTOIMMUNE SUSCEPTIBILITY LOCI USING IMMUNOCHIP IDENTIFIES NOVEL SUSCEPTIBILITY 

LOCI FOR PSORIATIC ARTHRITIS / J. Bowes* - P. Ho - E. Korendowych - N. McHugh - J. Packham - I. N. Bruce - A. Barton 

THU0004 CAMP RESPONSIVE ELEMENT MODULATOR (CREM) ALPHA CONTRIBUTES TO DECREASED NOTCH-1 EXPRESSION IN 

T CELLS FROM PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) / T. Rauen* - A. Grammatikos - C. M. Hedrich - 

V. C. Kyttaris - K. Tenbrock - U. Raffetseder - J. Floege - G. C. Tsokos 

THU0005 AN IMMUNOCHIP BASED INTERROGATION OF SCLERODERMA SUSCEPTIBILITY VARIANTS / J. Charlesworth - 

J. Stankovich - P. Lewis - J. Byron - W. Stevens - J. Sahhar - S. Proudman - J. Roddy - P. Nash - K. Tymms - M. Brown - J. Zochling* 

THU0006 COMBINATORIAL CONTROL OF TH1 AND TH17 CELL FUNCTIONS BY SINGLE-NUCLEOTIDE POLYMORPHISMS AT 

GENES ASSOCIATED WITH THE IL-23 SIGNALING PATHWAY IN SPONDYLOARTHRITIS / L. Rogge* - M. Coffre - M. Roumier 

- M. Rybczynska - E. Sechet - H. Law - L. Gossec - M. Dougados - E. Bianchi 

THU0007 ANALYSIS OF PROTEIN ACETYLATION AND HISTONE DEACETYLASE EXPRESSION IN THE SYNOVIAL TISSUE REVEALS 

COMPLEX RELATIONSHIPS BETWEEN EPIGENETIC REGULATORY MECHANISMS AND INFLAMMATION IN RHEUMA- 

TOID ARTHRITIS / A. M. Grabiec* - C. Ospelt - L. G. M. van Baarsen - I. E. van Es - S. Gay - P. P. Tak - K. A. Reedquist 

THU0008 META-ANALYSIS OF THE ASSOCIATION OF SMOKING AND PTPN22 R620W GENOTYPE ON AUTOANTIBODY STATUS 

AND RADIOLOGICAL EROSIONS IN RHEUMATOID ARTHRITIS / L. H.Taylor* - S.Twigg - J. J.Worthington - P. Emery - A.W. Morgan 

- A. G. Wilson - M. D. Teare on behalf of UKRAGG 

THU0009 DIFFERENTIAL EXPRESSION OF DKK1 IN SYNOVIAL FIBROBLASTS FROM RESOLVING AND EARLY RHEUMATOID 

ARTHRITIS / M. Juarez* - D. Scheel Toellner - L.Yeo - K. Howlett - R. Bayley - B. de Paz - R. Hardy - K. Raza - M. Cooper - C. Buckley 

- A. Filer 

THU0010 TRANSCRIPTIONAL PROFILING OF RHEUMATOID ARTHRITIS FIBROBLAST-LIKE SYNOVIOCYTES IDENTIFIES A SUBSET 

OF INFLAMMATORY GENES WITH AU-RICH 3’-UNTRANSLATED REGIONS WHICH ARE SUPPRESSED BY HISTONE 

DEACETYLASE INHIBITORS VIA REDUCTION OF MRNA STABILITY / A. M. Grabiec* - A. M. Willemsen - A. H. C. van Kampen 

- P. P. Tak - K. A. Reedquist 

THU0011 MIR-223 EXPRESSION IN SERUM AND CD3+ PERIPHERAL CELLS OF RHEUMATOID ARTHRITIS / I. Muscari - C. Giannitti* 

- S. Niccolini - I. Fineschi - G. D. Sebastiani - I. Prevete - A. Iuliano - E. Balistreri - I. Gennai - G. Minisola - A. Spreafico - 

M. Galeazzi 

THU0012 TGFµ RECEPTOR POLYMORPHISMS IN SYSTEMIC SCLEROSIS RELATED PULMONARY ARTERIAL HYPERTENSION: 

RESULTS FROM A MULTICENTER EUSTAR STUDY OF EUROPEAN CAUCASIAN PATIENTS / E. Koumakis* - J. Wipff - M. 

Matucci-Cerinic - G. Riemekasten - P. Airo - D. Cusi - H. E. Wichmann - U. Müller-Ladner - P.Vlachoyiannopoulos - G. Chiocchia 

-Y. Allanore on behalf of EUSTAR network 

THU0013 INTERACTION BETWEEN TWO COMMON HLA ANTIGENS DEFINES A SUBSET OF INDIVIDUALS AT A VERY HIGH RISK 

FOR ANKYLOSING SPONDYLITIS / F. van Gaalen* - W.Verduyn - D. Roelen - S. Böhringer - T. Huizinga - D. van der Heijde - 

R. Toes 

THU0014 ASSOCIATION BETWEEN A POLYMORPHISM IN THE FRACTALKINE RECEPTOR, CX3CR1, AND RHEUMATOID 

ARTHRITIS / J. Stack* - K. Hegarty - G. Murphy - M. O'Sullivan - L. Fanning - L. Healy - M. Daly - S. Harney - F. Shanahan - 

M. Molloy 

THU0015 ASSOCIATION OF ACID PHOSPHATASE LOCUS 1*C ALLELE WITH THE RISK OF CARDIOVASCULAR EVENTS IN 

RHEUMATOID ARTHRITIS PATIENTS / M. Teruel* - J.-E. Martin - C. González-Juanatey - R. López-Mejias - J. A. Miranda-Filloy 

- R. Blanco - A. Balsa - D. Pascual-Salcedo - L. Rodriguez-Rodriguez - B. Fernández-Gutierrez - A. M. Ortiz - I. González-Alvaro 

- C. Gómez-Vaquero - N. Bottini - J. Llorca - M. A. González-Gay - J. Martin 

THU0016 INVESTIGATION OF RA GENETIC SUSCEPTIBILITY LOCI CONTRIBUTION TO RESPONSE OUTCOMES FOLLOWING 

CONVENTIONAL DMARD TREATMENT IN EARLY RA / M. D. Morgan* - S. Twigg - E. M. A. Hensor - P. G. Conaghan - 

J. Worthington - P. Emery - J. H. Barrett - A. W. Morgan on behalf of YEAR Consortium 

THU0017 GENETIC MARKERS OF METOTHREXATE ADVERSE REACTIONS IN RHEUMATOID ARTHRITIS PATIENTS / N. Dostanko* 

- V.Yagur 

THU0018 SUMO SPECIFIC PROTEASES 5 AND 7 CONTRIBUTE TO THE INBALANCED SUMOYLATION LEVEL OF RHEUMATOID 

ATHRITIS SYNOVIAL FIBROBLASTS / S. Strietholt* - M. A. Peters - S. Frank - A. Hillmann - G. Kollias - T. Pap 

THU0019 GENOME-WIDE PATHWAY ANALYSIS OF GENOME-WIDE ASSOCIATION STUDIES ON PSORIASIS AND BEHCET’S 

DISEASE / Y. H. Lee* 

* Presenting author



Cartilage, synovium and osteoimmunology 

THU0020 SERUM PYRIDINOLINE LEVELS PREDICT THE SEVERITY OF FUTURE JOINT DESTRUCTION IN RHEUMATOID ARTHRITIS 

/ A. Krabben* - R. Knevel - T. W. J. Huizinga - G. Cavet - A. H. M. van der Helm-van Mil 

THU0021 CARTILAGE ZONE SPECIFIC PROTEINS: A QUANTITATIVE PROTEOMIC ANALYSIS / P. Fernández-Puente - L. Lourido - 

V. Calamia - J. Mateos - C. Ruiz-Romero - M. Lotz - F. J. Blanco* 

THU0022 ENHANCED EXPRESSION OF SUPPRESSOR OF CYTOKINE SIGNALING 3 IN ARTHRITIC CARTILAGE DYSREGULATES 

HUMAN CHONDROCYTE FUNCTION / F.Van De Loo* - B. van den Brand - S.Veenbergen - M. Bennink - E. Blaney-Davidson 

- H. van Beuningen - P. van der Kraan - W. van den Berg 

THU0023 A NOVEL ROLE FOR ELR+ CXC CHEMOKINE SIGNALING IN CARTILAGE HOMEOSTASIS / J. Sherwood* - G. Nalesso - 

J. Bertrand - P. Achan - L. Brandolini - T. Pap - C. Pitzalis - F. Dell'Accio 

THU0024 DIFFERENCES BETWEEN HEALTHY AND OSTEOARTHRITIS PROTEOMIC PROFILES OF BONE MARROW MESEN- 

CHYMAL STEM CELLS UNDERGOING CHONDROGENESIS / B. Rocha - V. Calamia - J. Mateos - P. Fernández-Puente - 

L. Lourido - C. Fernández-Costa - C. Fernández-López - N. Oreiro - C. Ruiz-Romero - F. J. Blanco* 

THU0025 EXPRESSION OF INTERLEUKIN-20 AND ITS RECEPTORS IN OSTEOBLASTS AND OSTEOCLASTS IN BONE TISSUE FROM 

PATIENTS WITH RHEUMATOID ARTHRITIS / J. Rømer* - P. A. Usher - M. N. Nielsen - J. Mandelbaum - M. Jackerott 

THU0026 P62/SQSTM1 LINKS REACTIVE OXYGEN SPECIES FORMATION AND OBESITY TO INCREASED TNFALPHA-MEDIATED 

JOINT DESTRUCTION VIA ITS SIGNALLING DOMAINS / A. Korb-Pap* - A. Hillmann - M. Heitzmann - S. Bürgis - G. Kollias 

- S. Hermann - M. Schäfers - A. Gessner - T. Pap - T. Weide - H. Pavenstädt 

THU0027 TREM-1 STIMULATION INHIBITS HUMAN OSTEOCLASTOGENESIS VIA DOWN-REGULATION OF M-CSF RECEPTOR 

EXPRESSION / B. Lee* - T.-H. Kim - E. Kwon - S. J. Choi - Y. H. Lee - J. Sohn - G. G. Song - J. D. Ji 

THU0028 FIBROBLAST-LIKE SYNOVIOCYTES INHIBIT TNF- AND RANKL-INDUCED HUMAN OSTEOCLAST PRECURSOR DIFFER- 

ENTIATION FOLLOWING EXPOSURE TO IL-1BETA / B. P. Harvey* - F. Syed - Z. Kaymakcalan 

THU0029 ANATOMICAL VARIATION IN THE MORPHOLOGY OF THE POSTERIOR CRUCIATE LIGAMENT SYNOVIO-ENTHESEAL 

COMPLEX AND CORRELATION WITH DEGENERATIVE CHANGE / D. Binks* - D. Bergin - A. Hindley - D. McGonagle - 

A. Radjenovic 

THU0030 EVIDENCE FOR GOOD INTRINSIC MESENCHYMAL STEM CELL ACTIVITY IN GELATINOUS HEBERDEN’S NODES IN 

OSTEOARTHRITIS AT CLINICAL PRESENTATION / T. Baboolal - S. Boxall - C. Buckley - A. L. Tan - S. Churchman - S. Calder - 

D. Kouroupis - P. Giannoudis - R. Hodgson - E. Jones - D. McGonagle* 

THU0031 BLOCKING AVB3 INTEGRIN WITH CILENGITIDE AFFECTS OSTEOCLASTOGENESIS IN VITRO AND PREVENTS 

COLLAGEN INDUCED ARTHRITIS IN VIVO / D. Sykoutri* - G. Nisha - S. Hayer - P. Mandl - J. S. Smolen - G. Prager - K. Redlich 

THU0032 INVOLVEMENT OF ER STRESS SIGNALS, PERK, IRE1, GRP78 IN RANKL-INDUCED, C-FOS AND NFATC1-MEDIATED 

OSTEOCLASTOGENESIS / W.-H.Yoo - E.-G. Lee* - M.-S. Sung - M. J. Hong - Y. K. Hong - C.-H. Lee - M. S. Lee 

THU0033 SET7/9 AND SIRT1 INDUCE PROMOTER-DRIVEN COLLAGEN 2ALPHA1 EXPRESSION IN 3D CULTURED HUMAN 

CHODROCYTES / H. Oppenheimer* - H. Meir - A. Haze - L. Kandel - M. Leibergall - M. Dvir-Ginzberg 

THU0034 RHEUMATOID ARTHRITIS BONE FRAGILITY IS ASSOCIATED WITH INCREASED DKK1 EXPRESSION AND DISTUR- 

BANCES IN THE BONE TURNOVER REGULATING GENES / J. Caetano-Lopes* - A. Rodrigues - A. Lopes - A. C. Vale - 

J. Monteiro - M. F.Vaz - A. Nazarian - H. Canhão - J. E. Fonseca 

THU0035 THROMBIN AND PLASMIN INDUCED PROTEOGLYCAN RELEASE IN HUMAN CARTILAGE IS PAR-DEPENDENT / 

L. Nieuwenhuizen* - R. Schutgens - G. Roosendaal - S. Mastbergen - D. Biesma - F. Lafeber 

THU0036 PPAR GAMMA AGONIST ROSIGLITAZONE COULD INHIBIT RA-FLS INDUCED OSTEOCLASTOGENESIS BY DOWN- 

REGULATING RANKL EXPRESSION AND SUPPRESSION OF ERK PHOSPHORYLATION / X. N. Wei - L. Dai* - L. J. Zhu - 

Y. Q. Mo - D. H. Zheng - B.Y. Zhang 

THU0037 IMMUNE COMPLEX-INDUCED INHIBITION OF OSTEOCLASTOGENESIS IS MEDIATED VIA ACTIVATING, BUT NOT 

INHIBITORY FCGAMMA RECEPTORS ON MYELOID PRECURSOR CELLS / L. C. Grevers* - P. L. van Lent - T. J. de Vries - 

V. Everts - W. B. van den Berg 

THU0038 HISTOLOGIC FEATURES OF OSTEOCHONDRAL JUNCTION IN JOINT DISORDERS / O. Addimanda* - B. Pavloska - L. Pulsatelli 

- G. Lisignoli - A. Facchini - R. Meliconi 

THU0039 EVIDENCE OF HLA-B27 IN HEALTHY INDIVIDUALS AND PATIENTS WITH UVEITIS IS A RISK FACTOR FOR ALTERATIONS 

IN BONE METABOLISM / S. Schmidt* - S. Finzel - J. Rech - M. Englbrecht - R. Said-Nahal - M. Breban - G. Schett 

THU0040 HISTOLOGY OF NASAL TISSUE DESTRUCTION IN GPA PATIENTS IS REFLECTED IN HUMAN TISSUE TRANSPLANTS OF 

GPA PATIENTS IN IMMUNODEFICIENT MICE / S. Ullrich* - N. Kesel - U. Schumacher - W. L. Gross - M. Laudien - A. Müller 

- K. Holl-Ulrich 

THU0041 GROWTH FACTORS INFLUENCE ADHESIVE PROPERTIES OF FIBROBLASTS FROM PATIENTS WITH RHEUMATOID 

ARTHRITIS, OSTEOARTHRITIS AND SYSTEMIC SCLEROSIS / S. Lefevre* - A. Lehr - S. Rehart - M. Rickert - J. Steinmeyer - 

A. Günther - U. Müller-Ladner - E. Neumann 

THU0042 THE DEVELOPMENT AND CHARACTERISATION OF COMPETITION ELISA FOR MEASUREMENT OF ACTIVE ADAMTS-4 

IN SERUM AND SYNOVIAL FLUID / Y. He - Q. L. Zheng - M. A. Karsdal - A.-C. Bay-Jensen* 



53


54 

Rheumatoid arthritis - comorbidity and clinical aspects 

THU0043 PREVALENCE OF CEREBRAL AMYLOID ANGIOPATHY IN RHEUMATOID ARTHRITIS / Á. Apáthy* - M. Bély 



THU0044 DIFFERENT TYPE OF CAROTID ARTERIAL WALL REMODELING IN RHEUMATOID ARTHRITIS AS COMPARED TO 

HEALTHY SUBJECTS / A. M. Van Sijl* - K. van den Hurk - M. J. Peters - V. P. van Halm - G. Nijpels - C. D. Stehouwer - 

Y. M. Smulders - A. E.Voskuyl - J. M. Dekker - M. T. Nurmohamed 

THU0045 SCORE AND FRAMINGHAM PREDICT CV DISEASE INCIDENCE IN RA PATIENTS BETTER THAN INTIMA-MEDIA THICK- 

NESS / A. M. Van Sijl* - I. A. van den Oever - H. G. Raterman - M. J. Peters - V. P. van Halm - M. Boers - Y. M. Smulders - 

A. E. Voskuyl - M. T. Nurmohamed 

THU0046 PREVALENCE OF VITAMIN D DEFICIENCY IN RHEUMATOID ARTHRITIS PATIENTS: ASSOCIATION WITH ANAEMIA OF 

INFLAMMATION AND EFFECT OF VITAMIN D SUPPLEMENTATION / A. Abou-Raya* - S. Abou-Raya - M. Helmii 

THU0047 CAROTID PLAQUE CHARACTERISTICS ARE ASSOCIATED WITH DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS / A. G. P. Semb* 

- S. Rollefstad - S. Provan - T. K. Kvien - E. Stranden - I. Olsen - J. Hisdal 

THU0048 RADIUS 1: CORRELATION BETWEEN SERIOUS INFECTION EVENTS (SIES) AND RHEUMATOID ARTHRITIS (RA) DISEASE 

ACTIVITY IN PATIENTS REQUIRING A CHANGE IN THERAPY / A. Weaver* - O. Troum - M. Hooper - A. Koenig - S. Chaudhari 

- J.-Y. Feng - D. Wenkert 

THU0049 A PROPOSED EFFECTIVE STRATEGY TO SCREENING LATENT TB INFECTION IN RA PATIENTS / B. Mehta* - E. Zapantis - 

O. Petryna - P. Efthimiou 

THU0050 CARDIOVASCULAR RISK IN KOREAN PATIENTS WITH RHEUMATOID ARTHRITIS / C.-B. Choi* - Y.-K. Sung - S.-K. Cho - 

S.-Y. Park - J. Shim - J. J. Kim - C. N. Son - S.-C. Bae on behalf of KORONA investigators 

THU0051 AUTOINMUNE THYROID DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS: CASE – CONTROL STUDY / R. Gomez 

- J. M. Gutierrez - D. G. Fernandez-Avila* - M. C. Diaz - P. Aschner on behalf of Javeriana Investigation Group in Rheumatic 

Diseases 

THU0052 DURATION AND SEVERITY OF THE DISEASE IS IMPORTANT RISK FACTOR FOR CARDIAC AUTONOMIC NEUROPATHY 

AND ARTERIAL STIFFNESS IN WOMEN WITH RHEUMATOID ARTHTRITIS / D. S. Novikova* - T. Popkova - E. Udachkina - 

T. Lisitsyna - A. Novikov - E. Alexandrova - A.Volkov - E. Nasonov 

THU0053 REDUCED ENDOTHELIUM-INDEPENDENT VASCULAR REACTIVITY IS INDICATIVE OF CAROTID ATHEROSCLEROSIS IN 

PATIENTS WITH RHEUMATOID ARTHRITIS WITHOUT OVERT CARDIOVASCULAR DISEASE / E. Myasoedova* - S. Myasoedova 

- S. Obzherina - N. Svyatova - N. Shostak 

THU0054 URINARY TRACT INFECTIONS IN PATIENT WITH RHEUMATIC DISEASE: A RETROSPECTIVE STUDY / E. Sahinbegovic* - 

J. Zwerina - B. Parschalk - G. Schett - M. Englbrecht 

THU0055 INTERSTITIAL PNEUMONITIS ASSOCIATED WITH RHEUMATOID ARTHRITIS IS MORE PREVALENT IN AGED MALE 

WITH A HIGHER RF LEVEL, AND FREQUENTLY COMBINED WITH EMPHYSEMA / E. Matsubara* - S. Okiyama - S. Inokuma 

- K. Onishi - S. Nakachi - H. Asashima - K. Wakabayashi - K. Hagiwara - S. Kobayashi 

THU0056 IMPAIRED BETA CELL SIGNALING IS PRESENT IN NON DIABETIC RHEUMATOID ARTHRITIS PATIENTS / I. Ferraz-Amaro 

- M. González-Gay -V. Hernández-Hernández - M. Arce-Franco - E. Delgado-Frías* - M. Gantes - J. Muñiz - M. Dominguez-Luis 

- A. Herrera-García - J. Garcia-Dopico - L. Medina-Vega - A. Rodríguez-Vargas - F. Diaz-Gonzalez 

THU0057 DIFFERENTIAL IMPACT OF TRADITIONAL CARDIAC RISK FACTORS ON CORONARY PLAQUE PREVALENCE IN 

CORONARY ARTERY DISEASE (CAD)-NAÏVE SUBJECTS WITH RHEUMATOID ARTHRITIS COMPARED TO CONTROLS / 

G. A. Karpouzas* - J. Malpeso - T.-Y. Choi - S. Munoz - M. Budoff 

THU0058 PERIODONTAL DISEASE IS ASSOCIATED WITH RHEUMATOID ARTHRITIS (RA) BUT ITS SEVERITY IS NOT CORRELATED 

WITH RA DISEASE ACTIVITY / I. A. Choi* - J.-H. Kim - Y. M. Kim - K. H. Kim - H. W. Kim - K. Shin - E.Y. Lee - E. B. Lee - Y.-M. Lee 

-Y. W. Song 

THU0059 REDUCTION OF INFLAMMATION WITH ABATACEPT AND TOCILIZUMAB RESULTS IN LOWER N-TERMINAL PRO BRAIN 

NATRIURETIC PEPTIDE LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM TWO PROSPECTIVE 

COHORT STUDIES / I.V. D. Oever* - M. T. Nurmohamed 

THU0060 RISK FACTORS OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS / J. Kur-Zalewska * - 

M. Tlustochowicz - W. Tlustochowicz 

THU0061 ANEMIA IN PATIENTS WITH RHEUMATOID ARTHRITIS: A CROSS-SECTIONAL STUDY / J. Back* - E. Baecklund - G. Birgegard 

THU0062 ANALYSIS OF PERIOPERATIVE CLINICAL FEATURES AND COMPLICATIONS IN PATIENTS WITH RHEUMATOID 

ARTHRITIS TREATED WITH BIOLOGIC AGENTS / K. Ishii* - Y. Mochida - K. Harigane - Y.Yamada - N. Mitsugi - T. Saito 

THU0063 DOES BIOLOGIC TREATMENT MODIFY THE RELATIONSHIP OF THE VARIABLES ASSOCIATED WITH FATIGUE IN 

PATIENTS WITH RHEUMATOID ARTHRITIS? THE PEPS STUDY OF TOCILIZUMAB IN REAL LIFE / L. Gossec* - S. Rouanet - 

G. Steinberg - B. Combe 

THU0064 COMPARISON OF ESTIMATED FRACTURE RISK USING THE FRAX INDEX CALCULATED WITH AND WITHOUT BONE 

DENSITOMETRY IN PATIENTS WITH EARLY ARTHRITIS / L. Del Olmo* - P. Aguado - J. Coya - L. Lojo - L. Nuño - S. Gil - 

E. Martín Mola - A. Balsa 

THU0065 ROLE OF RETINOL BINDING PROTEIN 4 IN INSULIN RESISTANCE OF RHEUMATOID ARTHRITIS PATIENTS / M. Flores- 

Rodríguez* - I. Ferraz-Amaro - V. Hernández-Hernández - J.Viotti - C. Rodríguez de la Rosa - M. González-Gay - M. Arce-Franco 

- E. Delgado-Frías - M. Gantes - J. Muñiz - M. Dominguez-Luis - A. Herrera-García - J. García-Dopico - L. Medina-Vega - 

A. Rodríguez-Vargas - F. Diaz-Gonzalez 

* Presenting author



THU0066 SMOKING FUNCTIONS AS A NEGATIVE REGULATOR OF IGF-1 LEVELS AND ACTIVATES THE CASCADE OF ADIPOKINE 

SIGNALING MOLECULES IN PATIENTS WITH RHEUMATOID ARTHRITIS / R. Doria Medina - M. Erlandsson - S. Lindblad 

Silfverswärd - M. Bokarewa* 

THU0067 USE OF CARDIOVASCULAR DRUGS IN PATIENTS WITH RA, OVERALL AND IN PATIENTS WITH A HISTORY OF ACUTE 

ISCHEMIC CARDIAC EVENTS / M. Holmqvist* - J. Eriksson - J. Askling 

THU0068 PREVALENCE OF DYSLIPIDAEMIA IN AN EARLY ARTHRITIS RHEUMATOID COHORT (ESPOIR COHORT). LACK OF 

IMPROVEMENT AFTER 4 YEARS OF FOLLOW-UP / M. Margerit* - P. Nguyen - B. Pereira - Y. Allanore - X. Le Loët - A. C. Rat - 

M. Soubrier 

THU0069 INCREASED RATE OF DIASTOLIC HEART FAILURE IN RHEUMATOID ARTHRITIS CORRELATES WITH SYSTEMIC 

INFLAMMATION AND PERSISTENT DISEASE ACTIVITY, INDEPENDENT FROM TREATMENT STRATEGY / M. Gottwald* - 

T. Schau - M. Neuss - D. Ridjab - I. Fischer - C. Butter - M. Zaenker 

THU0070 RHEUMATOID ARTHRITIS WITH MULTIFOCAL MIGRATORY VASCULOGENIC PNEUMONIA REFRACTORY TO ANTIBI- 

OTICS / M. Bély* - Á. Apáthy 

THU0071 HOSPITALIZATION AND RISK OF HOSPITALIZED INFECTION IN PATIENTS WITH RHEUMATOID ARTHRITIS BASED ON 

IORRA COHORT / N. Sugimoto* - A. Nakajima - E. Inoue - A. Kobayashi - D. Hoshi - K. Shidara - E. Sato - Y. Seto - E. Tanaka - 

A. Taniguchi - S. Momohara - H.Yamanaka 

THU0072 FREQUENCY OF FALLS AND FALL-RELATED RISK FACTORS IN PATIENTS WITH RHEUMATOID ARTHRITIS / N.Toroptsova* 

- O. Nikitinskaya 

THU0073 A PROPOSED MECHANISM FOR AUTONOMIC DYSFUNCTION IN RHEUMATOID ARTHRITIS – REDUCED VAGAL 

ACTIVITY RELATED TO HIGH INTRATHECAL IL-1B LEVELS / R. Altawil* - D. ,. Kadetoff, - M. Westman - M. Jensen-Urstad - 

M. Andersson - E. Kosek - J. Lampa 

THU0074 DIFFERENT RISK FACTORS ARE ASSOCIATED WITH SERIOUS INFECTION IN RHEUMATOID ARTHRITIS PATIENTS WITH 

AND WITHOUT PULMONARY COMORBIDITIES; ANALYSES FROM THE REAL DATABASE / R. Sakai* - M. Tanaka - T. Nanki 

- H.Yamazaki - K. Watanabe - R. Koike - N. Miyasaka - M. Harigai on behalf of the REAL Study Group 

THU0075 THE RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH RHEUMATOID ARTHRITIS COMPARED TO THE 

GENERAL POPULATION: A VERY LARGE COHORT STUDY / S. C. Kim* - S. Schneeweiss - J. Liu - D. H. Solomon 

THU0076 STRAIN ECHOCARDIOGRAPHY FOR THE EVALUATION OF MYOCARDIAL FUNCTION IN PATIENTS WITH RHEUMATOID 

ARTHRITIS / N. M. Fine - C. S. Crowson - G. Lin - J. K. Oh - H. R.Villarraga - S. E. Gabriel* 

THU0077 CONCOMITANT FIBROMYALGIA AND DEPRESSION MIGHT BE A CAUSE OF DISCREPANCY BETWEEN BOOLEAN 

REMISSION AND DAS28 REMISSION IN RHEUMATOID ARTHRITIS / S.Yimaz Öner* - M. Can - P. Atagündüz - H. Direskeneli 

- N. Inanç 

THU0078 POLYMORPHISMS OF THE GENES ENCODING CD40 AND GROWTH DIFFERENTIATION FACTOR 15 AND IN THE 9P21.3 

REGION IN PATIENTS WITH RHEUMATOID ARTHRITIS AND CARDIOVASCULAR DISEASE / S. Rantapää Dahlqvist* - 

L. Ärlestig 

THU0079 FATIGUE IN RHEUMATOID ARTHRITIS PATIENTS: THE IMPACT OF DISEASE ACTIVITY, PAIN, DISABILITY AND DEPRES- 

SIVE DISORDERS / T. A. Lisitsyna * - O. Seravina - O. Kovalevskaya - D. Veltishchev - A. Zeltyn - D. Novikova - T. Popkova - 

A. Novikov - E. Alexandrova - E. Nasonov 

THU0080 EFFICACY OF VACCINATION AGAINST PANDEMIC A H1N1 INFLUENZA IN JAPANESE PATIENTS WITH RHEUMATOID 

ARTHRITIS - ANALYSIS FROM THE IORRA COHORT - / T. Kobashigawa* - A. Nakajima - E. Tanaka - E. Inoue - A. Taniguchi - 

S. Momohara - H.Yamanaka 

THU0081 ASSESSING THE CARDIOVASCULAR RISK BURDEN IN PATIENTS WITH RHEUMATOID ARTHRITIS: ROLE OF ANNUAL 

REVIEW CLINIC / V. Patel* - U. Karjigi - R. Abernethy - J. Dawson - A. Clewes - J. Novak - A. Cox - J. Williams - T. O'Rourke 

THU0082 AN EVALUATION OF FLARE IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS USING THE OMERACT PRELIMINARY 

FLARE QUESTIONNAIRE / V. P. Bykerk* - S. J. Bartlett - E. Choy - G. Boire - C. Hitchon - J. Pope - C. Thorne - B. Haraoui - 

E. Keystone - C. O. Bingham III on behalf of CATCH 

THU0083 ABNORMAL VOLUMETRIC DENSITY AND MICROARCHITECTURE AT THE RADIUS IN CHINESE FEMALE PATIENTS WITH 

RHEUMATOID ARTHRITIS: A CASE-CONTROL STUDY / Y. Zhu* - E. K. Li - V. W. Hung - P.-C. Leung - A. W. Kwok - L. Qin - 

L.-S. Tam 

THU0084 THE RELATIONSHIP BETWEEN SERUM LEPTIN:ADIPONECTIN RATIO, INSULIN RESISTANCE, AND CAROTID ATHERO- 

SCLEROSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS / Y. Kang* - M. I. Kang - H. J. Park - S. W. Lee - S. K. Lee - Y. B. Park 

THU0085 DEPRESSION AND ITS RELATIONSHIPS IN MOROCCAN PATIENTS WITH RHEUMATOID ARTHRITIS / Y. Ibn Yacoub* - 

B. Amine - S. El kabbaj - N. Hajjaj-Hassouni 

Rheumatoid arthritis - other biologic treatment 

THU0086 SEROPOSITIVITY AND RESPONSE TO RTX: DATA FROM THE CERERRA COLLABORATION / K. Chatzidionysiou* - E. Lie - 

E. Nasonov - G. Lukina - M. Hetland - U. Tarp - I. Ancuta - K. Pavelka - D. Nordström - C. Gabay - H. Canhao - M. Tomsic - 

P. van Riel - J. Gomez-Reino - T. Kvien - R. van Vollenhoven 

THU0087 ONE SINGLE INFUSION OF RITUXIMAB 1G MIGHT BE SUFFICIENT IN THE LONG-TERM MANAGEMENT OF RHEUMA- 

TOID ARTHRITIS PATIENTS RESPONDING TO A FIRST CYCLE OF RITUXIMAB (2 X 1G): RESULTS OF A 2-YEAR MULTI- 

CENTER RANDOMIZED CONTROLLED TRIAL / M. Dougados* - B. Combe - X. Le Loët - J. Tebib - J. Sibilia - S. Rouanet - 

R. Jourdan - X. Mariette 



55


56 



THU0088 ABNORMAL MEMORY B-CELL RECONSTITUTION FOLLOWING ANTI-CD20 THERAPY FOR AUTOIMMUNE DISEASES 

PREDICTS CLINICAL RELAPSE / G. Arumugakani* - A. Rawstron - R. Tooze - A. Cherukuri - A. Varghese - E. Vital - P. Emery - 

D. McGonagle 

THU0089 RESPONSE TO ABATACEPT AND TOCILIZUMAB IN PATIENTS WHO HAD FAILED RITUXIMAB– INITIAL SINGLE CENTRE 

EXPERIENCE / S. Das* - S. Horton - E.Vital - D. Bryer - P. Emery - M. Buch 

THU0090 SAFETY AND EFFICACY OF ATACICEPT IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RHEUMATOID 

ARTHRITIS: RESULTS FROM THE ATACICEPT FOR REDUCTION OF SIGNS AND SYMPTOMS IN RHEUMATOID ARTHRITIS 

TRIAL (III) / R. F. van Vollenhoven* - S. Wax - S. Copt - P. P. Tak 

THU0091 COMPARISON OF THE CLINICAL UTILITY OF ANTI-IL-6 RECEPTOR ANTIBODY THERAPY AND ANTI-TNF THERAPY IN 

AA AMYLOIDOSIS IN RHEUMATIC DISEASE / Y. Okuda* - M. Ohnishi - K. Takasugi 

THU0092 THE ADVANTAGE OF EARLY INTERVENTION BY TOCILIZUMAB FOR RHEUMATOID ARTHRITIS - FULL ANALYSIS OF 

ALL-CASE POSTMARKETING SURVEILLANCE IN 7,901 PATIENTS IN JAPAN / H.Yamanaka* - M. Harigai - S. Inokuma - N. Ishiguro 

- J. Ryu - S. Takei - T. Takeuchi - Y. Tanaka - Y. Sano - T. Koike 

THU0093 CLINICAL, RADIOGRAPHIC, AND IMMUNOGENIC EFFECTS AFTER 1 YEAR OF TOCILIZUMAB (TCZ)-BASED TREATMENT 

STRATEGY WITH AND WITHOUT METHOTREXATE (MTX) IN RA: THE ACT-RAY STUDY / M. Dougados* - K. Kissel - 

P. G. Conaghan - E. Martin-Mola - G. Schett - H. Amital - R. M. Xavier - O. Troum - C. Bernasconi - T. W. J. Huizinga 

THU0094 DIRECT COMPARISON OF FOUR BIOLOGICAL AGENTS IN BIO-NAÏVE RHEUMATOID ARTHRITIS PATIENTS / Y.Yonemoto* 

- K. Okamura - K. Takeuchi - M. Matsushita - T. Kaneko - T. Kobayashi - T. Aramaki - K. Takagishi 

THU0095 EARLY RESPONSE TO ABATACEPT PLUS MTX IN MTX-IR RA PATIENTS USING POWER DOPPLER ULTRASONOGRAPHY: 

AN OPEN-LABEL STUDY / M. D’Agostino* - R. Wakefield - H. Berner Hammer - O.Vittecoq - M. Galeazzi - P. Balint - E. Fillipucci 

- I. Moller - A. Iagnocco - E. Naredo - M. Ostergaard - C. Gaillez - W. Kerselaers - K. Van Holder - M. Le Bars on behalf of 

OMERACT-US Task Force 

THU0096 MAVRILIMUMAB IN RHEUMATOID ARTHRITIS: RESULTS OF A PHASE 2 DOUBLE-BLIND, PLACEBO CONTROLLED 

STUDY / G. Burmester* - M. Weinblatt - I. McInnes - O. Barbarash - E. Esfandieri - M. Sleeman - A. Godwood - F. Magrini on 

behalf of EARTH Study group 

THU0097 SYSTEMATIC REVIEW OF THE SAFETY OF PROTEIN KINASE INHIBITORS IN CLINICAL TRIALS IN RHEUMATOID 

ARTHRITIS / E. Salgado* - J. R. Maneiro - L. Carmona - J. J. Gomez-Reino 

THU0098 LONG-TERM EFFECTS OF RITUXIMAB ON B-CELL COUNTS AND AUTOANTIBODY PRODUCTION IN RHEUMATOID 

ARTHRITIS: USE OF HIGH-SENSITIVITY FLOW-CYTOMETRY FOR MORE SENSITIVE ASSESSMENT OF B-CELL DEPLE- 

TION / A.Váncsa* - L. Gergely - Z. Szabó - S. Szilvia - N. Bodnár - E.Végh - G. Szücs - S. Szántó - Z. Szekanecz 

THU0099 MONITORING OF ABATACEPT IN RHEUMATOID ARTHRITIS PATIENTS WITH PREVIOUS FAILURE TO BIOTHERAPIES 

SUGGESTS THAT CTLA-4/CD3E AND/OR CD28/CTLA-4 MRNA RATIO MAY PREDICT RESPONSE TO TREATMENT AT 3 

MONTHS / A. Eljaafari* - M.-L. Tartelin - H. Aissaoui - P. Miossec 

THU0100 RESULTS FROM A 2-PART, PROOF-OF-CONCEPT, DOSE-RANGING, RANDOMIZED, DOUBLE-BLIND, PLACEBO- 

CONTROLLED, PHASE 2 STUDY OF SIRUKUMAB, A HUMAN ANTI-IL-6 MONOCLONAL ANTIBODY, IN PATIENTS WITH 

ACTIVE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY / B. Hsu* - S. Sheng - J. S. Smolen - M. E. Weinblatt 

THU0101 SECONDARY LOSS OF EFFICACY OF RITUXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: HOW OFTEN DOES IT 

OCCUR AND WHAT DOES IT MEAN? / C. Marin- Huertas* - E. Becerra - I. De la Torre - G. Cambridge - J. C. Edwards - 

M. J. Leandro 

THU0102 EULAR-DAS28 VERSUS RAPID3 FOR TREATMENT MONITORING IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED 

WITH RITUXIMAB / C. M. Ancuta* - C. Belibou - E. Ancuta - S. Miu - R. Chirieac 

THU0103 SYNOVIAL PLASMA CELLS PREDICT RELAPSE AFTER RITUXIMAB THERAPY IN RHEUMATOID ARTHRITIS / E.Vital* - 

Y. M. El-Sherbiny - K. Henshaw - S. Dass - S. Das - M. Buch - F. Ponchel - P. Emery 

THU0104 NO EXPRESSION OF AN ALTERNATIVE CD20 TRANSCRIPT VARIANT IN B CELLS FROM PATIENTS WITH RHEUMATOID 

ARTHRITIS / M. Deschamps - B. Gaugler - P. Saas - C. Ferrand - E. Toussirot* on behalf of CIC Biotherapy 506 

THU0105 EFFECT OF SIRUKUMAB ON HEPCIDIN LEVELS AND MARKERS OF ANEMIA: RESULTS OF A PHASE 2B TRIAL IN 

PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY / G. Toedter* - S. Sague - X. Wu - 

M. Curran - B. Hsu 

THU0106 RITUXIMAB AFTER FIRST ANTI-TNF FAILURE IS MORE EFFICIENT WITH HIGH IMPACT IN REDUCING TIME AND COSTS 

TO ACHIEVE SUPERIOR RATES OF LOW DISEASE ACTIVITY AND REMISSION / I. Ancuta* - C. Codreanu - R. Ionescu - 

M. Parvu - M. Bojinca 

THU0107 CCL19, A CHEMOKINE INVOLVED IN B-CELL TRAFFICKING, IS RELATED TO THE DECREASE OF BLOOD MEMORY B- 

CELLS AND PREDICTS THE CLINICAL RESPONSE TO RITUXIMAB IN RHEUMATOID ARTHRITIS: RESULTS FROM THE 

SMART STUDY / J. Sellam* - S. Rouanet - H. Hendel-Chavez - K. Abbed - B. Combe - J. Sibilia - X. Le¨Loët - J. Tebib - R. Jourdan 

- M. Dougados - Y. Taoufik - X. Mariette 

THU0108 GLOBAL MOLECULAR EFFECTS OF TOCILIZUMAB THERAPY IN SYNOVIAL BIOPSIES OF EARLY RA PATIENTS / J. Ducreux* 

- A. Nzeusseu Toukap - F. A. Houssiau - P. Durez - B. Lauwerys 

THU0109 TREATING TO TARGET ULTRASOUND WITH CLINICAL REMISSION BETTER EFFECTS THAN CLINICAL REMISSION IN 

RRP / K. Kume* - K. Amano - K. Hatta - H. Ohta 

THU0110 AFFINITY AND POTENCY OF THE ANTI-NKG2A MAB NNC141-0100: IMPLICATIONS FOR MABEL AND DOSING IN THE 

FIRST-IN-MAN TRIAL IN RHEUMATOID ARTHRITIS / L. Alifrangis* - P. André - V. Pascal - E. Bonnet - L. Radzikowski - 

M. B. Petersen - M. Bléry 

THU0111 SECUKINUMAB TREATMENT IMPROVES ACR50, HAQ-DI AND EULAR REMISSION RATES IN PATIENTS WITH RHEUMA- 

TOID ARTHRITIS / M. Genovese* - H. Kellner - P. Durez - C. E. Codding - G. Ligozio - H. B. Richards - C. Escrig - S. Mpofu 

* Presenting author



THU0112 EFFECTS OF INFLAMMATORY ACTIVITY AND THERAPEUTIC INTERLEUKIN-6 RECEPTOR (IL-6R) BLOCKADE ON IL-6R 

ALPHA EXPRESSION AND STAT3 PHOSPHORYLATION IN RHEUMATOID ARTHRITIS (RA) / M. Skwarek - B. Heschel - M. 

Winzer - M. Aringer* 

THU0113 PREDICTIVE FACTORS OF RESPONSE TO RITUXIMAB THERAPY MODIFY THE ACCELERATED ATHEROSCLEROSIS IN 

PATIENTS WITH RHEUMATOID ARTHRITIS / M. Benucci* - G. Saviola - M. Manfredi - F. Atzeni - P. Sarzi Puttini 

THU0114 ABATACEPT AS AN EFFECTIVE TREATMENT IN THE MANAGEMENT OF POOR PROGNOSIS ACPA NEGATIVE UNDIFFER- 

ENTIATED ARTHRITIS / M. H. Buch* - J. E. Freeston - C. Rakieh - E. Middleton - A. L. Tan - D. Pickles - J. Ward - S. Horton - 

S. Das - R. Wakefield - P. Emery 

THU0115 THE EFFECTS OF COSTIMULATION BLOCKADE PERFORMED BY ABATACEPT: DECREASED PRODUCTION OF G-IFN BY 

CD8+ T CELLS AND OF IL-17 BY CD4+ T CELLS AFTER IN VITRO STIMULATION IN GOOD CLINICAL RESPONDERS / 

M. Scarsi* - S. Piantoni - M. Chiarini - C. Zanotti - L. Imberti - A. Tincani - P. Airò 

THU0116 SAFETY AND EFFICACY OF COURSES OF RITUXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS - RITAM STUDY / 

N. S. Damjanov* - D. Stefanovic - A. Dimic - T. Ilic - M. Lazarevic 

THU0117 ABATACEPT CAN DEMONSTRATE MAXIMUM EFFICACY WITHOUT BACKGROUND METHOTREXATE TREATMENT IN 

RHEUMATOID ARTHRITIS / N.Takahashi* - T. Kojima - K. Funahashi - D. Kato - H. Matsubara - Y. Hattori - N. Ishiguro on behalf 

of TBCR study group 

THU0118 25 HYDROXYVITAMIN D INTERFERE WITH THE CLINICAL RESPONSE TO RITUXIMAB IN RHEUMATOID ARTHRITIS / 

R. M'Barek - T. Dupré - F. Tubach - P. Dieudé - E. Palazzo - G. Hayem - K. Dawidowicz - S. Ottaviani - T. Alfaiate - V. Leçon-Malais 

- A. Boutten - O. Meyer* 

THU0119 LACK OF EFFECT OF SECUKINUMAB TREATMENT ON THE LIPID PROFILE IN PATIENTS WITH RHEUMATOID 

ARTHRITIS: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE II STUDY / P. Durez* - 

M. Genovese - H. Kellner - C. Codding - G. Ligozio - H. Richards - C. Escrig - S. Mpofu 

THU0120 LONG-TERM SAFETY OF RITUXIMAB: 10-YEAR FOLLOW-UP IN THE RHEUMATOID ARTHRITIS GLOBAL CLINICAL 

TRIAL PROGRAMME / R. F. van Vollenhoven* - P. Emery - C. O. Bingham - E. Keystone - R. Fleischmann - D. E. Furst - N. Tyson 

- A. Mehbob - P. B. Lehane 

THU0121 THE INTERFERON TYPE I SIGNATURE TOWARDS PREDICTION OF NON-RESPONSE TO RITUXIMAB IN RHEUMATOID 

ARTHRITIS PATIENTS / H. Raterman - S.Vosslamber* - S. de Ridder - M. Nurmohamed - W. Lems - M. Boers - M. van der Wiel 

- B. Dijkmans - C.Verweij - A.Voskuyl 

THU0122 SAFETY OF SURGERY IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED BY RITUXIMAB IN ROUTINE CARE: DATA 

FROM THE FRENCH AIR REGISTRY / S. Godot* - J. E. Gottenberg - S. Paternotte - I. Pane - B. Combe - J. Sibilia - R.-M. Flipo - 

T. Schaeverbeke - P. Ravaud - E. Toussirot - F. Berenbaum - X. Mariette - D. Wendling - J. Sellam 

THU0123 STATINS DO NOT INFLUENCE CLINICAL RESPONSE AND B CELL DEPLETION AFTER RITUXIMAB TREATMENT IN 

RHEUMATOID ARTHRITIS / S. Das* - M. Fernandez Matilla - S. Dass - E.Vital - P. Emery 

THU0124 IMPORTANCE OF MONITORING OF C-REACTIVE PROTEIN LEVEL TO PREDICT ACHIEVEMENT OF BETTER CLINICAL 

OUTCOME DURING TREATMENT WITH TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS / T. Kojima* - 

K. Funahashi - N. Takahashi - D. Kato - H. Matsubara - Y. Hattori - Y.Yabe - N. Ishiguro on behalf of TBCR study group 

THU0125 A MULTI-CENTER, DOUBLE-DUMMY, DOUBLE-BLIND STUDY OF SUBCUTANEOUS (SC) ABATACEPT (ABA) COMPARED 

WITH INTRAVENEOUS (IV) ABA IN JAPANESE RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO 

METHOTREXATE / T. Matsubara* - H. Inoue - M. Iwahashi - A.Yamazaki - T. Takeuchi on behalf of Japan Abatacept Study Group 

THU0126 MULTICENTER RETROSPECTIVE STUDY: RESPONSE TO TOCILIZUMAB IN CLINICAL PRACTICE IS NOT INFLUENCED BY 

THE NUMBER OF PREVIOUS BIOTHERAPY OR BY ASSOCIATION WITH A DMARD / Y.-M. Pers* - C. Fortunet - E. Constant 

- J. Lambert - A. Mazouyes - M.Valnet - H. Marotte - P. Gaudin - D. Wendling - J.-F. Maillefert - C. Jorgensen 

Rheumatoid arthritis - non biologic treatment and small molecules 

THU0127 FUNCTIONAL ACTIVITY OF MEMBRANE-BOUND GLUCOCORTICOID RECEPTORS / C. Strehl* - T. Gaber - M. Jakstadt - 

M. Hahne - P. Hoff - G.-R. Burmester - F. Buttgereit 

THU0128 THE EXTRA-LOW-DOSE METHOTREXATE TREATMENT FACILITATES THE INTRACELLULAR ACCUMULATION OF 

LONGER CHAIN SUBGROUPS OF METHOTREXATE POLYGLUTAMATES / Y. Koyama* - K. Hase - D. Hidaka - S. Nagano - 

T. Ota - A. Uchino - J. Nakagawa 

THU0129 SELECTIVE ELIMINATION OF PATHOGENIC TH17 CELLS FROM PERIPHERAL BLOOD OF RHEUMATOID ARTHRITIS 

PATIENTS BY A PURIFIED FUNGAL POLYSACCHARIDE / A. Alunno* - E. Pericolini - E. Gabrielli - O. Bistoni - S. Caterbi - 

E. Bartoloni - S.-K. Chow - A. Casadevall - A.Vecchiarelli - R. Gerli 

THU0130 ASSESSMENT OF TRANSAMINASITIS WITH DAILY METHOTREXATE THERAPY IN PATIENTS WITH INFLAMMATORY 

RHEUMATIC DISEASES. A LONG-TERM FOLLOW-UP COHORT STUDY / M. U. Martinez Martinez* - A. Sánchez-Arriaga - 

C. Abud-Mendoza 

THU0131 TOFACITINIB (CP-690,550), AN ORAL JANUS KINASE INHIBITOR: ANALYSIS OF MALIGNANCIES ACROSS THE RHEUMA- 

TOID ARTHRITIS CLINICAL PROGRAMME / X. Mariette* - J. R. Curtis - E. B. Lee - R. Riese - I. Kaplan - R. Chew - J. Geier - 

L. Wang - J. D. Bradley 

THU0132 COMPARISON OF DOSE ESCALATION OF INFLIXIMAB AND THE ADDITION OF TACROLIMUS IN RHEUMATOID 

ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO INFLIXIMAB AND METHOTREXATE COMBINATION 

THERAPY / Y.Yonemoto* - K. Okamura - T. Kaneko - T. Kobayashi - K. Takagishi 

THU0133 INTRA-ARTICULAR METHOTREXATE: CLINICAL AND POWER DOPPLER ULTRASONOGRAPHY STUDY OF SYNOVITIS 

IN MEDIUM SEIZED JOINTS OF RHEUMATOID ARTHRITIS PATIENTS / M. Mortada* - A. Solyman 



57


58 



THU0134 BIOMARKERS OF METOTHREXATE ADVERSE REACTIONS IN RHEUMATOID ARTHRITIS PATIENTS / N. Dostanko* - 

V. Yagur - N. Soroka 

THU0135 ‘INDISPENSABLE OR INTOLERABLE?’ A RETROSPECTIVE REVIEW OF METHOTREXATE DISCONTINUATION IN 

RHEUMATOID ARTHRITIS / A. J. Badcock* - A. P. Malaviya - A. J. Ostor 

THU0136 CARDIOVASCULAR SAFETY FINDINGS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOFACITINIB 

(CP-690,550), A NOVEL, ORAL JAK INHIBITOR / C. Charles-Schoeman* - P. Wicker - U. Sechtem - M. A. Gonzalez-Gay - 

S. Wood - M. Boy - J. Geier - D. Gruben - K. Soma - R. Riese - J. Bradley 

THU0137 EFFECTIVENESS AND TOLERANCE INFILTRATION INTRAARTICULAR CORTICOSTEROID ACCORDING TO DOSE / 

D. F. Pereira* - R. N.V. Furtado - J. Natour - N. P. Machado on behalf of Discipline of Rheumatology of the Federal University of 

São Paulo (UNIFESP), São Paulo, Brazil 

THU0138 PHARMACOKINETICS OF FOSTAMATINIB IN PATIENTS WITH IMPAIRED RENAL FUNCTION: A PHASE I STUDY / P. Martin 

- S. Oliver - M. Gillen - T. Marbury - D. Millson* 

THU0139 PHARMACOKINETICS OF FOSTAMATINIB IN PATIENTS WITH IMPAIRED HEPATIC FUNCTION: A PHASE I STUDY / 

P. Martin - S. Oliver - M. Gillen - T. Marbury - D. Millson* 

THU0140 TOFACITINIB (CP-690,550), AN ORAL JANUS KINASE INHIBITOR: ANALYSIS OF GASTROINTESTINAL ADVERSE EVENTS 

ACROSS THE RHEUMATOID ARTHRITIS CLINICAL PROGRAMME / E. B. Lee * - J. R. Curtis - R. Riese - C. Connell - R. Chew 

- M. Boy - E. Maller - C. Su - L. Wang - J. Bradley 

THU0141 BIOMARKER ASSESSMENT OF VX-509, AN INVESTIGATIONAL SELECTIVE JAK3 INHIBITOR, IN HEALTHY VOLUNTEERS / 

I. M. Catlett* - X. Luo - M. S. Penney - M. E. Pray - G. Spencer-Green - M. Botfield - T. Hoock 

THU0142 FENOFIBRATE REDUCES INFLAMMATION BUT HAS NO EFFECT ON ENDOTHELIAL PROGENITOR CELLS IN PATIENTS 

WITH RHEUMATOID ARTHRITIS / I. Shirinsky* - N. Kalinovskaya - O. Polovnikova - V. Shirinsky 

THU0143 TOFACITINIB (CP-690,550), AN ORAL JANUS KINASE INHIBITOR: ANALYSES OF EFFICACY ENDPOINTS BY SUBGROUPS 

IN A POOLED PHASE 2 AND 3 RHEUMATOID ARTHRITIS STUDY POPULATION / J. Kremer* - C. Zerbini - E. B. Lee - 

D. Gruben - S. Krishnaswami - S. H. Zwillich - T. Koncz - J. Bradley - C. A. Mebus 

THU0144 INDUCTION OF REMISSION AND INHIBITION OF JOINT DAMAGE IN PATIENTS WITH RHEUMATOID ARTHRITIS 

TREATED WITH MONO- OR COMBINATION THERAPY USING NON-BIOLOGICAL DMARDS IN ROUTINE CLINICAL 

PRACTICE / K. Katayama* - T. Okubo - T. Sato 

THU0145 A MULTI-BIOMARKER DISEASE ACTIVITY (MBDA) SCORE MEASURES RHEUMATOID ARTHRITIS DISEASE ACTIVITY IN 

PATIENTS TREATED WITH THE JAK INHIBITOR TOFACITINIB / K.Yamaoka* - S. Kubo - K. Sonomoto - S. Hirata - A.Voinov - 

M. Rowe - G. Cavet - K. Saito - Y. Tanaka 

THU0146 CLINICAL ANALYSIS OF HEPATITIS B VIRUS REACTIVATION ASSOCIATED WITH NON-BIOLOGICAL DISEASE- 

MODIFYING ANTIRHEUMATIC DRUG(S) IN PATIENTS WITH RHEUMATOID ARTHRITIS / Y.-Q. Mo - L. Dai* - D.-H. Zheng 

- J.-D. Ma - Y.-H. Li - C.-J. Zou - L.-J. Zhu - B.-Y. Zhang 

THU0147 COMPARISON OF BIOLOGICAL HASARDS OF 166-HOLMIUM-PHYTATE AND 90-YTTRIUM USED FOR RADIOSYNOV- 

IORTHESIS / S. Kiss - R.Vig - Z. Nagy - P. Geher - M. Szentesi* 

THU0148 QUALITY OF LIFE AND KNEE FUNCTION OF THE PATIENTS WITH RHEUMATOID ARTHRITIS AFTER ARTHROSCOPIC 

SYNOVECTOMY / M. Lipina* - M. Makarov - V. Amirdjanova - S. Makarov - V. Pavlov - G.Vardicova - V. Kolomacky - A. Roskidaylo 

THU0149 TREAT TO TARGET EARLY RHEUMATOID ARTHRITIS CLINIC: HIGH RATES OF REMISSION AND LOW DISEASE ACTIVITY 

ON TREATMENT WITH CONVENTIONAL DISEASE MODIFYING DRUGS / O. Semenova* - H. Thompson - S. Kallankara - 

O. Olabambo - Y. Patel - E. Baguley 

THU0150 LARGE DIFFERENCES IN AFFORDABILITY AND AVAILABILITY OF SYNTHETIC DMARDS ACROSS 46 EUROPEAN 

COUNTRIES / P. Putrik* - S. Ramiro - M. Pavlova - T. Kvien - T. Uhlig - A. Boonen on behalf of Working Group Equity in Treatment 

for RA across the European region 

THU0151 EFFECTS OF TOFACITINIB (CP-690,550), AN ORAL JANUS KINASE INHIBITOR, OR ADALIMUMAB ON PATIENT 

REPORTED OUTCOMES IN A PHASE 3 STUDY OF ACTIVE RHEUMATOID ARTHRITIS / R. F. van Vollenhoven* - 

G. Wallenstein - E. B. Lee - R. Fleischmann - S. H. Zwillich - D. Gruben - T. Koncz - J. Bradley - B. Wilkinson - V. Strand 

THU0152 HOW SHOULD THE PRIMARY ENDPOINT BE ANALYSED IN RHEUMATOID ARTHRITIS TRIALS WHICH MANDATE 

RESCUE PRIOR TO THE CLINICAL ENDPOINT? – ANALYSIS OF THREE PHASE 3 TRIALS OF TOFACITINIB / R. Fleischmann* 

- D. Gruben - S. Krishnaswami - S. H. Zwillich - B. Benda - C. A. Mebus - J. Bradley 

THU0153 IMPROVEMENTS IN DISEASE ACTIVITY SCORE BY BASELINE STATUS: POOLED ANALYSIS OF FIVE PHASE 3 STUDIES 

WITH TOFACITINIB (CP-690,550) IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS / R. M. Fleischmann* - 

S. Krishnaswami - D. Gruben - S. H. Zwillich - C. Mebus - J. D. Bradley 

THU0154 ADVERSE EFFECTS OF GLUCOCORTICOID THERAPY IN RHEUMATOID ARTHRITIS (RA): A SYSTEMATIC REVIEW AND 

META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS / S. Tarp* - E. M. Bartels - J. R. Kirwan - D. E. Furst - M. Boers - 

T. Woodworth - H. Bliddal - B. Danneskiold-Samsøe - L. E. Kristensen - S. Thirstrup - M. Rasmussen - R. Christensen 

THU0155 THE ADDITION OF ANOTHER DISEASE-MODIFYING ANTI-RHEUMATIC DRUG TO METHOTREXATE IN PLACE OF 

INFLIXIMAB IMPROVES THE RATE OF INFLIXIMAB-FREE SUSTAINED REMISSION / T. Kurasawa* - H. Nagasawa - K. Amano 

- T. Takeuchi - H. Kameda 

THU0156 RESPONSE OF RA ON MRI-DETECTED SYNOVITIS TO DOUBLE FILTRATION PLASMAPHERESIS / X.Yu* - L. Wang - P. Xu 

THU0157 TRIPTERYGIUM WILFORDII MULTIGLYCOSIDE COMBINED REGIMEN AS LONG-TERM MAINTENANCE THERAPY IN 

CHINESE RHEUMATOID ARTHRITIS PATIENTS / F. Lian - Y. Wang* - H. Xu - D. Chen - Z. Zhan - L. Liang - Q. Qiu - Y.Ye - 

X.Yang 

* Presenting author



SLE, Sjögren's and APS - clinical aspects (other than treatment) 

THU0158 SIX YEAR FOLLOW-UP STUDY OF BONE MINERAL DENSITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / 

J. Jacobs* - L.-A. Korswagen - A. Schilder - L. van Tuyl - B. Dijkmans - W. Lems - A.Voskuyl - I. Bultink 

THU0159 INCIDENCE AND PREVALENCE OF MAJOR CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN SYSTEMIC LUPUS 

ERYTHEMATOSUS (SLE): A 3 YEAR PROSPECTIVE EVALUATION AND CLINICAL CORRELATIONS IN 370 PATIENTS / E. I. 

Kampylafka* - H. Alexopoulos - M. L. Kosmidis - D. B. Panagiotakos - P. G.Vlachoyiannopoulos - M. C. Dalakas - H. M. Moutsopoulos 

- A. G. Tzioufas 

THU0160 WHITE MATTER LESIONS ARE PREDOMINANTLY DEMYELINATING IN SYSTEMIC LUPUS ERYTHEMATOSUS. AN 

SUPPORT VECTOR MACHINES CLASSIFICATION OF TEXTURE PARAMETERS / A.T. Lapa - M. P. Bento - L. Rittner - H. H. Ruocco 

- G. Castellano - B. D. Damasceno - L. T. L. Costallat - S. Appenzeller* - R. Lotufo - F. Cendes 

THU0161 NEUROPSYCHIATRIC INVOLVEMENT AND SLE: PERFORMANCE OF A NEW ALGORITHM FOR ATTRIBUTION OF NP 

EVENTS TESTED ON AN ITALIAN MULTICENTER COHORT / A. Bortoluzzi* - S. Bombardieri - C. Casu - F. Conti - S. De Vita 

- A. Doria - I. Farina - G. Ferraccioli - E. Gremese - E. Mansutti - M. Mosca - M. Padovan - M. Piga - A. Tincani - P. Tomietto - 

C. Tani - G.Valesini - M. Zen - A. Mathieu - M. Govoni on behalf of the Italian Study Group for the Neuropsychiatric Involvement 

in Systemic Lupus Erythematosus 

THU0162 THROMBOTIC MICROANGIOPATHY IN RENAL BIOPSIES FROM PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / 

J. Gerhardsson - A. Zickert - B. Sundelin - E. Svenungsson - I. Gunnarsson* 

THU0163 PREDICTORS OF METABOLIC SYNDROME AT ENROLMENT INTO A MULTICENTRE INTERNATIONAL INCEPTION 

COHORT OF PATIENTS WITH SLE / B. Parker* - M. B. Urowitz - M. Lunt - I. N. Bruce on behalf of SLICC Registry for 

Atherosclerosis 

THU0164 RISK OF SERIOUS INFECTIONS IN REUMATOID ARTHRITIS AND OTHER CHRONIC INFLAMMATORY IMMUNE- 

MEDIATED DISEASES TREATED WITH TNF ANTAGONISTS OR RITUXIMAB / T. Cobo-Ibáñez* - M. A. Descalzo - S. Muñoz- 

Fernández - E. Loza - L. Carmona - J. J. Gómez-Reino on behalf of the BIOBADASER 2.0 Study Group 

THU0165 HIGH RATE OF CARDIOVASCULAR EVENTS IN LUPUS PATIENTS AT 5 YEAR FOLLOW UP AND ASSOCIATION OF 

CLASSICAL AND LUPUS RELATED RISK FACTORS / S. Skeoch* - S. Haque - B. Parker - Y. Ahmad - L. S. Teh - I. Bruce 

THU0166 REBAMIPIDE IN THE TREATMENT OF XEROSTOMIA IN SJÖGREN’S SYNDROME: RANDOMIZED PLACEBO- 

CONTROLLED STUDY / A. Abou-Raya* - S. Abou-Raya - N. Sallam - M. Helmii 

THU0167 EVALUATION OF TWO ASSAYS FOR ANTIPHOSPHOLIPID ANTIBODIES IN 712 SLE PATIENTS; CLINICAL ASSOCIATIONS 

DEPEND ON ISOTYPES AND CUT-OFF LEVELS / A. Vikerfors* - A.-B. Johansson - J. Gustafsson - A. Jonsen - D. Leonard - 

A. Zickert - G. Nordmark - G. Sturfelt - A. Bengtsson - L. Rönnblom - I. Gunnarsson - K. Elvin - E. Svenungsson 

THU0168 SERUM PROGRANULIN LEVELS ARE ELEVATED IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS, REFLECTING 

DISEASE ACTIVITY / A. Tanaka* - H. Tsukamoto - H. Mitoma - N. Ueda - M. Ayano - S.-I. Ohta - Y. Inoue - Y. Arinobu - H. Niiro 

- T. Horiuchi - K. Akashi 

THU0169 TRAF3IP2 GENE POLYMORPHISMS ARE ASSOCIATED WITH SUSCEPTIBILITY TO SYSTEMIC LUPUS ERYTHEMATOSUS / 

C. Perricone* - D. Di Fusco - C. Ciccacci - F. Ceccarelli - E. Cipriano - F. R. Spinelli - P. Borgiani - G.Valesini - F. Conti 

THU0170 THE EFFECT OF THE ANTIPHOSPHOLIPID SYNDROME (APS) ON SURVIVAL IN 679 PATIENTS WITH SLE: A PROSPEC- 

TIVE STUDY / C. C. Mok* - L.Y. Ho - K. L.Yu - C. H. To 

THU0171 THERAPEUTIC RESPONSE OF LUPUS NEPHRITIS BASED ON PATHOLOGICAL FINDINGS IN YOKOHAMA CITY UNIVER- 

SITY HOSPITAL / D. Kishimoto* - A. Ihata - R. Watanabe - T. Watanabe - K. Terauchi - K. Kobayashi - T. Uehara - K. Takase - 

M. Hama - R.Yoshimi - A. Ueda - M. Takeno - Y. Ishigatsubo 

THU0172 THE ROLE OF T REGULATORY LYMPHOCYTES IN LUPUS NEPHRITIS / D. P. E. Margiotta* - K. Giannakakis - M. Vadacca - 

A. Gigante - R. Cianci - A. Onetti Muda - A. Afeltra 

THU0173 SUPERVISED PHYSICAL EXERCISE IMPROVES ENDOTHELIAL FUNCTION AND INCREASE ENDOTHELIAL PROGEN- 

ITOR CELLS NUMBER IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / E.T. Reis Neto* - A. E. Silva - L. M. Camargo 

- P. Semedo - M. M. Pinheiro - N. P. Silva - E. I. Sato 

THU0174 ENDOTHELIAL MICROPARTICLES AND CIRCULATING ENDOTHELIAL PROGENITOR CELLS IN PRIMARY SJÖGREN’S 

SYNDROME PATIENTS: A POTENTIAL MARKER OF ENDOTHELIAL DAMAGE? / E. Bartoloni* - A. Alunno - M. Pirro - 

O. Bistoni - G. Schillaci - F. Bagaglia - F. Luccioli - G. Santoboni - G. Mirabelli - F. Cannarile - E. Mannarino - R. Gerli 

THU0175 T CELL REACTIVITY TO B2 GLYCOPROTEIN I IN SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTI-PHOSPHOLIPID 

SYNDROME: CORRELATION WITH SUBCLINICAL ATHEROSCLEROSIS / F. R. Spinelli* - C. Alessandri - E. Marocchi - 

F. Ceccarelli - A. Capozzi - M. Sorice - M. Arca - M. Pacelli - B. Buttari - R. Riganò - E. Profumo - G.Valesini - F. Conti 

THU0176 SUBCLINICAL MYOCARDIAL DYSFUNCTION IN PRIMARY ANTIPHOSPHOLIPID SYNDROME ASSESSED BY SPECKLE 

TRACKING ECHOCARDIOGRAPHY / G. Medina* - E. Calderon-Aranda - E. Gomez-Bañuelos - O.Vera-Lastra - L. J. Jara 

THU0177 ESR AS A PREDICTOR OF SLE DISEASE ACTIVITY AND DAMAGE / G. Stojan* - H. Fang - L. Magder - M. Petri 

THU0178 CIRCULATING FREE PROTEIN S LEVELS MAY BE LINKED TO CARDIOVASCULAR EVENTS AND VENOUS THROMBOSIS 

IN SLE / G. J. Silverman* - J. Jung - E. Akhter - M. Petri - C. Gronwall 

THU0179 PREVALENCE, ETIOLOGY AND RISK FACTORS FOR PULMONARY ARTERIAL HYPERTENSION IN A COHORT OF 

PATIENTS WITH LUPUS / I. Rúa-Figueroa * - F. León - A. Gª Quintana - S. Ojeda - F. Francisco - M. Gª Bello - P. Cabrera - 

N. Ojeda - J. Pulido - A. Naranjo - J. Ortega - G. P-Peñate 

THU0180 PREVALENCE AND CLINICAL SIGNIFICANCE OF SEVERE INFECTION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHE- 

MATOSUS: PRELIMINARY DATA FROM RELESSER (REGISTRY OF LUPUS OF THE SPANISH SOCIETY OF RHEUMA- 

TOLOGY) / I. Rúa-Figueroa * - J. Pego-Reigosa - M. Galindo - J. López-Longo - J. Calvo-Alen - M. J. Gª Yebenes - E. Tomero - 

E. Uriarte - C. Fito - A. S-Atrio - A. Olivé on behalf of RELESSER investigators from EAS-SER Group 



59


60 



THU0181 SERUM LEVEL OF SYNDECAN-1 IS ASSOCIATED WITH DISEASE ACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS 

ERYTHEMATOSUS / K.-J. Kim - J.-Y. Kim* - S.-J. Park - I.-W. Baek - C.-H.Yoon - W.-U. Kim - C.-S. Cho 

THU0182 DYSLIPOPROTEINEMIA AND ITS RELATION WITH THE ACTIVITY OF THE DISEASE AND ITS TREATMENT IN A LARGE 

SPANISH MULTICENTRIC LUPUS COHORT / J. Pego-Reigosa* - I. Rúa - C. Mouriño - M. Galindo - F. López-Longo - J. Calvo 

- M. García-Yébenes - E. Tomero - E. Uriarte - C. Fito - A. Sánchez - A. Olivé - M. Freire - A. F-Nebro on behalf of the 

RELESSER Group 

THU0183 CIGARETTE SMOKING AND ANTIPHOSPHOLIPID ANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS / J. Gustafsson* 

- I. Gunnarsson - S. Pettersson - A. Zickert - A.Vikerfors - E. Hellbacher - S. Möller - K. Elvin - J. F. Simard - E. Svenungsson 

THU0184 IDENTIFICATION OF BIOMARKERS IN SLE PREGNANCIES USING URINARY PROTEOMICS / K. Schreiber* - K. Bramham - 

H. Mistry - O. Barrutia-Ateka - S. Lynham - A. Weston - M. A. Ward - L. M. Bertolaccini - L. C. Chappell - M. A. Khamashta 

THU0185 INDEPENDENT RISK FACTORS OF ENDOTHELIAL DYSFUNCTION (ED) AND ATHEROSCLEROSIS (AS) DEVELOPMENT 

IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) / K. Amosova* - O. Iaremenko - I. Matiyashchuk 

THU0186 CARDIAC VALVE ABNORMALITIES IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS DETECTED BY TRANSTHO- 

RACIC AND TRANSESOPHAGEAL ECHOCARDIOGRAPHY (TTE AND TEE) / L. S. Kholopov* - O. I. Dyadyk - A. E. Bagriy - 

V. O. Gajdukov - O.V. Samojlova 

THU0187 COMPLEMENT C4 GENE POLYMORPHISMS, SERUM PROTEIN LEVELS AND PROTEIN FUNCTIONAL ACTIVITY IN 

RELATIONSHIP WITH CLINICAL MANIFESTATIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / L.-A. 

Korswagen* - J. Jacobs - D. Wouters - I. Bultink - A. Schilder - D. Hamann - A.Voskuyl 

THU0188 LYMPHOPROLIFERATIVE COMPLICATIONS IN THE COURSE OF PRIMARY SJÖGREN’S SYNDROME: PREVALENCE AND 

COMMON FEATURES IN A LARGE COHORT OF PATIENTS / L. Quartuccio* - C. Baldini - R. Priori - E. Bartoloni Bocci - 

F. Carubbi - M. Isola - M. Maset - S. Salvin - N. Luciano - G. Picarelli - A. Alunno - A. Marrelli - R. Gerli - G. Valesini - 

S. Bombardieri - S. De Vita 

THU0189 INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / M. U. Martinez Martinez* - 

D. A. Herrera Van Oostdam - M. Magaña Aquino - L. Baranda Cándido - C. Abud Mendoza 

THU0190 ULTRASONAGRAPHIC ASSESSMENT OF SUBMANDIBULAR GLANDS IN ANTI-CENTROMERE ANTIBODY POSITIVE AND 

NEGATIVE PRIMARY SJOGREN’S SYNDROME PATIENTS / N. Hashimoto* - S. Uchiyama - M. Kitano - T. Iwasaki - H. Sano - 

T. Hashimoto 

THU0191 VISFATIN IN PATIENTS WITH LUPUS NEPHRITIS.CORRELATION WITH DISEASE ACTIVITY / N. Fouda* - N. Abaza - R. El 

Hilaly - H. El Said - R. El Kabarity 

THU0192 MYOSITIS IN PRIMARY SJÖGREN SYNDROME: DATA FROM A MULTICENTER COHORT / S. Colafrancesco* - A. Gattamelata 

- M. Modesti - A. Minniti - G. D'Amati - C. Giordano - M. Maset - L. Quartuccio - E. Bartoloni - F. Carrubi - P. Cipriani - C. Baldini 

- N. Luciano - S. De Vita - R. Gerli - R. Giacomelli - S. Bombardieri - G.Valesini - R. Priori 

THU0193 COMPARATIVE EVALUATION OF CUMULATIVE DAMAGE IN ADULT AND CHILDHOOD ONSET SYSTEMIC LUPUS 

ERYTHEMATOSUS / K. D. O. Peliçari - M. Postal - N. A. Sinicato - L. T. L. Costallat - R. Marini - S. Appenzeller* 

THU0194 ASSOCIATION BETWEEN AUTOANTIBODIES AND SOLUBLE FACTORS IN CEREBROSPINAL FLUIDS FROM PATIENTS 

WITH NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS / T. Fujii* - T. Yokoyama - S. Kondo-Ishikawa - 

N. Yamakawa - M. Nakano - N.Yukawa - H.Yoshifuji - K. Ohmura - T. Mimori 

THU0195 IFNB AND ITS RESPONSE PROTEINS IP-10 AND SIGLEC-1 AS BIOMARKERS OF DISEASE ACTIVITY IN SYSTEMIC LUPUS 

ERYTHEMATOSUS / T. Rose* - A. Gruetzkau - C. Dähnrich - A. Dzionek - H. Hirseland - G. Riemekasten - W. Schlumberger - 

P. Enghard - A. Radbruch - G.-R. Burmester - F. Hiepe - R. Biesen 

THU0196 BONE MICROARCHITECTURE AND BIOMECHANICAL PROPERTIES IN CHINESE FEMALE PATIENTS WITH SYSTEMIC 

LUPUS ERYTHEMATOSUS DAMAGE / X. L. Tang* - T.Y. Zhu - L. Qin - L. S. Tam - E. K. Li 

THU0197 TIME TO RECOVERY FROM PROTEINURIA IN LUPUS NEPHRITIS PATIENTS RECEIVING STANDARD OF CARE TREAT- 

MENT / Z. Touma* - M. B. Urowitz - D. Ibañez - D. D. Gladman 

Vasculitis 

THU0198 SERUM ANGIOPOIETIN-2 LEVEL STRONGLY REFLECTS THE DISEASE ACTIVITY AND RENAL FUNCTION IN ANCA- 

ASSOCIATED VASCULITIS / Y. Wada* - Y. Nozawa - H. Sato - T. Nakatsue - S. Murakami - T. Kuroda - M. Nakano - I. Narita 

THU0199 SUCCESSFUL OUTCOMES OF PREGNANCY IN PATIENTS WITH ANCA VASCULITIS / A. Croft* - S. W. Smith - S. Carr - 

S.Youssouf - A. Salama - C. Pusey - L. Harper - M. Morgan 

THU0200 CLINICAL AND RADIOLOGICAL CHARACTERISTICS OF INTERSTITIAL LUNG DISEASE IN JAPANESE PATIENTS WITH 

MICROSCOPIC POLYANGIITIS / A. Maeda* - H.Yamada - Y.Yamasaki - T. Shibata - H. Nagafuchi - Y. Kurihara - S. Ozaki 

THU0201 COGNITIVE IMPAIRMENT IN BEHÇET’S DISEASE IS NOT ASSOCIATED TO SYSTEMIC DISEASE ACTIVITY, CUMULATIVE 

PREDNISONE DOSE OR WHITE-MATTER LESIONS / L. A. Dutra - A. W. S De Souza* - H. Alessi - P. Braga Neto - B. D. V. S. 

Guedes - C. R. Gonçalves - A. J. da Rocha - P. H. Bertolucci - O. G. P. Barsottini 

THU0202 PROSPECTIVE EVALUATION OF AORTIC STRUCTURAL DAMAGE (ANEURYSM/DILATATION) USING A PREDEFINED 

SCREENING PROTOCOL IN BIOPSY-PROVEN GIANT-CELL ARTERITIS PATIENTS DURING LONG-TERM FOLLOW-UP / 

A. García-Martínez* - P. Arguis - S. Prieto-González - J. Hernández-Rodríguez - G. Espígol - M. Corbera - M. Alba - I. Tavera - 

E. Planas - M. C. Cid 

THU0203 CROSS-SECTIONAL ASSESSMENT OF DAMAGE IN TAKAYASU ARTERITIS WITH A VALIDATED TOOL / A. Omma - B. Erer* 

- O. Karadag - N.Yilmaz - F. Alibaz Oner - F.Yildiz - S. Kiraz - H. Direskeneli - E. Erken - A. Gul - L. Ocal - M. Inanc - S. Kamali 

THU0204 LUMBAR INTERSPINOUS BURSITIS IN ACTIVE POLYMYALGIA RHEUMATICA / C. Salvarani* - L. Barozzi - M. G. Catanoso - 

L. Boiardi - N. Pipitone - P. Macchioni - G. Pazzola - G. Bajocchi - O. Addimanda - F. Muratore 

* Presenting author



THU0205 THE TEMPORAL APPEARANCE OF SYMPTOMS AND SIGNS IN CHURG STRAUSS SYNDROME: FROM THE PRODROMAL 

PHASE TO DAMAGE / C. Baldini* - P. Pepe - M. Latorre - A. della Rossa - V. Seccia - P. Iannicelli - V. Giorgerini - S. Galimberti - 

A. Tavoni - P. L. Paggiaro - S. Bombardieri 

THU0206 POPULATION-BASED EPIDEMIOLOGY AND DESCRIPTION OF BEHCET’S DISEASE IN THE AFRICAN DESCENT POPULA- 

TION OF MARTINIQUE, FRENCH WEST INDIES / C. Deligny* - L. Antonio - H. Merle - P. Numéric - A. Signate - V. Dehlinger 

- G. Jean Baptiste - S. Arfi 

THU0207 ACUTE SERUM AMYLOID A AND TLR2 ACTIVATION INDUCES PRO-INFLAMMATORY MECHANISMS IN A NOVEL EX 

VIVO TEMPORAL ARTERY EXPLANT CULTURE/MODEL OF GIANT CELL ARTERITIS / D. Molloy* - M. Connolly - 

J. McCormick - M. Haroon - D. J.Veale - C. Murphy - E. Molloy - U. Fearon 

THU0208 FATIGUE IS AN IMPORTANT PROBLEM IN PATIENTS WITH BEHCET’S SYNDROME / D. Buyuktas* - G. Hatemi - S. Yuksel 

Findikoglu - K. Tascilar - S. Ugurlu - S.Yurdakul 

THU0209 EFFICACY OF ANTI-TNF THERAPY IN 15 PATIENTS WITH REFRACTORY TAKAYASU’S ARTERITIS: LONG TERM UNICEN- 

TRIC FOLLOW-UP / E. Tombetti* - E. Baldissera - S. Franchini - F. Motta - P. Aiello - G. Cavalli - M. G. Sabbadini 

THU0210 THE COMPARISON OF CHILDHOOD POLYARTERITIS NODOSA AND CUTANEOUS POLYARTERITIS NODOSA / 

E. Demirkaya* - T. Turker - N. Ruperto - R. Cuttica - P. Brogan - P. Quartier - J. Anton - N. Ayaz - S. Garay - G. Espada - 

R. Khubchandani - F. Zulian - A. Bagga - A. Belot - C. A. Silva - S. M. Al-Mayouf - A. I. Estrella - S. Oliveira - C. S. Magalhães - 

A. Martini - S. Ozen 

THU0211 GASTROINTESTINAL MANIFESTATIONS OF BEHÇET’S DISEASE IN JAPAN: A STUDY OF 43 PATIENTS / H. Ideguchi* - 

A. Suda - M. Takeno - S. Ohno - Y. Ishigatsubo 

THU0212 INFLIXIMAB THERAPY FOR CHRONIC PROGRESSIVE NEURO-BEHÇET’S DISEASE: A 6-YEAR FOLLOW-UP STUDY / 

H. Kikuchi* - Y. Kimura - K. Asako - M. Takayama - H. Kono - Y. Ono - S. Hirohata 

THU0213 CYCLOPHOSPHAMIDE HAS NO EFFICACY IN JAPANESE PATIENTS WITH RENAL VASCULITIS ASSOCIATED WITH ANTI- 

NEUTROPHIL CYTOPLASMIC ANTIBODY-POSITIVE MICROSCOPIC POLYANGIITIS / I. Nakaya* - M. Iwabuchi - Y. Tsuchiya 

-Y. Shibagaki - T.Yamaguchi - S. Fukuhara - Y. Oe - M.Yahata - J. Soma - T. Sato - Y. Taguma 

THU0214 TREATMENT OF REFRACTORY GIANT CELL ARTERITIS WITH CYCLOPHOSPHAMIDE. A RETROSPECTIVE ANALYSIS OF 

35 PATIENTS FROM THREE TERTIARY CARE CENTERS / J. Loock* - J. C. Henes - I. Kötter - T. Witte - P. Lamprecht - M. Schirmer 

- W. L. Gross 

THU0215 INCIDENCE OF WEGENER’S GRANULOMATOSIS IN FINLAND IN 1981-2000 — DIFFERENT AGE GROUP PROPORTIONS 

IN FOUR 5-YEAR PERIODS / J. H. Takala* - H. Kautiainen - M. Leirisalo-Repo 

THU0216 SUBGLOTTIC STENOSIS AND TRACHEOBRONCHITIS IN GRANULOMATOSIS WITH POLYANGIITIS (GPA, WEGENER`S) 

ARE ASSOCIATED WITH A HIGH BURDEN OF DISEASE AND DAMAGE / J. Holle* - C. Röhl - M. Laudien - M. Both - K. Holl- 

Ulrich - W. Gross 

THU0217 NAILFOLD VIDEOCAPILLAROSCOPY IN PATIENTS WITH GRANULOMATOSIS WITH POLYANGIITIS (WEGENER´S): AN 

OBSERVATIONAL STUDY. / J. Uceda - R. Martinez - M. L.Velloso - J. L. Marenco* 

THU0218 HEMATOLOGICAL MALIGNANCIES (OTHER THAN LYMPHOMA) IN PATIENTS WITH GRANULOMATOUS POLYANGI- 

ITIS (WEGENER) / E. Baecklund - K. Hjorton* - J. Askling - A. Knight 

THU0219 ANTI-SACCHAROMYCES CEREVISAE ANTIBODIES (ASCA) IN ACTIVE BEHÇET’S DISEASE: A MARKER OF INTESTINAL 

INVOLVEMENT? / L. L. Prado* - K. L. Augusto - P. F. Magalhães - V. T.Viana - C. G. S. Saad - C. R. Gonçalves 

THU0220 RITUXIMAB FOR ANCA ASSOCIATED VASCULITIS: A SYSTEMATIC REVIEW / L. Silva* - R. Blanco - V. Martínez-Taboada - 

E. Loza - S. Muñoz-Fernández - J. M. Pego - I. Rúa-Figueroa on behalf of The Group for the Study of Systemic Autoimmune 

Diseases of the Spanish Society of Rheumatology 

THU0221 LUNG PHYSIOLOGY IMPAIRMENT IN ANCA-ASSOCIATED VASCULITIS (AASV) / L. F. Flores-Suarez* - S. Cardenas - 

L. Torre-Bouscoulet - S. Toral 

THU0222 DIFFERENCES IN CLINICAL PRESENTATION AND OUTCOME IN PATIENTS WITH EARLY VERSUS LATE ONSET GIANT- 

CELL ARTERITIS (GCA): ANALYSIS OF 94 PATIENTS / M. A. C. Alba * - A. García-Martínez - G. Espigol-Frigole - I. Tavera- 

Bahillo - S. Prieto-González - J. Hernández-Rodríguez - M. C. Cid 

THU0223 GENETICS OF BEHÇET’S DISEASE IN SARDINIA: TWO DISTINCT EXTENDED HLA HAPLOTYPES HARBOR THE B*51 

ALLELE IN NORMAL POPULATION AND IN PATIENTS / M. Piga* - F. Paladini - S. Lai - G. Passiu - C. Carcassi - R. Sorrentino 

- A. Mathieu 

THU0224 PREVALENCE OF ANTIBODIES AGAINST FERRITIN PEPTIDES: EPITOPE MAPPING OF HUMAN FERRITIN HEAVY CHAIN 

IN GCA AND PMR / N. T. Baerlecken* - K. Große - R. E. Schmidt - T. Witte 

THU0225 PREVALENCE OF TAKAYASU’S ARTERITIS IN IZMIR, TURKEY: A MULTICENTER STUDY / Y. Kucukyavas - K. Aksu - D. Solmaz 

- G. Can - A. Taylan - S. Akar - I. Sari* - M. Birlik - F. Onen - N. Akkoc 

THU0226 CLINICAL FEATURES AND MORTALITY CAUSES IN A LARGE COHORT OF SPANISH PATIENTS WITH ANCA ASSOCIATED 

VASCULITIDES / R. Solans-Laqué* - L. Caminal - L. Saez - J. J. Rios - M. Zamora - X. Solanich - M. Rodriguez - M. Lopez-Dupla 

- M. J. Castillo - E. Fonseca - J. L. Calleja - P. Fanlo - M. Abdilla on behalf of the Registro Español de Vasculitis Sistémicas (REVAS) 

from the Internal Medicine Society 

THU0227 ANCA-ASSOCIATED VASCULITIS: A RETROSPECTIVE STUDY FROM WESTERN INDIA / S. Nagaraj* - P. Joshi - V. Sharma - 

A. Buche - G. Mangat - R. Samant - C. Balakrishnan 

THU0228 SERUM IL-33 LEVEL IN BEHÇET’S DISEASE AND RHEUMATOID ARTHRITIS / S. S. Koca* - E. Donder - F. Deniz - M. Ozgen 

- N. Ilhan - A. Isik 

THU0229 DUAL EFFECTS OF TESTOSTERONE IN BEHCET’S DISEASE : IMPLICATIONS FOR A ROLE IN DISEASE PATHOGENESIS / 

T. Akdeniz* - G.Y. Demirel - M. Karakas - M. Bicakcigil - H. Direskeneli - O. Deyneli - S.Yavuz 



61


62 



THU0230 RESPONSE TO TREATMENT WITH AZATHIOPRINE IN BEHCET'S SYNDROME PATIENTS WITH DIFFERENT ORGAN 

INVOLVEMENT AND DOCUMENTATION OF IMPROVEMENT USING PATIENT REPORTED OUTCOMES IN ROUTINE 

CLINICAL CARE / Y.Yazici* - A. L. Regens - C. J. Swearingen 

Scleroderma, myositis and related syndromes - clinical aspects and treatment 

THU0231 THE EFFICACY OF TACROLIMUS IN PATIENTS WITH INTERSTITIAL LUNG DISEASES COMPLICATED WITH 

POLYMYOSITIS OR DERMATOMYOSITIS / T. Kurita* - S.Yasuda - K. Oba - K. Otomo - H. Shida - T. Watanabe - Y. Kanetsuka - 

M. Kono - T. Odani - Y. Fujieda - Y. Kon - T. Horita - N. Sato - T. Atsumi 

THU0232 PREGNANCY OUTCOME IN IDIOPATHIC INFLAMMATORY MYOPATHY PATIENTS IN A MULTICENTER STUDY / M.Vincze* 

- A.Váncsa - K. Dankó - L. Plestilova - J.Vencovsky - K. Gheorghe - I. Lundberg - P. Charles - H. Balsam - E. Wegier-Szewczyk 

THU0233 MYOPATHY IS A POOR PROGNOSTIC FEATURE IN SYSTEMIC SCLEROSIS. RESULTS FROM THE CANADIAN SCLERO- 

DERMA RESEARCH GROUP (CSRG) COHORT / M. Jung* - M. Baron - M. Hudson - A. Bonner - J. E. Pope on behalf of Canadian 

Scleroderma Research Group 

THU0234 SYSTEMATIC LITERATURE REVIEW: EFICACY OF RAYNAUD PHENOMENON PHARMACOLOGYCAL TREATMENT IN 

SYSTEMIC SCLEROSIS PATIENTS / P. Garcia De La Peña Lefebvre* - M. B. Nishishinya - C. A. Pereda - J. Roman Ivorra - 

P. Carreira - E. Loza - I. Rúa-Figueroa - S. Muñoz-Fernández 

THU0235 IDENTIFYING AND QUANTIFYING PROGNOSTIC FACTORS IN SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG 

DISEASE USING A TIME-VARYING COVARIATE SURVIVAL MODEL / O. A. Moore* - N. Goh - T. Corte - H. Rouse - 

O. Hennessy - V. Thakkar - J. Byron - J. Sahhar - J. Roddy - P.Youssef - P. Nash - J. Zochling - S. M. Proudman - W. Stevens - 

M. Nikpour on behalf of Australian Scleroderma Interest Group 

THU0236 LOW GRADE EROSIVE ARTHRITIS IS A GENUINE AND FREQUENT DISEASE MANIFESTATION OF SYSTEMIC SCLEROSIS 

/ E. Akbayrak - I. H. Tarner - U. Müller-Ladner - R. Dinser* 

THU0237 IMPACT OF RECURRENT ISCHEMIC DIGITAL ULCERS ON HAND DISABILITY IN SYSTEMIC SCLEROSIS / L. Mouthon* - 

P. Carpentier - A. Khau Van Kien - P. Clerson - H. Maillard - E. Hachulla - C. Frances - E. Diot - C. Lok - E. Puzenat - A. Sparsa - 

A. Bérezné - V. Gressin - M.-A. Richard 

THU0238 LONG-TERM FOLLOW-UP OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE 

SYSTEMIC SCLEROSIS / H. Tsukamoto* - T. Horiuchi - T. Miyamoto - H. Niiro - Y. Arinobu - Y. Inoue - M. Ayano - A. Tanaka - 

N. Ueda - M. Harada - K. Akashi 

THU0239 CARDIOVASCULAR RISK FACTORS IN ADULTS WITH POLYMYOSITIS AND DERMATOMYOSITIS – A MULTICENTER 

STUDY / L. C. Diederichsen* - A. C. Diederichsen - J. A. Simonsen - P. Junker - K. Søndergaard - I. E. Lundberg - N. Tvede - A. F. 

Christensen - L. Dreyer - L. Ejstrup - S. Jacobsen 

THU0240 ROSUVASTATIN IMPROVES IMPAIRED ENDOTHELIAL FUNCTION AND LOWERS HIGH SENSITIVITY CRP IN PATIENTS 

WITH SYSTEMIC SCLEROSIS – A PROSPECTIVE CASE-SERIES STUDY / O. Timár - Z. Szekanecz - G. Kerekes - J. Végh - 

A. V. Oláh - Z. Csiki - K. Dankó - S. Szamosi - Á. Németh - P. Soltész - G. Szücs* 

THU0241 ETHNIC BUT NOT GENDER DIFFERENCES IN DISEASE MANIFESTATIONS IN DERMATOMYOSITIS PATIENTS / 

A. Tjärnlund* - L. Rider - F. Miller - V. P. Werth - I. E. Lundberg on behalf of the International Myositis Classification Criteria Project 

(IMCCP) consortium 

THU0242 INCIDENCE AND RISK FACTORS FOR LOW BONE MINERAL DENSITY IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC): 

A CASE-CONTROL STUDY / C. C. Mok* - P. T. Chan - K. M. Ma 

THU0243 STANDARDIZED MORTALITY RATIOS AND PREDICTORS OF SURVIVAL IN 215 SOUTHERN CHINESE PATIENTS WITH 

INFLAMMATORY MYOPATHIES / C. H. To* - C. C. Mok - H. So - M. L.Yip - K.Y. S.Ying 

THU0244 ADDITIVE VALUE OF SCLERODERMA HEALTH ASSESSMENT QUESTIONNAIRE (SHAQ) SCORES OVER HAQ DISABILITY 

INDEX VALUES FOR MEASURING DISABILITY AND QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC SCLEROSIS / 

C. Becker* - D. Huscher - M. O. Becker - N. Hunzelmann - G. Riemekasten 

THU0245 RITUXIMAB HAS A BENEFICIAL EFFECT ON LUNG FUNCTION AND SKIN FIBROSIS IN PATIENTS WITH SYSTEMIC 

SCLEROSIS. AN OPEN LABEL STUDY / D. Daoussis* - S.-N. C. Liossis - I. Antonopoulos - T. Markatseli - G.Yiannopoulos - 

A. A. Drosos - A. P. Andonopoulos 

THU0246 PSYCHIATRIC DISORDERS IN RHEUMATOLOGY: EVALUATION OF A SCREENING PROTOCOL IN 100 HOSPITALIZED 

PATIENTS / F. Lumetti* - D. Giuggioli - A. Manfredi - D. Ferrari - E. Tedeschini - E. Simoni - M. Rigatelli - C. Ferri 

THU0247 HOME: THE EFFECT OF SYSTEMIC SCLEROSIS ON THE BLOOD FLOW IN THE HANDS / H. Knaapen* - A. E. Voskuyl - 

P. L. van Daele - J. P. J. Bloemsaat-Minekus - M. C.Vonk - A. J. M. Schuerwegh 

THU0248 EFFICACY OF IMATINIB MESYLATE ON SCLERODERMA ASSOCIATED PULMONARY ARTERIAL HYPERTENSION. 

H. Maki* - M. Hatano - A.Yao - T. Imamura - T. Inaba - T. Shiga - K. Kinugawa - R. Nagai 

THU0249 C - REACTIVE PROTEIN (CRP) IS ASSOCIATED WITH HIGH DISEASE ACTIVITY IN SSC AND ILD. RESULTS FROM THE 

CANADIAN SCLERODERMA RESEARCH GROUP (CSRG) / C. Muangchan - S. Harding - S. Khimdas - A. Bonner - M. Baron - 

J. E. Pope* on behalf of Canadian Scleroderma Research Group 

THU0250 CARDIOVASCULAR RISK ASSESSMENT IN SYSTEMIC SCLEROSIS USING THE SCORE CHART AND RECLASSIFICATION 

BY PRESENCE OF PLAQUES ON ULTRASONOGRAPHY / J. L. Rosales Alexander* - B. Joven - C. Magro Checa - E. Raya Alvarez 

- P. E. Carreira 

THU0251 ASSOCIATIONS OF SYSTEMIC SCLEROSIS AND OTHER AUTOIMMUNE DISEASES (ANALYSIS OF 153 PATIENTS FROM A 

SINGLE EUSTAR CENTRE) / K. Simic Pasalic* - N. Damjanov - G. Marinkovic 

THU0252 IMMUNOPROTEASOME SUBUNITS ARE UP-REGULATED IN INFLAMMATORY MYOPATHIES / K. M. Ghannam* - 

L. Martinez Gamboa1 - L. Naumann - S. Krause - M. Fettke - G. R. Burmester - E. Feist 

* Presenting author



THU0253 ANTI-PM-SCL AUTOANTIBODIES IN POLYMYOSITIS AND DERMATOMYOSITIS / L. Plestilova* - K. Gheorghe - I. E. 

Lundberg - M.Vincze - K. Dankó - P. Charles - Z. Betteridge - N. McHugh - J.Vencovsk˘ 

THU0254 CORRELATION BETWEEN MUSCLE PATHOLOGY FINDINGS AND CLINICAL VARIABLES IN PATIENTS WITH INFLAM- 

MATORY MYOSITIS / S. Wangkaew - S. Suwansirikul - K. Aroonrungwichian - N. Kasitanon* - W. Louthrenoo 

THU0255 MARKED INCREASE IN SERUM KL-6 AND SP-D LEVELS DURING 1ST 4 WEEKS AFTER TRATMENT PREDICTS POOR 

PROGNOSIS IN PATIENTS WITH ACTIVE INTERSTITIAL PNEUMONIA ASSOCIATED WITH POLYMYOSITIS/DERMATO- 

MYOSITIS / S. Arai* - K. Kurasawa - R. Maezawa - H. Okada - T. Owada - T. Fukuda 

THU0256 EFFECTIVENESS OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INTERSTITIAL LUNG 

DISEASES IN PATIENTS WITH SYSTEMIC SCLEROSIS / T. Odani* - S.Yasuda - M. Kono - T. Kurita - Y. Fujieda - K. Otomo - 

Y. Kon - T. Horita - T. Atsumi 

THU0257 INVESTIGATION OF PARAMETERS OF ORAL APERTURE IN 131 PATIENTS WITH SYSTEMIC SCLEROSIS IN A THREE-YEAR 

SINGLE-CENTRE PROSPECTIVE STUDY / Z. Bálint - H. Farkas - K. Horváth - C.Varjú - G. Kumánovics - L. Czirják - T. Minier* 

THU0258 N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE IN A NOVEL SCREENING ALGORITHM FOR PULMONARY ARTERIAL 

HYPERTENSION IN SYSTEMIC SCLEROSIS / V. Thakkar* - W. Stevens - D. Prior - O. Moore - J. Byron - K. Patterson - P. Hissaria 

- J. Roddy - J. Zochling - J. Sahhar - P. Nash - K. Tymms - D. Celermajer - E. Gabbay - P.Youssef - S. Proudman - M. Nikpour on 

behalf of Australian Scleroderma Interest Group 

THU0259 THE LEVELS OF ADIPONECTIN ARE DECREASED IN THE SKIN AND SERA OF DIFFUSE CUTANEOUS SYSTEMIC 

SCLEROSIS PATIENTS / Y. Kubo* - S. Fukushima - M. Jinnin - T. Makino - I. Kajihara - A. Ichihara - K. Makino - H. Ihn 

Spondyloarthritis - treatment 

THU0260 CIRCULATING LEVELS OF TNF-LIKE CYTOKINE 1A (TL1A) ARE INCREASED IN PATIENTS WITH ANKYLOSING 

SPONDYLITIS / M. Konsta* - M. Tektonidou - A. Iliopoulos - G. Bamias - P. P. Sfikakis 

THU0261 CONTINUOUS NSAID USE REVERTS THE EFFECTS OF INFLAMMATION ON RADIOGRAPHIC PROGRESSION IN 

PATIENTS WITH ANKYLOSING SPONDYLITIS / F. Kroon* - R. Landewé - M. Dougados - D. van der Heijde 

THU0262 SCLEROSTIN DOES NOT PREDICT RADIOGRAPHIC PROGRESSION IN PATIENTS ON ANTI-TNF THERAPY – NEW 

RESULTS FROM THE EUROPEAN ANKYLOSING SPONDYLITIS (AS) INFLIXIMAB COHORT (EASIC) / X. Baraliakos* - 

F. Heldmann - J. Listing - G. Schett - T. Appelboom - J. Brandt - F. van den Bosch - M. Breban - G. Burmester - M. Dougados 

- P. Emery - H. Gaston - M. Gruenke - I. van der Horst-Bruinsma - R. Landewé - M. Leirisalo-Repo - J. Sieper - K. de Vlam - 

J. Braun on behalf of EASIC 

THU0263 DEVELOPMENT OF CHRONIC INFLAMMATORY CHANGES ON WHOLE BODY MAGNETIC RESONANCE IMAGING IN 

PATIENTS WITH EARLY AXIAL SPONDYLOARTHRITIS AFTER TWOYEARS OF CONTINUOUS TREATMENT WITH ETANER- 

CEPT – 2 YEAR DATA OF THE ESTHER TRIAL / I.-H. Song* - K.-G. Hermann - H. Haibel - C. Althoff - D. Poddubnyy - J. Listing 

- A. Weiss - E. Lange - B. Freundlich - M. Rudwaleit - J. Sieper 

THU0264 ADALIMUMAB SIGNIFICANTLY REDUCES RECURRENCE RATE OF ANTERIOR UVEITIS IN PATIENTS WITH ANKYLOSING 

SPONDYLITIS / C. van Denderen* - I. M.Visman - M. T. Nurmohamed - M. S. Suttorp-Schulten - I. E. van der Horst-Bruinsma 

THU0265 EARLY CHANGE IN BONE RESORPTION PREDICTS DISCONTINUATION OF TUMOR NECROSIS FACTOR-ALPHA 

BLOCKING THERAPY IN PATIENTS WITH ANKYLOSING SPONDYLITIS / S. Arends* - A. Spoorenberg - P. M. Houtman - 

M. K. Leijsma - C. G. M. Kallenberg - E. Brouwer - E. van der Veer 

THU0266 SARCOPENIA REVERSAL IN ANKYLOSING SPONDYLITIS (AS) UNDER ANTI-TNF THERAPY: A 24-MONTH LONGITU- 

DINAL ANALYSIS / M. A. Barros* - C. S. Saad - L. Takayama - J. C. Moraes - A. C. Medeiros - E. Bonfa - R. M. Pereira 

THU0267 A RANDOMIZED CONTROLLED TRIAL OF THE EFFICACY OF INCENTIVE SPIROMETER EXERCISE ON PULMONARY 

FUNCTIONS OF PATIENTS WITH ANKYLOSING SPONDYLITIS STABILIZED BY TUMOR NECROSIS FACTOR INHIBITOR 

THERAPY / B. S. Koo* - M. W. So - W. J. Seo - Y.-G. Kim - C.-K. Lee - B.Yoo 

THU0268 LOCAL INFLIXIMAB INJECTION OF SACROILIAC JOINTS IN EARLY AXIAL SPONDYLOARTHROPATHIES: IMPACT ON 

PARAMETERS OF DISEASE ACTIVITY / E. Soliman* - G. El-tantawy - K. Matrawy - A. Aldawoudy - A. Naguib 

THU0269 SPINAL AND SACROILIAC INFLAMMATION AS DETECTED BY MAGNETIC RESONANCE IMAGING IN PATIENTS WITH 

ANKYLOSING SPONDYLITIS, BEFORE AND AFTER 12 WEEKS THERAPY WITH NON-STEROIDAL ANTI-INFLAMMATORY 

DRUGS / E. Tyukhova - A. Smirnof - O. Rumyanceva - A. Bochkova* 

THU0270 EUROPEAN ANKYLOSING SPONDYLITIS (AS) INFLIXIMAB COHORT (EASIC) LONG-TERM EXTENSION: EFFICACY AND 

SAFETY OF INFLIXIMAB OVER A TIME PERIOD OF MORE THAN 7 YEARS IN PATIENTS WITH AS / F. Heldmann* - 

X. Baraliakos - J. Brandt - I. van der Horst-Bruinsma - R. Landewé - J. Sieper - G. R. Burmester - F. van den Bosch - K. de Vlam - 

H. Gaston - M. Grünke - T. Appelboom - P. Emery - M. Dougados - M. Leirisalo-Repo - M. Breban - J. Braun 

THU0271 INCREASE IN BONE MINERAL DENSITY AND DECREASE IN WNT3A, OPG, CTX-I AND OSTEOCALCIN IN PATIENTS 

WITH ANKYLOSING SPONDYLITIS TREATED WITH ALENDRONATE / H. Forsblad-d'Elia* - M. Nurkkala - K. Zetterberg - 

E. Klingberg - H. Carlsten on behalf of Center for Bone and Arthritis Research 

THU0272 EFFICACY OF ORAL PREDNISOLONE IN ACTIVE ANKYLOSING SPONDYLITIS – RESULTS OF A DOUBLE BLIND 

PLACEBO CONTROLLED TRIAL / H. Haibel* - C. Fendler - J. Listing - J. Callhoff - J. Braun - J. Sieper 

THU0273 SIMILAR RESPONSE RATES IN PATIENTS WITH ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIAL 

SPONDYLOARTHRITIS AFTER ONE YEAR OF TREATMENT WITH ETANERCEPT - RESULTS OF THE ESTHER TRIAL / 

I.-H. Song* - K.-G. Hermann - H. Haibel - C. Althoff - D. Poddubnyy - J. Listing - A. Weiß - E. Lange - B. Freundlich - M. Rudwaleit 

- J. Sieper 



63


64 



THU0274 DOUBLE-BLIND, PLACEBO-CONTROLLED, 28-WEEK TRIAL OF EFFICACY AND SAFETY OF INFLIXIMAB PLUS 

NAPROXEN VS NAPROXEN ALONE IN PATIENTS WITH EARLY, ACTIVE AXIAL SPONDYLOARTHRITIS TREATED WITH A 

SUBMAXIMAL DOSE OF NSAIDS: PRELIMINARY RESULTS OF INFAST PART I / J. Sieper* - J. Lenaerts - J. Wollenhaupt - 

V. I. Mazurov - L. Myasoutova - S.-H. Park - Y.-W. Song - R.Yao - D. Chitkara - N.Vastesaeger 

THU0275 SUSTAINED EFFICACY OF ADALIMUMAB IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 

WEEK 68 RESULTS FROM ABILITY 1 / J. Sieper* - D. van der Heijde - M. Dougados - F.Van den Bosch - P. Goupille - S. Sarkar - 

A. L. Pangan 

THU0276 A RANDOMIZED, OPEN-LABEL STUDY TO EXPLORE WHETHER PARTIAL REMISSION CAN BE MAINTAINED WITH 

NAPROXEN OR NO TREATMENT IN PATIENTS WITH EARLY, ACTIVE AXIAL SPONDYLOARTHRITIS: PRELIMINARY 

RESULTS OF INFAST PART II / J. Sieper* - J. Lenaerts - J. Wollenhaupt - V. I. Mazurov - L. Myasoutova - S.-H. Park - Y.-W. Song 

- R.Yao - D. Chitkara - N.Vastesaeger 

THU0277 ABSENCE OF RADIOGRAPHIC PROGRESSION AT TWO YEARS IN A COHORT OF PATIENTS WITH NON- RADIOGRAPHIC 

AXIAL SPONDYLOARTHRITIS TREATED WITH TNFA BLOCKERS / J. G. Lopez Velandia* - M. Almirall - J. Perez Ruiz - J. Maymó 

Guarch - M. P. Lisbona - A. Pàmies - I. Silvia - J. Carbonell 

THU0278 THE EFFECT OF ANTI-TUMOR NECROSIS FACTOR THERAPY WITH GOLIMUMAB ON RADIOGRAPHIC PROGRESSION 

IN DEFINITE ANKYLOSING SPONDYLITIS: 4-YEAR RESULTS / J. Braun* - D. van der Heijde - K.-G. Hermann - X. Baraliakos 

- A. Deodhar - A. Beutler - M. Mack - W. Xu - B. Hsu - R. Inman 

THU0279 ABSENCE OF RADIOGRAPHIC PROGRESSION OF HIP ARTHRITIS IN PATIENTS WITH ANKYLOSING SPONDYLITIS 

TREATED WITH INFLIXIMAB FOR 6 YEARS / M. Konsta* - V. K. Bournia - P. P. Sfikakis - D. Karras - A. Iliopoulos 

THU0280 EFFICACY AND SAFETY OF ADALIMUMAB IN PATIENTS WITH PERIPHERAL SPONDYLOARTHRITIS: RESULTS FROM A 

PHASE 3 STUDY / P. Mease* - J. Sieper - F.Van den Bosch - P. Rahman - K. Obermeyer - A. L. Pangan 

THU0281 EFFICACY OF ETANERCEPT THERAPY WITH AN EVERY OTHER WEEK REGIMEN IN PATIENTS WITH ANKYLOSING 

SPONDYLITIS / R. De Stefano* - E. Frati - L. Menza - M. Galeazzi 

THU0282 CLINICAL EFFICACY TO A SECOND ANTI-TNF THERAPY IS ASSOCIATED WITH THE DEVELOPMENT OF ANTIBODIES 

AGAINST THE FIRST ANTI-TNF THERAPY IN PATIENTS WITH SPONDYLOARTRHITIS / S. García Carazo* - C. Plasencia 

- D. Pascual Salcedo - G. Bonilla Hernan - L. Lojo - A. Villalba - L. Nuño - L. Del Olmo - S. Gil Barato - P. Alcocer Amores - 

F. Arribas - E. Perez - E. Martin Mola - A. Balsa 

THU0283 PREDICTIVE FACTORS OF RESPONSE AT 12 WEEKS IN PATIENTS WITH ANKYLOSING SPONDYLITIS STARTING 

BIOLOGICAL THERAPIES - RESULTS FROM THE PORTUGUESE REGISTER - REUMA.PT / S. Ramiro* - P. Machado - R. Roque 

- H. Santos - J. Polido-Pereira - D. Peixoto - C. Duarte - F. Pimentel-Santos - C. Silva - J. E. Fonseca - F. Teixeira - A. Marques - 

F. Araújo - J. Branco - J. A. P. da Silva - J. Costa - J. Pereira da Silva - L. Miranda - J. Canas da Silva - H. Canhão - A. van Tubergen 

- D. van der Heijde - R. Landewé - M. J. Santos 

THU0284 METALLOPROTEINASE-3 (MMP-3) IS A PREDICTOR FOR ANTI-TNFA RESPONSE IN PATIENTS WITH ANKYLOSING 

SPONDYLITIS (AS) / V. Navarro-Compán* - R. Mondéjar-García - R. Ariza-Ariza - V. Moreira-Navarrete - C. Leyva-Prado - 

C. González-Rodríguez - F. Navarro-Sarabia 

THU0285 NO EVIDENCE FOR A ROLE OF THE HYPOTHESIZED SEQUENCE INFLAMMATION - FATTY DEGENERATION – NEW 

BONE FORMATION IN PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH INFLIXIMAB OR OTHER ANTI-TNF 

AGENTS OVER 5 YEARS / X. Baraliakos* - F. Heldmann - J. Callhoff - J. Listing - D. Pappas - J. Braun 

THU0286 CLINICAL EFFICACY AND SAFETY OF INFLIXIMAB – FIRST RESULTS AFTER A DECADE OF CONTINUOUS TREATMENT 

IN ANKYLOSING SPONDYLITIS / X. Baraliakos* - J. Listing - C. Fritz - H. Haibel - R. Alten - G. Burmester - A. Krause - S. Schewe 

- M. Schneider - H. Sörensen - R. Schmidt - J. Sieper - J. Braun 

Basic science in paediatric rheumatology 

THU0287 GLYCOSYLATION OF VITAMIN D BINDING PROTEIN REDUCED IN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS AT RISK 

OF DISEASE EXTENSION / D. S. Gibson* - S. Finnegan - G. Manning - M. Duncan - S. Pennington - T. Moore - M. Rooney 

THU0288 PROTEOMIC PROFILING OF THE SYNOVIAL MEMBRANE IN EARLY UNTREATED JUVENILE IDIOPATHIC ARTHRITIS / 

S. Finnegan* - D. S. Gibson - M. Rooney 

THU0289 MICRORNA SIGNATURE IN PEDIATRIC LUPUS NEPHRITIS: A PILOT STUDY / P. Costa Reis* - P. A. Russo - K. E. Sullivan 

THU0290 PERIPHERAL MONONUCLEAR CELLS OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS PATIENTS HAVE NO INTRINSIC 

DEFECT IN INTERFERON-GAMMA SIGNALING / K. Put* - A. Avau - T. Mitera - S. Put - B. Bader-Meunier - P. Quartier - 

C. Wouters - P. Matthys 

THU0291 NEUTROPHIL APOPTOSIS IS NOT AFFECTED BY GLUCOCORTICOID OR DMARD TREATMENT IN JUVENILE-ONSET 

SYSTEMIC LUPUS ERYTHEMATOSUS / F. Gohar* - L. Ballantine - M. W. Beresford 

THU0292 STIMULATION OF JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS BLOOD CELLS INDUCES IL-17 PRODUCTION / 

L. Ballantine* - A. Midgley - L. Watson - M. Beresford 

THU0293 JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS (JSLE) AND JUVENILE DERMATOMYOSITIS (JDM) PATIENTS HAVE A 

DISTINCT PROFILE OF SOLUBLE APOPTOSIS MOLECULES / B. L. Liphaus* - M. H. B. Kiss - S. Carrasco - C. A. Silva - 

C. Goldenstein-Schainberg 

THU0294 REGULATORY T CELLS/TH17 BALANCE IN THE PATHOGENESIS OF PEDIATRIC BEHÇET DISEASE / T.-A. Tran* - A. Hubert 

- A. Letierce - B. Terrier - G. Geri - D. Saadoun - I. Kone-Paut - M. Rosenzwajg 

THU0295 ISOTYPE CHARACTERIZATION OF ANTI-INFLIXIMAB ANTIBODIES IN PEDIATRIC PATIENTS WITH RHEUMATIC 

DISEASES TREATED WITH INFLIXIMAB / M. Kosmač* - N. Toplak - G. Simonini - R. Cimaz - V. Čurin Sˇerbec - T. Avčin 

THU0296 MATRIX INTERFERENCE OF IL-6, IL-17, IL-21 AND TNF-ALPHA MEASUREMENT IN JUVENILE-ONSET SYSTEMIC LUPUS 

ERYTHEMATOSUS SERUM AND PLASMA / J. Ong* - D. Harris - G. Jeffers - L. Watson - L. Ballantine - M. Beresford 

* Presenting author



Paediatric rheumatology 

THU0297 HIGH PREVALENCE OF HAND AND WRIST IMPAIRMENTS IN JUVENILE IDIOPATHIC ARTHRITIS (JIA) / A. F. Hoeksma* - 

W. G. Zinger - M. A. van Rossum - K. M. Dolman - J. Dekker - L. D. Roorda 

THU0298 DISEASE SELF-MANAGEMENT IN ADOLESCENTS WITH CHRONIC MUSCULOSKELETAL AND RHEUMATIC DISEASES / 

A. Abou-Raya* - S. Abou-Raya 

THU0299 IL-1 INHIBITION IN A PATIENT WITH POLYMORPHISM IN THE INTERLEUKIN 1-RECEPTOR TYPE 1 GENE AND CLINICAL 

PHENOTYPE OF CRMO/DIRA / C. Zimmer* - M. Moll - N. Rieber - R. Goldbach-Mansky - I. Aksentijevich - J. Kuemmerle- 

Deschner 

THU0300 REDUCED ARTICULAR CARTILAGE THICKNESS IN JOINTS WITHOUT A HISTORY OF ACTIVE ARTHRITIS IN CHILDREN 

WITH JUVENILE IDIOPATHIC ARTHRITIS / D. Pradsgaard* - A. Spannow - C. W. Heuck - T. Herlin 

THU0301 NEOPTERIN (NPT) AND SOLUBLE INTERLEUKIN 2 RECEPTOR (SIL-2R) AS USEFUL MARKERS OF DISEASE ACTIVITY IN 

JUVENILE IDIOPATHIC ARTHRITIS (JIA) / E. Olesinska* - J. Postepski - J. Tabarkiewicz - B. Wilczynska - E. Tuszkiewicz-Misztal 

THU0302 SAFETY AND EFFICACY OF TOCILIZUMAB THERAPY IN CHILDREN WITH SYSTEMIC ONSET OF JUVENILE IDIOPATHIC 

ARTHRITIS / E. Alexeeva* - R. Denisova - S.Valiyeva - T. Bzarova - K. Isayeva - T. Sleptsova - E. Mitenko 

THU0303 THE EFFICACY AND SAFETY OF IBANDRONIC ACID FOR INTRAVENOUS ADMINISTRATION FOR TREATMENT OF 

SEVERE SYSTEMIC OSTEOPOROSIS IN PATIENTS WITH JUVENILE ARTHRITIS / S. Valiyeva - E. Alexeeva* - T. Bzarova - 

R. Denisova - K. Isayeva - T. Sleptsova - E. Mitenko 

THU0304 EFFICACY OF BIOLOGIC THERAPIES FOR PEDIATRIC RHEUMATIC DISEASES ASSOCIATED UVEITIS / E. Denisova* - 

L. Katargina - A. Starikova - N. Lubimova 

THU0305 COST-UTILITY OF TOCILIZUMAB IN THE TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS IN FINLAND / 

T. Hallinen - E. J. Soini* - A. Diamantopoulos - F. Dejonckheere - V.Vihervaara - A. Hautala - K. Aalto 

THU0306 PREDICTORS OF OUTCOME IN A COHORT OF ITALIAN CHILDREN/ADOLESCENTS WITH PRIMARY RAYNAUD’S 

PHENOMENON: A MULTICENTER STUDY / F. Falcini* - V. Denaro - F. Cuoco - G. Martini - S. Cappelli - A. Petaccia - F. Corona 

- G. Carnesecchi - F. La Torre - M. Matucci Cerinic - D. Rigante 

THU0307 VALIDATION OF JADAS IN INTERNATIONAL LEAGUE AGAINST RHEUMATISM (ILAR) SUBTYPES OF JUVENILE 

IDIOPATHIC ARTHRITIS (JIA) / F. Mcerlane* - M. W. Beresford - E. M. Baildam - S. E. Chieng - J. Davidson - H. E. Foster - 

J. Gardner-Medwin - M. Lunt - L. R. Wedderburn - K. L. Hyrich - W. Thomson 

THU0308 INDIRECT COMPARISON OF ACR RESPONSE OF BIOLOGIC TREATMENTS IN ACTIVE SJIA / A. Diamantopoulos - C. LeReun 

- R. Westhovens - F. Dejonckheere* 

THU0309 MEASLES, MUMPS AND RUBELLA VACCINATION SAFETY IN PATIENTS WITH JUVENILE RHEUMATIC DISEASES TAKING 

IMMUNOSUPPRESSIVE DRUGS / G. S. Pileggi* - M. T. R. A. Terreri - C. P. Barbosa - V. P. L. Ferriani 

THU0310 PERFORMANCE OF THE JUVENILE ARTHRITIS DISEASE ACTIVITY SCORE JADAS COMPARED TO THE ACR PEDIATRIC 

MEASURES OF RESPONSE IN 1470 JUVENILE IDIOPATHIC ARTHRITIS PATIENTS / G. Horneff* - K. Minden - I. Foeldvari on 

behalf of BIKER cooperative working group 

THU0311 WHAT HAPPENS WHEN ETANERCEPT IS DISCONTINUED IN “REMISSION” IN PATIENTS WITH JUVENILE IDIOPATHIC 

ARTHRITIS? / G. Horneff* - H. I. Hupppertz - I. Foeldvari - K. Minden 

THU0312 REDUCTION OF CONCOMITANT TREATMENT UPON THERAPY WITH ETANERCEPT IN JUVENILE IDIOPATHIC 

ARTHRITIS / G. Horneff* - K. Minden on behalf of German BIKER registry collaborative working group 

THU0313 IS MRI A RELIABLE TOOL FOR MONITORING CHRONIC NON BACTERIAL OSTEOMYELITIS? / G. Zanon* - S. Corradin - 

G. Martini - F.Vittadello - F. Zulian 

THU0314 BONE STATUS OF CHILDREN BORN FROM MOTHERS WITH AUTOIMMUNE DISEASES TREATED DURING PREGNANCY 

WITH LOW MOLECULAR WEIGHT HEPARIN AND/OR PREDNISONE / I. Pagnini* - G. Simonini - L. Cavalli - G. la Marca - 

S. Sollai - A. Iuliano - M. L. Brandi - F. Bellisai - M. Galeazzi - L. Cantarini - R. Cimaz 

THU0315 LONG-TERM OUTCOME OF JUVENILE IDIOPATHIC ARTHRITIS (JIA): A FRENCH MULTICENTER STUDY BASED ON 353 

PATIENTS / I. Melki* - C. Garcin - P. Quartier - C. Job Deslandre - I. Lemelle - P. Landais - B. Bader-Meunier - A.-M. Prieur 

THU0316 UPDATE ON THE JUVENILE SYSTEMIC SCLEROSIS INCEPTION COHORT. WWW.JUVENILESCLERODERMA.COM / 

I. Foeldvari* - C. Ehlers - C. Len - M. M. Katsicas - A. Tae - T. Kalinich - I. Kone-Paut - L. Mouthon - Y. Uziel on behalf of Juvenile 

Scleroderma Working Group of the PRES 

THU0317 LATENT CLASS ANALYSIS TO UNDERSTAND THE IMPACT OF RECENT-ONSET JIA ON PATIENT’S PERCEIVED HEALTH- 

RELATED QUALITY OF LIFE / J. Klotsche* - I. Liedmann - M. Niewerth - G. Horneff - J.-P. Haas - K. Minden 

THU0318 A PROSPECTIVE COMPARATIVE STUDY OF THREE METHODS OF ASSESSMENT OF THE KNEE JOINT IN JUVENILE 

IDIOPATHIC ARTHRITIS: CLINICAL EXAMINATION, ULTRASOUND AND MRI (A NEWLY DEVELOPED KNEE MRI 

SCORING SYSTEM) / L. Pascoli* - N. J. Napier - M. Wray - M. Mc Carron - C. Mc Allister - M. Rooney 

THU0319 DISEASE COURSE, OUTCOME AND PREDICTORS OF OUTCOME IN AN UNSELECTED COHORT OF INDIVIDUALS WITH 

JUVENILE CHRONIC ARTHRITIS FOLLOWED FOR 17 YEARS / L. Bertilsson* - B. Andersson-Gäre - A. Fasth - I. F. Petersson - 

H. Forsblad-d'Elia 

THU0320 DEVELOPMENT AND TESTING OF THE READINESS FOR ADULT CARE IN RHEUMATOLOGY (RACER) QUESTIONNAIRE 

FOR ADOLESCENTS WITH RHEUMATIC CONDITIONS / J. Stinson - L. Spiegel* - K. Watanabe Duffy - L. Tucker - E. Stringer 

- B. Hazel - J. Hochman - N. GIll - K. Spadafora - M. Kaufman 

THU0321 110 PATIENTS WITH ENTHESITIS RELATED ARTHRITIS: A DEMOGRAPHIC AND CLINICAL STUDY FROM A TERTIARY 

LEVEL PEDIATRIC RHEUMATOLOGY CENTRE IN INDIA / M. Agarwal* - M. Jariwala - S. Sawhney - R. Prakash 



65


66 



THU0322 DOES INTENSE SYNOVIAL ENHANCEMENT IN TEMPOROMANDIBULAR JOINTS OF JUVENILE IDIOPATHIC ARTHRITIS 

PATIENTS CORRELATE WITH DISEASE ACTIVITY? / L. Zwir - M. T. Terreri* - S. Sousa - A. Fernandes - A. S. Guimarães - 

M. O. Hilário 

THU0323 ACHIEVEMENT OF CLINICAL REMISSION IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS AFTER A LONG-TERM 

(2 - 5 YEARS) ETANERCEPT EXPOSURE: A NATIONAL REFERRAL CENTER’S EXPERIENCE. (PRELIMINARY REPORT) / 

M. Trachana* - P. Pratsidou-Gertsi - G. Pardalos 

THU0324 RITUXIMAB FOR SEVERE DISEASE FLARES IN CHILDHOOD ANCA VASCULITIDES / M. Twilt* - R. Schneider - A. Bell-Peter 

- C.Yang - S. Dell - S. M. Benseler 

THU0325 OUTCOME OF PATIENTS WITH OLIGOARTICULAR ONSET OF JUVENILE IDIOPATHIC ARTHRITIS: DATA FROM THE 

GERMAN PAEDIATRIC RHEUMATOLOGIC DATABASE -A LONGITUDINAL STUDY / M. Niewerth* - J. Klotsche - A. Raab - 

A. Zink - G. Ganser - I. Foeldvari - K. Minden 

THU0326 DRUG SURVIVAL AND REASONS FOR DISCONTINUATION OF THE FIRST COURSE OF BIOLOGICAL THERAPY IN 301 

JUVENILE IDIOPATHIC ARTHRITIS PATIENTS / M. Romano* - I. Pontikaki - M. Gattinara - I. Ardoino - C. Donati - P. Boracchi 

- P. L. Meroni - V. Gerloni 

THU0327 RADIOLOGICAL PERIPHERAL INVOLVEMENT AT HANDS, FEET AND HIPS IN YOUNG ADULTS WITH POLYARTICULAR 

IDIOPATHIC JUVENILE ARTHRITIS / M. Elhai* - R. Bazeli - V. Freire - A. Feydy - A. Kahan - C. Job-Deslandre - J. Wipff 

THU0328 CHANGES IN HEALTH-RELATED QUALITY OF LIFE IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS PATIENTS AFTER 

SINGLE DOSE OF CANAKINUMAB / N. Wulffraat* - T. Kallinich - L. McCann - R. Brik - L. Rutkowska-Sak - M. Ferrandiz - 

K. Lheritier - D. Kim - A. Gnanasakthy - H. Ozdogan 

THU0329 OPG/RANK/RANKL IN PATHOGENESIS OF OSTEOPOROSIS OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) SUBTYPES / 

N. Abdel-Wahab* - T. M. Khedr - E. A. Alkady - E. Mosad on behalf of Sonya Rashad 

THU0330 DAMAGE IN JUVENILE-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS / P. Costa Reis* - J. Isgro - S. Nativ - C.Yildirim-Toruner 

- A. Starr - L. Imundo - A. Eichenfield 

THU0331 MANAGEMENT OF OSTEOPOROSIS IN CHILDREN: EXPERIENCE FROM A PEDIATRIC RHEUMATOLOGY CENTER / 

R. Campanilho-Marques* - F. Ramos - J. Romeu - J. A. Pereira da Silva on behalf of Rheumatology Department, Hospital de Santa 

Maria - Lisbon; Rheumatology Research Unit, Instituto de Medicina Molecular 

THU0332 PREDICTORS OF POOR GROWTH IN CHILDREN WITH EARLY JUVENILE IDIOPATHIC ARTHRITIS: RESULTS FROM THE 

CHILDHOOD ARTHRITIS PROSPECTIVE STUDY (CAPS) / R. Carrasco* - L. R. Wedderburn - H. E. Foster - E. Baildam - 

J. Gardner-Medwin - A. Chieng - J. Davidson - W. Thomson - K. Hyrich 

THU0333 EFFECTIVENESS AND LONG-TERM FOLLOW UP OF RECOMBINANT IL-1RA AS FIRST LINE THERAPY IN NEWLY ONSET 

JUVENILE IDIOPATHIC ARTHRITIS / S. Vastert* - W. De Jager - B. J. Noordman - D. Holzinger - W. Kuis - B. Prakken - 

N. Wulffraat 

THU0334 DIFFERENCES IN THE FEATURES OF FAMILIAL MEDITERRANEAN FEVER AMONG PATIENTS FROM EUROPE AS 

COMPARED TO THOSE FROM THE EASTERN MEDITERRANEAN COUNTRIES / S. Ozen* - E. Demirkaya - G. Amaryan - 

I. Koné-Paut - P. Woo - Y. Uziel - M. Finetti - P. Quartier - C. Modesto - E. Papadopoulou-Alataki - S. Nielsen - M. Hofer - A. Polat 

- T. Turker - A. Insalaco - L. Cantarini - S. M. Al-Mayouf - J. Frenkel - H. Ozdogan - N. Ruperto - M. Gattorno 

THU0335 SUPPORT VECTOR MACHINES CLASSIFICATION OF TEXTURE PARAMETERS OF WHITE MATTER LESIONS IN CHILD- 

HOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS. POSSIBLE MECHANISM TO DISTINGUISH BETWEEN DEMYELI- 

NATION AND ISCHEMIA / A.T. Lapa - M. P. Bento - L. Rittner - H. H. Ruocco - G. Castellano - B. P. Damasceno - L.T. L. Costallat 

- R. Lotufo - F. Cendes - S. Appenzeller* 

THU0336 PREVALENCE AND CLINICAL SIGNIFICANCE OF WHITE MATTER HYPERINTENSITIES IN JUVENILE SYSTEMIC LUPUS 

ERYTHEMATOSUS (JSLE) / A. T. Lapa - L. Ferretti - N. A. Sinicato - M. Postal - R. Marini - F. Cendes - S. Appenzeller* 

THU0337 SUBCLINICAL FUNCTIONAL LUNG ABNORMALITIES IN JUVENILE ONSET SYSTEMIC LUPUS ERYTHEMATOSUS (JSLE) 

/ S. M. Rashad* - K. M. Darwish - E. A. Abbda - H. M. Abozaid - M. S. Khalil 

THU0338 INCIDENCE OF SELECTED OPPORTUNISTIC INFECTIONS AMONG CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS 

/ T. Beukelman* - F. Xie - J. W. Baddley - L. Chen - E. Delzell - C. Grijalva - N. Patkar - K. G. Saag - K. Winthrop - J. R. Curtis 

THU0339 POWER DOPPLER ULTRASONOGRAPIC FINDINGS IN HEALTHY PEDIATRIC ENTHESISES / V. Ravagnani* - S. Pieropan - 

G. Barausse - G. Sidoti - A. Boner - A.Volpe - P. Caramaschi - D. Biasi - S. Adami 

THU0340 CYTOKINES’ STUDY IN PATIENTS WITH DIFFERENT SUBTYPES OF JUVENILE IDIOPATHIC ARTHRITIS / Y. Boyko* - 

V. Chernyshov 

Fibromyalgia and pain in rheumatic diseases 

THU0341 ASSESSMENT OF ART THERAPY PROGRAM FOR WOMEN WITH FIBROMYALGIA: RANDOMIZED, CONTROLLED, 

BLINDED STUDY / A. S. Baptista - A. Jones* - F. P. Cardoso - B. Schaffir - E. R. W. Coelho - A. Orlandi - J. Natour 

THU0342 NEUROPATHIC PAIN IN PATIENTS WITH SYSTEMIC SCLEROSIS / F. Teixeira* - D. Peixoto - J. Costa - C. Afonso - D. Araujo 

THU0343 METABOLIC SYNDROME AND ITS COMPONENTS IN FIBROMYALGIA PATIENTS / F. Ursini* - S. Naty - M. Calabria - 

M. Labonia - R. D. Grembiale on behalf of Rheumatology Research Unit 

THU0344 DAS-28, SDAI AND CDAI IN THE PATIENTS WITH RHEUMATOID ARTHRITIS AND CONCOMITANT FIBROMYALGIA / 

J. Toms* - P. Bradna - T. Soukup - Z. Hrncir 

THU0345 SIMILARITIES BETWEEN FIBROMYALGIA AND CHRONIC FATIGUE SYNDROME: A SINGLE DISEASE? / J. Rivera* - 

A. Collado - J. Alegre - J. Blanch - J. Vidal - A. Arias - J. Carbonel on behalf of FSGCDB Group (Fibromyalgia and SFC Spanish 

Genetic and Clinical Data Bank). Foundation FF. 

* Presenting author



THU0346 DEPRESSIVE SYMPTOMS AND HEART RATE VARIABILITY IN PATIENTS WITH FIBROMYALGIA / J. W. Lee* - S. G. Lee - 

Y. E. Park - S. H. Park - J. H. Lee - S. H. Baek - G. T. Kim 

THU0347 EFFICACY AND SAFETY OF WHOLE BODY CRYOTHERAPY IN FIBROMYALGIC PATIENTS / L. Bettoni* - F. G. Bonomi - 

V. Zani - A. Indelicato - G. Banfi 

THU0348 ADHERENCE AND EFFECTIVENESS OF A SIMPLE PROGRAM OF HOME-MADE STRETCHING IN FIBROMYALGIA / 

L. Cavagna* - R. Caporali - L. Lepri - S. Rossi - S. Balduzzi - E. Prisco - C. Montecucco 

THU0349 ASSESSMENT OF DRY EYE SYMPTOMS IN PRIMARY FIBROMYALGIA / M. Antivalle* - M. Battellino - A. Batticciotto - M. C. Ditto 

- A. Mutti - V.Varisco - F. Atzeni - P. Sarzi-Puttini 

THU0350 SMOKING IS ASSOCIATED WITH REDUCED IGF-1 LEVELS AND HIGHER PAIN EXPERIENCE IN PATIENTS WITH 

FIBROMYALGIA / M. Bokarewa* - J. Bjersing - H. Alhafed - M. Erlandsson - M. Dehlin - K. Mannerkorpi 

THU0351 NEGATIVE LIFE EVENTS BEFORE THE DISEASE ONSET AND DISEASE OUTCOME IN LONG TERM FOLLOW UP OF PAIN, 

SLEEP, FATIGUE AND GENERAL WELL-BEING / M. L. Kukkurainen* - M. Sallinen - M. Mikkelsson - U. M. Anderberg - 

H. Kautiainen on behalf of Marja Leena Kukkurainen 

THU0352 TROCHANTERIC BURSITIS: IS THERE ULTRASONOGRAPHIC EVIDENCE TO SUGGEST INFLAMMATION? / N. Schlesinger* 

- P. Dundeva-Baleva - A. Abdel-Megid - A. Borham 

THU0353 THE PREVALENCE OF VITAMIN D DEFICIENCY IN 55 NEW PATIENTS DIAGNOSED WITH FIBROMYALGIA AT FIRST VISIT 

TO RHEUMATOLOGY OUTPATIENT CLINICS IN CORK, IRELAND / O. E. Hussein* - W. J. Tee - M. J. Regan 

THU0354 ATTENTIONAL IMPAIRMENT IN CHRONIC CENTRAL AND PERIPHERAL PAIN: CONTROLLED STUDY / S. Akdogan - 

F. Ayhan - P. Borman* 

THU0355 MONOTHERAPY VERSUS COMBINATION THERAPY IN THE TREATMENT OF FIBROMYALGIA / S. Metyas* - M. Ibrahim - 

E. C. Ortiz - S. Maher - D. Arkfeld 

THU0356 BENEFITS OF A MULTIDISCIPLINARY TREATMENT IN WOMEN WITH FIBROMYALGIA AND OBESITY / S. Castro* - 

R. Fontova - M. J. Poveda - A. Castel - R. Qanneta - S. Montull - R. Periñan - I. Miralles - N. Aragonés - I. Salvat - R. Cascón 

- S. Monterde - A. Padrol - C. Añez - M. Rull on behalf of Multidimentional Pain Research Group. IISPV. Tarragona. Spain 

THU0357 PREDICTIVE VALUE OF EXERCISE STRESS TEST (24H TEST&RE-TEST) AND COGHEALTH© IN DIFFERENTIAL DIAGNOSIS 

OF CHRONIC FATIGUE SYNDROME VS. FIBROMYALGIA / S. Garcia-Blanco* - V. Poca-Dias - C. Santos - A. Cuscó-Segarra - 

V. Torrente-Segarra - F. J. Garcia-Fructuoso 

THU0358 THE GERMAN FIBROMYALGIA CONSUMER REPORTS – A CROSS-SECTIONAL SURVEY / W. Häuser* 

THU0359 A BIO-PSYCHO-SOCIAL APPROACH FOR ASSESSING ASSOCIATIONS WITH CHANGES IN PERCEIVED HEALTH IN 

RECENTLY DIAGNOSED FIBROMYALGIA PATIENTS / Y. Van Eijk-Hustings* - M. Kroese - A. Boonen - M. Bessems-Beks - 

R. Landewé 

Infection-related rheumatic diseases 

THU0360 INTERFERON-GAMMA RELEASE ASSAYS IN RHEUMATIC PATIENTS: BASELINE STUDY AND IN THE COURSE OF ANTI- 

TUMOR NECROSIS FACTOR-ALPHA AGENTS / M. Martínez-Morillo - S. Mínguez - L. Mateo - I. Latorre - J. Domínguez - 

D. Grados - B. Tejera - A. Riveros* - S. Holgado - A. Olivé - X. Tena 

THU0361 PARANEOPLASTIC ARTHRITIS: A MULTI-CENTERED EXPERIENCE / B. Kisacik* - A. M. Onat - T. Kasifoglu - Y. Pehlivan - 

O. N. Pamuk - E. Dalkilic - S. Dönmez - S.Y. Bilge - S.Yilmaz - H. Erdem - R. Mercan - M. A. Ozturk - C. Bes - M. Soy - S. Erten 

- V. Cobankara - S. Senel - F. A. Oner - H. Direskeneli - S.Yilmaz - S. Kul - G.Y. Cetin - M. Sayarlioglu 

THU0362 ISOLATED SACRAL TUBERCULOSIS: REPORT OF THREE CASES / F. Lazrak* - F.-Z. Elouazzani - F.-Z. Abourazzak - L. tahiri 

- M. benzagmout - M. El Faiz Chaoui - T. Harzy 

THU0363 LATENT TUBERCULOSIS INFECTION AND VIRAL HEPATITIS IN A COLOMBIAN COHORT OF PATIENTS WITH BIOLO- 

GICAL THERAPY / F. Gonzalez-Malaver* - C. M. Guzman-Vergara - J. M. Bello-Gualtero - J. Varela - A. M. Mesa-Betancourt 

- J. Londoño - R.Valle-Oñate 

THU0364 LONGTERM FOLLOW-UP FOR PATIENTS MIT RETROPERITNOEAL FIBROSIS AFTER MEDICAL AND SURGICAL TREAT- 

MENT / H. Cash* - C. Noack - T. F. Fuller - G. Riemekasten 

THU0365 SYPHILITIC UVEITIS: A MULTICENTER STUDY OF 50 CASES / I. Pérez-Martín* - R. Blanco - A. Fonollosa - M. Sorribas - 

D. Díaz-Valle - A. Adán - V. Llorens - L. Distefano - M. Cordero - A. Blanco - J. Cañal - M. A. González Gay 

THU0366 DOES BEING A HEPATITIS B VIRUS CARRIER DECREASE APPLYING TO HOSPITAL IN PATIENTS WITH RHEUMATOID 

ARTHRITIS AND ANKYLOSING SPONDYLITIS? / O. Karadag* - N.Yilmaz - A.Yazici - B. Kisacik - S.Yilmaz - T. Kasifoglu - 

U. Kalyoncu - H. Temiz - B. Baysal - A. M. Onat 

THU0367 JOINT ECHINOCOCCOSIS: A REPORT OF THREE NEW CASES / W. Hamdi* - M. M. Ghannouchi - M. Bouaziz - F. M. Ladeb 

- M. M. Kchir 

THU0368 RISK OF HERPES VIRUSES INFECTIONS (HSV,VZV) DURING ANTI-TNF THERAPY IN PATIENTS WITH INFLAMMATORY 

RHEUMATIC DISEASES. SYSTEMATIC REVIEW AND META-ANALYSIS / H. Che - J. Morel - B. Combe - C. Lukas* 

THU0369 SEPTIC ARTHRITIS: CHANGING TRENDS IN EPIDEMIOLOGY OVER TWO DECADES / R. Kalagate - A. Rivera - C. H. Pritchard 

- L. H. Brent* 

THU0370 RISK INFECTION ASSESSMENT IN RHEUMATOID ARTHRITIS PATIENTS FROM THE PORTUGUESE BIOREPORTAR AND 

REGISTAR DATABASES / I. Silva* - F. Araújo - M. Mateus - J. C. Branco 



67


68 



Other orphan diseases 

THU0371 INCREASED EXPRESSION OF INFLAMMATORY CYTOKINES AND CHEMOKINES IN AN AUTOINFLAMMATORY 

DISORDER, NAKAJO-NISHIMURA SYNDROME / K. Arima* - N. Kanazawa - F. Furukawa - H. Ida - K.Yoshiura 

THU0372 MRI QUANTIFICATION OF FAT INFILTRATION IN SKELETAL MUSCLE OF PATIENTS WITH CAMPTOCORMIA / S. Guis* - 

J. P. Mattei - Y. Le Fur - N. Cuge - E. Soulier - P. Cozzone - D. Bendahan 

THU0373 CLINICAL PRESENTATION OF ERDHEIM-CHESTER DISEASE: DATA FROM A COHORT OF 10 PATIENTS AND REVIEW OF 

THE LITERATURE / G. Cavalli* - B. Guglielmi - C. Campochiaro - A. Berti - M. G. Sabbadini - L. Dagna 

THU0374 ARTICULAR SYMPTOMS IN CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME : A RETROSPECTIVE FRENCH STUDY / 

L. Houx* - X. Guennoc - E. Hachulla - I. Koné-Paut - P. Quartier - G. Grateau - P. Pillet - M. Hamidou - I. Lemelle - A. Pagnier - 

B. Neven - C. Richez - V. Devauchelle-Pensec 

THU0375 MALONDIALDEHYDE SERUM LEVELS AND MYCOARDIAL GLOBAL STRAIN IN IDIOPATHIC INFLAMMATORY 

MYOPATHY / K. Ramirez-Santillan* - M.Vazquez-Zaragoza - A. Camargo-Coronel - E. Gomez - B. Mendoza-Perez - L. Moreno- 

Ruiz - A. Chavez-Negrete - L. Barile-Fabris 

THU0376 SERUM LEPTIN, RESISTIN, VISFATIN AND ADIPONECTIN LEVELS IN TUMOR NECROSIS FACTOR RECEPTOR-ASSOCI- 

ATED PERIODIC SYNDROME (TRAPS) / L. Cantarini* - L. Obici - G. Simonini - R. Cimaz - M. R. Bacarelli - G. Merlini - A.Vitale 

- O. M. Lucherini - M. G. Brizi - M. Galeazzi - A. Fioravanti 

THU0377 EFFICACY, SAFETY AND PHARMACOKINETICS OF THE ANTI-INTERLEUKIN-1 BETA ANTIBODY CANAKINUMAB IN 

PATIENTS WITH SCHNITZLER SYNDROME / H. D. De Koning* - J. Schalkwijk - J. van der Ven-Jongekrijg - M. Stoffels - 

J. W. van der Meer - A. Simon 

THU0378 INTERLEUKIN-6 BLOCKING THERAPY BY TOCILIZUMAB IN PATIENTS WITH MULTICENTRIC CASTLEMAN’S DISEASE 

RESULTS IN A SIGNIFICANT DECREASE IN SERUM LEVELS OF IGG4 AND IGE / M. Murakami* - T. Matsutani - C. Aoki - 

H.-M. Lee - Y. Li - N. Nishimoto 

THU0379 A 20 YEAR SINGLE CENTRE EXPERIENCE OF AA AMYLOIDOSIS DEMONSTRATING CHANGES IN ITS EPIDEMIOLOGY / 

H. J. Lachmann* - J. D. Gillmore - A. D. Wechalekar - S. D. Gibbs - J. H. Pinney - D. M. Rowczenio - H. Trojer - T. Lane - C. P. 

Venner - S. M. Banypersad - J. A. Gilbertson - F. T. Hunt - D. Gopaul - D. F. Hutt - N. Wassef - M. B. Pepys - P. N. Hawkins 

THU0380 ENTHESOPATHY IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER AND ITS ASSOCIATION WITH MEFV GENE 

M694V VARIANT / A. Tufan - R. Mercan - M. E. Tezcan - A. Kaya - B. Bitik - M. A. Ozturk* - S. Haznedaroglu - B. Goker 

THU0381 CLINICAL DETERMINANTS OF ATTACK PRODROME IN PATIENTS WIHT FAMILIAL MEDITERRANEAN FEVER / A. Tufan- 

R. Mercan - M. E. Tezcan - A. Kaya - B. Bitik - M. A. Ozturk* - S. Haznedaroglu - B. Goker 

THU0382 FAMILIAL MEDITERRANEAN FEVER (FMF) - DISEASE ACTIVITY AND QUALITY OF LIFE IN ADULT PATIENTS OF TURKISH 

ANCESTRY LIVING IN TURKEY OR GERMANY / A. Giese* - A. Örnek - M. Kurucay - L. Kiliç - S. S?endur - S. Kiraz - E. Lainka 

- B. F. Henning 

THU0383 KIKUCHI’S DISEASE AND SYSTEMIC LUPUS ERYTHEMATOUS: A SYSTEMATIC LITERATURE REVIEW / B. Sopeña * - 

A. Chamorro - L. Gonzalez - A. Rivera - B. Maure - M. Freire - C. Martínez-Vázquez 

THU0384 SPONTANEOUS PANNICULITIS (WEBER-CHRISTIAN DISEASE): CLINICAL COURSE VARIANTS / B. S. Belov* - O. N. Egorova 

- O.V. Pushkova - Y. A. Karpova - S. G. Radenska-Lopovok 

THU0385 COGAN SYNDROME: A PORTUGUESE SINGLE CENTER COHORT REPORT / C. Ponte A. Castro* - C. Macieira - C. Miranda 

Rosa - J. A. Pereira da Silva 

THU0386 EFFICACY OF LONG-TERM TREATMENT WITH BIOLOGIC AGENTS IN REFRACTORY ADULT ONSET STILL’S DISEASE: A 

SINGLE CENTRE EXPERIENCE ON 16 PATIENTS / E. Della Torre* - S. Franchini - E. Baldissera - G. Cavalli - E. P. Bozzolo - 

M. G. Sabbadini 

THU0387 RELATIONSHIP BETWEEN PATTERNS OF CLINICAL PRESENTATION UVEITIS AND FINAL IMMUNOLOGIC DIAGNOSIS 

/ E. Toledano* - Z. Rosales - Ó. Fontseré - C.Vadillo - R. Méndez - M. Á. Descalzo - E. Loza - E. Pato 

THU0388 TOCILIZUMAB STRONGLY SUPPRESSES THE SERUM AMYLOID A LEVEL IN REFRACTORY ADULT – ONSET STILL’S 

DISEASE ASSOCIATED AMYLOIDOSIS / H. M. Al Attia* - M. A. Ibrahim 

THU0389 ERYTHEMA OVER THE JOINT MAY HELP TO DISTINGUISH FAMILIAL MEDITERRANEAN FEVER FROM OTHER RHEUMA- 

TOLOGIC CONDITIONS / S. Ugurlu - F. Mehmedali - F. Nalci - A. Gurbuz - B. Canbay - Y. Sengul - G. Hatemi - H. Ozdogan* 

THU0390 PROLONGED DISEASE-FREE INTERVAL IN FAMILIAL MEDITERRANEAN FEVER: A DISTINCT SUBSET WITH UNIQUE 

CLINICAL, DEMOGRAPHIC AND MOLECULAR CHARACTERISTICS / I. Ben-Zvi* - T. Krichely-Vachdi - O. Feld - M. Lidar - 

S. Kivity - A. Livneh 

THU0391 ANTI-TNF THERAPY IN SEVERE AND REFRACTORY SARCOIDOSIS: MULTICENTER STUDY OF 25 PATIENTS / I. Pérez- 

Martín* - R. Blanco - N. Ortego - V. Llorens-Bellés - A. Adán - A. Olivé - W. A. Sifuentes Giraldo - S. González - C. Bejerano - 

M. C. González-Vela - M. A. González-López - H. Fernández-Llaca - A. Oterino - M. J. Sedano - M. Agudo - A. Corrales - 

V. M. Martínez-Taboada - M. A. Gónzalez-Gay 

THU0392 BETA-CONFIDENT-REGISTRY: EFFICACY AND SAFETY OF CANAKINUMAB IN CRYOPYRIN ASSOCIATED PERIODIC 

SYNDROME - 18 MONTH FOLLOW-UP / J. Kuemmerle-Deschner* - P. Hawkins - H. Hoffman - T. Van der Poll - U. Walker - 

H. Tilson 

THU0393 THE CLINICAL OBSERVATIONAL STUDY OF ADULT ONSET STILL’S DISEASE IN A LARGE COHORT OF KOREAN 

PATIENTS / J. J. Kim* - K. H. Jung - Y. B. Joo - C. B. Choi - Y. K. Sung - J. B. Jun - T. H. Kim - S. C. Bae - D. H.Yoo 

THU0394 MACROPHAGE ACTIVATION SYNDROME IN ADULT ONSET STILL’S DISEASE: A SINGLE CENTER EXPERIENCE / 

L. O. Damian* - I. Felea - S.-P. Simon - M. Lupse - C. Bodolea - L. Ghib - R. Mocanu - S. Rednic 

* Presenting author



THU0395 TUMOUR NECROSIS FACTOR-ALPHA AS A MASTER REGULATOR OF INFLAMMATION IN ERDHEIM-CHESTER 

DISEASE: RATIONALE FOR THE SUCCESSFUL TREATMENT OF TWO PATIENTS WITH INFLIXIMAB / L. Dagna* - A. Corti - 

S. Langheim - B. Guglielmi - G. Cavalli - F. De Cobelli - C. Doglioni - G. Fragasso - M. G. Sabbadini - M. Ferrarini 

THU0396 EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH TNF RECEPTOR ASSOCIATED PERIODIC SYNDROME 

(TRAPS) / M. Gattorno* - L. Obici - A. Meini - V. Tormey - K. Abrams - N. Davis - C. Andrews - H. Lachmann 

THU0397 EFFICACY OF PAMIDRONATE IN CHILDREN WITH OSTEOGENESIS IMPERFECTA : AN OPEN PROSPECTIVE STUDY / 

M. El Rakaawi* - N. Hammoumraoui - S. Mellal - F. Sadouki - S. Lehtihet - W. Kerri - H. Djoudi 

THU0398 EFFICACY OF RITUXIMAB AND OTHER IMMUNOSUPPRESSANTS FOR IGG4-RELATED DISEASE / M. Yamamoto* - 

H. Takahashi - Y. Naishiro - T. Tabeya - K. Ishigami - Y. Shimizu - H.Yajima - M. Matsui - C. Suzuki - H.Yamamoto - S. Honda - 

T. Abe - Y. Suzuki - T. Himi - K. Imai - Y. Shinomura 

THU0399 IS PERNIO A MICROVASCULAR DISEASE? / M. Ozmen* - V. Kurtoglu - G. Can - E. F. Tarhan - D. Soysal - S. L. Aslan 

THU0400 INHIBITION OF IL-6 SIGNALLING: A NOVEL THERAPEUTIC APPROACH FOR FAMILIAL MEDITERRANEAN FEVER / 

N. Stein* - M. Witt - M. Baeuerle - H. Schulze-Koops - M. Gruenke 

THU0401 SUCCESSFUL USE OF CANAKINUMAB IN ADULT-ONSET STILL’S DISEASE REFRACTORY TO SHORT ACTING IL-1 

INHIBITORS / P. Efthimiou* - O. Petryna - B. Mehta - A. Kontzias - J. Cush 

THU0402 EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH NOMID/CINCA / R. Goldbach-Mansky* - C. Sibley - S. D. Felix 

- C. Brewer - K. King - C. Zalewski - H. J. Kim - R. Bishop - A. Chakraborty - L. Colin - A. Chioato 

THU0403 SINONASAL SARCOIDOSIS: REVIEW OF CLINICAL AND IMAGING FEATURES: 7 YEAR EXPERIENCE / R. Joshi* - J. Zenga 

- A. Getz - N. Debnath 

THU0404 VITAMIN D LEVEL IN PATIENTS WITH EARLY ARTHRITIS. A PRELIMINARY REPORT / R. Sokolik* - M. Madej - B. Nowak - 

L. Korman - P. Wiland 

THU0405 CHARACTERIZATION OF THE GROUP OF PATIENTS WITH IGG4-RELATED SYSTEMIC DISEASE IN RUSSIAN POPULA- 

TION / S. Sedyshev* - V.Vasilyev - A. Kovrigina 

THU0406 EVALUATION OF PERIODONTAL PARAMETERS IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER / S. Senel* - 

V. Bostanci - H. Toker - S. Safak 

THU0407 SERUM GHRELIN AND OBESTATIN LEVELS IN BEHÇET’S DISEASE / S. S. Koca* - M. Ozgen - R. Dayanan - M. Kara - N. Ilhan 

- A. Isik 

THU0408 DEEP INSPIRATORY BREATH HOLD PET/CT IS USEFUL FOR MONITORING OF ACTIVITY IN RHEUMATIC DISEASE 

ASSOCIATED LUNG INTERSTITIAL PNEUMONITIS / T. Uehara* - M.Takeno - K.Terauchi - D. Kishimoto - K.Takase - M. Hama 

- A. Ihata - A. Ueda - Y. Ishigatsubo 

THU0409 MIXED CONNECTIVE TISSUE DISEASE AND UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE: DO DOCTORS 

CLASSIFY CORRECTLY? / Y. B. Joo* - J. H. Kim - C.-B. Choi - T.-H. Kim - J.-B. Jun - S.-C. Bae - D.-H.Yoo - Y.-K. Sung 

THU0410 CHARACTERISATION OF INTERSTITIAL LUNG DISEASE ASSOCIATED WITH ADULT STILL'S DISEASE / Y. Takakuwa* - 

H.Yamada - H. Ito - S. Ooka - Y.Yamasaki - H. Nakano - M. Hiida - Y. Kurihara - S. Ozaki 

Diagnostics and imaging procedures 

THU0411 UTILITY OF ULTRASOUND SCORES IN ASSESSMENT ENTHESITIS ON ANTI-TNF THERAPY OF SPONDYLOARTHRITIS 

PATIENTS / A. M. Istrate* - E. de Miguel on behalf of Ioana Felea, Miguel Ángel Caracuel Ruíz, Eduardo Collantes-Estevéz 

THU0412 REACTIVE HYPEREMIA INDEX (RHI) IS ASSOCIATED WITH MACROVASCULAR DISEASE AND LUNG DISEASE IN 

SYSTEMIC SCLEROSIS / A. Meyer* - A. Theulin - A. Theulin - E. Chatelus - E. Chatelus - C. Sordet - R.-M. Javier - B. Geny - 

J.-E. Gottenberg - J. Sibilia 

THU0413 MAGNETIC RESONANCE IMAGING OF HANDS AND FEET JOINTS OF ACPA POSITIVE PERSONS WITHOUT CLINICAL 

ARTHRITIS / A. Krabben* - W. Stomp - L. K. P. M. Brakenhoff - D. M. F. M. van der Heijde - J. L. Bloem - T. W. J. Huizinga - 

M. Reijnierse - A. H. M. van der Helm-van Mil 

THU0414 DETERMINATION AND QUANTIFICATION OF SYNOVIAL INFLAMMATION BY MAGNETIC RESONANCE IMAGING IN 

SYSTEMIC SCLEROSIS / B. N. Stamenkovic* - A. M. Stankovic - A. N. Dimic - J. M. Nedovic - N. Damjanov - S. K. Stojanovic - 

D. Menkovic 

THU0415 INCREASED RIGIDITY OF SALIVARY GLANDS AS INDICATED BY SONOELASTOGRAPHY IS ASSOCIATED WITH 

REDUCED SALIVA PRODUCTION IN PRIMARY SJÖGREN’S SYNDROME / C. Dejaco* - T. DeZordo - D. Heber - R. Lipp - A. Lutfi 

- M. Magyar - D. Zauner - W. B. Graninger - J. Hermann 

THU0416 THE USEFULNESS OF A MUSCULOSKELETAL ULTRASOUND (MUS) SCORING SYSTEM FOR 22 HAND JOINTS EXAMI- 

NATION FOR THE DETECTION OF EARLY UNDIFFERENTIATED INFLAMMATORY ARTHRITIS AND TREATMENT 

DECISIONS MAKING IN ESTABLISHED INFLAMMATORY ARTHRITIS / C. Ciurtin* - M. Ehrenstein - M. Leandro - D. Dey - 

A. Nandagudi - V. Morris - I. Giles - J. Ioannou - D. Sen - M. Shipley - D. Isenberg 

THU0417 EXPOSURE, LATENT TUBERCULOSIS, OR DISSEMINATED INFECTION? THE ROLE OF TST, QUANTIFERON, AND MULTI- 

SITE CULTURES IN HIGH RISK PATIENTS ON TNF-INHIBITORS / D. Cooray - R. Moran - P. P. C. Chen - J. A. Louie - G. 

A. Karpouzas* 

THU0418 AUTOMATED INTERPRETATION OF ANCA PATTERNS – A NEW APPROACH IN THE SEROLOGY OF ANCA ASSOCIATED 

VASCULITIS / D. Roggenbuck* - I. Knütter - R. Hiemann - T. Brumma - T. Büttner - K. Großmann - K. Conrad - D. Reinhold - 

E. Csernok 



69


70 




THU0419 A NOVEL TECHNIQUE TO QUANTIFY BONE EROSIONS IN PATIENTS WITH RHEUMATOID DISEASES USING HIGH- 

RESOLUTION PQCT IMAGES / D. Toepfer* - S. Finzel - O. Museyko - G. Schett - K. Engelke 

THU0420 A CITRULLINATED AND MMP DEGRADATED VIMENTIN NEOEPITOPE AS A NOVEL RHEUMATIC BIOMARKER / E.Vassiliadis* 

- W. P. Maksymowych - C. Zhang - K. L. Duffin - C. Christiansen - D. J. Leeming - M. A. Karsdal - A. C. Bay-Jensen 

THU0421 INFLUENCE OF CLINICAL, LABORATORY AND IMAGE FINDINGS ON THE CRITERIA-BASED DIAGNOSIS AND CLASSI- 

FICATION OF PATIENTS IN NEW-ONSET SPONDYLOARTHRITIS UNITS: RESULTS FROM THE ESPERANZA COHORT / 

E. G. Tomero * - L. Carmona - J. Mulero - E. De Miguel - M. Gobbo - C. Martínez on behalf of ESPERANZA GROUP 

THU0422 ICG-ENHANCED FLUORESCENCE OPTICAL IMAGING REVEALS SUBCLINICAL DISEASE ACTIVITY IN RHEUMATOID 

AND PSORIATIC ARTHRITIS PATIENTS WHO HAVE ACHIEVED CLINICAL REMISSION / F. Spiecker* - S. G. Werner - 

C. Hermsen - M. Bahner - M. Backhaus - H.-E. Langer 

THU0423 CCL18 – A POTENTIAL BIOMARKER OF FIBRO-INFLAMMATORY ACTIVITY IN CHRONIC PERIAORTITIS / F. Kollert* - M. Binder 

- C. Probst - M. Uhl - A. Zirlik - G. Kayser - R. E.Voll - H.-H. Peter - G. Zissel - A. Prasse - K. Warnatz 

THU0424 NEAR-INFRARED SPECTROSCOPY DURING EXERCISE AND RECOVERY IN CHILDREN WITH JUVENILE DERMATO- 

MYOSITIS / G. E. A. Habers* - R. de Knikker - M. van Brussel - E. Hulzebos - D. F. Stegeman - A. van Royen - T. Takken 

THU0425 ASSOCIATIONS BETWEEN RADIOGRAPHIC AND CLINICAL OSTEOARTHRITIS FEATURES AND MRI-DEFINED BONE 

MARROW LESIONS IN THE FINGER JOINTS / I. K. Haugen* - P. Bøyesen - B. Slatkowsky-Christensen - S. Sesseng - D. van der 

Heijde - T. K. Kvien 

THU0426 IS CONTRAST MATERIAL NEEDED FOR THE MRI SCORING OF SYNOVITIS OF THE HAND IN PATIENTS WITH RHEUMA- 

TOID ARTHRITIS? – A SYSTEMATIC COMPARISON OF 0.23, 0.6, 1.5 AND 3.0 TESLA MRI / I. Eshed* - S. Krabbe - 

M. Østergaard - P. Bøyesen - J. Møller - F. Therkildsen - O. R. Madsen - S. Juhl Pedersen 

THU0427 NAIL FOLD CAPILLAROSCOPY IN LUPUS ERYTHEMATOSUS – EFFECT OF CLINICAL MANIFESTATIONS AND GENDER 

/ J. Richter* - P. Klein-Weigel - H. Acar - R. Fischer-Betz - M. Schneider - O. Sander 

THU0428 VALIDITY AND RELIABILITY OF 3D US FOR DETECTION OF EROSIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS 

USING MRI AS GOLD STANDARD / K. Ellegaard* - H. Bliddal - U. Døhn Møller - M. Henriksen - M. Boesen - R. Bouert - 

B. Danneskiold-Samsøe - S. Torp-Pedersen 

THU0429 WHICH DIAGNOSIS IN CASE OF POSITIVITY OF ANTI-CCP IN RHEUMATOLOGICAL DAILY PRACTICE? (EVALUATION 

OF THE PERFORMANCES OF ANTI-CCP IN 517 CONSECUTIVE PATIENTS) / L. Bialé* - C. Goulvestre - N. Kavian - M. Dougados 

THU0430 IMAGE PATTERN IN FLUORESCENCE OPTICAL IMAGING OF THE HANDS: DOES XIRALITE SUPPORT DIFFERENTIAL 

DIAGNOSIS? – A FEASIBILITY STUDY / M. Bahner* - C. Schwenke - M. Schirner 

THU0431 LOCALISATION OF BONE MARROW EDEMA IN SACROILIAC JOINTS IN SPONDYLOARTHRITIS PATIENTS: DOES THE 

SITE OF LESIONS CHANGE OVER A 3-MONTH PERIOD? / M. de Hooge* - R. van den Berg - M. Reijnierse - V. Navarro- 

Compán - F. van Gaalen - T. Huizinga - D. van der Heijde 

THU0432 BONE EROSIONS IN RHEUMATOID ARTHRITIS: ULTRASOUND FINDINGS IN THE EARLY STAGE OF THE DISEASE / 

M.-M. Tamas* - E. Filippucci - A. Becciolini - M. Gutierrez - L. Di Geso - K. Bonfiglioli - P.V.Voulgari - F. Salaffi - W. Grassi 

THU0433 PREVALENCE OF SUB-CLINICAL CAROTID ATHEROSCLEROSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND 

PSORIATIC ARTHRITIS: A NEW AUTOMATED RADIOFREQUENCY-BASED ULTRASOUND MEASUREMENT OF COMMON 

INTIMA-MEDIA THICKNESS / M. Gutierrez* - E. Naredo - L. Di Geso - I. Moller - A. Iagnocco - F. Salaffi - E. Filippucci - W. 

Grassi 

THU0434 THREE-DIMENSIONAL POWER DOPPLER SONOGRAPHIC EVALUATION OF FINGER JOINTS IN PATIENTS WITH 

RHEUMATOID ARTHRITIS / M. SATO* - M. TAKEMURA - K. SHIMIZU - T. WATANABE - D. FUKUOKA - R. SHINOHE - 

Y. SHINOHE 

THU0435 DETECTION OF SYNOVITIS, BONE EROSIONS, AND BONE MARROW OEDEMA IN PATIENTS WITH INFLAMMATORY 

HAND PAIN - A COMPARISON OF LOW FIELD MRI AND HIGH FIELD MRI / M. S. Saltzherr* - J. J. Luime - B. J. Ejbjerg - 

M. Østergaard - P. G. Conaghan - R. Ouwendijk - J. M. Hazes - G. S. Muradin 

THU0436 USEFULNESS OF SALIVARY GLANDS ULTRASONOGRAPHY IN THE NON INVASIVE EARLY DETECTION OF SUBCLIN- 

ICAL GLANDULAR INVOLVEMENT IN PSS / N. Luciano* - C. Baldini - R. Pascale - A. Paolicchi - F. Ferro - D. Caramella - 

S. Bombardieri 

THU0437 EVALUATION OF SEPARATE QUANTITATIVE RADIOGRAPHIC FEATURES ADDS TO THE PREDICTION OF INCIDENT 

RADIOGRAPHIC OSTEOARTHRITIS IN INDIVIDUALS WITH RECENT ONSET OF KNEE PAIN: FIVE-YEAR FOLLOW-UP IN 

THE CHECK COHORT / P. M. Welsing* - M. B. Kinds - A. C. Marijnissen - K. L.Vincken - M. A.Viergever - K. W. Drossaers-Bakker 

- J. W. Bijlsma - S. M. Bierma-Zeinstra - F. P. Lafeber 

THU0438 PREDICTIVE VALUE OF ULTRASOUND ON THE RESPONSE TO STEROID INFILTRATIONS IN THE PAINFUL SHOULDER: 

A PROSPECTIVE CONTROLLED SINGLE-BLIND STUDY OF 70 PATIENTS / P. Zufferey* - E. Naredo - Y. Henchoz - A. So 

THU0439 AN EVALUATION OF A NOVEL TECHNIQUE FOR FULLY AUTOMATIC SYNOVITIS QUANTIFICATION FROM PRE- AND 

POST-CONTRAST WRIST MRI / P. Mysling* - E. Dam - S. Zaim - H. K. Genant - T. Fuerst - M. Lillholm 

THU0440 EFFECTIVENEEFFECTIVENESS OF ULTRASOUND GUIDED CORTICOSTEROIDS INJECTIONS IN INTERDIGITAL 

MORTON'S NEUROMA A SURVEY OF 23 PATIENTS / R. Ghozlan* - F. zeitoun 

THU0441 ENTHESIS INFLAMMATION IN INFLAMMATORY BOWEL DISEASES WITHOUT SPONDYLOARTHRITIS / R. Martínez 

Pérez* - E. Rejón - S. Rodríguez Montero - J. L. Marenco de la Fuente 

THU0442 MR-DEFINED FAT INFILTRATION OF THE LUMBAR PARAVERTEBRAL MUSCLES DIFFERS BETWEEN NON- 

RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AND ESTABLISHED ANKYLOSING SPONDYLITIS / O. Akgul - 

S. Ozgocmen*



THU0443 DIFFERENTIAL DIAGNOSIS BETWEEN RHEUMATOID ARTHRITIS AND PERIPHERAL SPONDYLARTHROPATHIES: 

USEFULNESS OF SHOULDERS ULTRASONOGRAPHY / S. Ottaviani* - K. Dawidowicz - E. Palazzo - G. Gill - G. Hayem - 

O. Meyer - P. Dieudé 

THU0444 REVIEW OF ULTRASOUND FINDINGS IN PATIENTS WITH SHOULDER PAIN. SONOGRAFIC STUDY IN 735 PATIENTS / 

S. Muraja* - B. Markulinčič 

THU0445 HIGH ULTRASONOGRAPHIC SCORES PERSIST AMONG PATIENTS WITH RHEUMATOID ARTHRITIS IN CLINICAL 

REMISSION WITH NORMAL SERUM MMP-3 VALUES / T. Okano* - T. Koike - M. Tada - Y. Sugioka - K. Mamoto - S. Wakitani 

- H. Nakamura 

THU0446 TRABECULAR BONE TEXTURE PARAMETERS ARE CORRELATED WITH MAGNETIC RESONANCE IMAGING (MRI) BONE 

EDEMA AT HAND AND WRIST IN ACTIVE RHEUMATOID ARTHRITIS (RA) / T. Pham* - S. Trijau - R. Chapurlat - D. Loeuille 

- T. Schaeverbeke - C. Roux - C. L. Benhamou - O.Vittecoq - J. Sibilia - F. Mistretta - C. Hacquard Bouder 

THU0447 CALCULATION OF THE SMALLEST DETECTABLE CHANGE (SDC) OF RADIOGRAPHIC PROGRESSION IN CLINICAL 

TRIALS WITH MULTIPLE TIME POINTS: THE MEAN SDC IS A VALID APPROXIMATION OF THE OVERALL SDC / V. Navarro- 

Compán* - D. van der Heijde - H. Ahmad - C. Miller - R. Landewé 

Education 

THU0448 SAFETY COMPETENCES KNOWLEDGE AND BEHAVIOURAL SKILLS OF PATIENTS TREATED BY BIOLOGICS IN RHEUMA- 

TOLOGY / A.-C. Rat* - B. Fautrel - E. Flipon - L. Gossec - B.-D. Caritey - L. Margerie - H. Nataf - M. Piperno - B. Pallot Prades - 

R. M. Poilvert - V. Royant, - F. Sadji - C. Sordet - C. Thevenot - C. Beauvais 

THU0449 INTERNET USE BY PATIENTS AND RHEUMATOLOGISTS: RESULTS OF TWO PARALLEL INVESTIGATIONS IN FRANCE / 

D. Poivret* - I. Griffoul - D. Oziel - N. Legoupil - S. Perrot - G. Chales - J.-S. Giraudet-Le Quintrec 

THU0450 THERAPEUTIC PATIENT EDUCATION PROGRAM FOR OSTEOPOROSIS DISEASE: DEVELOPMENT, EVALUATION IN 

ASSOCIATION WITH A PATIENT GROUP / D. Poivret* - M.-E. Saint-Eve - V. Noirez - L. Carton - C. Cardon - F. Zito 

THU0451 IMPLEMENTATION OF THE OSTEOARTHRITIS CLINICAL GUIDELINE: RESULTS OF A CLUSTER RANDOMIZED TRIAL IN 

PRIMARY CARE / D. Maximov - O. Lesnyak* 

THU0452 DEVELOPING A LONGITUDINAL CURRICULUM TO IMPROVE RHEUMATOLOGICAL SKILLS IN UNDERGRADUATE 

MEDICAL STUDENTS / E. L. Bezerra* - F. A. Bezerra Neto - M. J.Vilar - G. D. Azevedo 

THU0453 A PICTORIAL INFORMATION LEAFLET IS USEFUL FOR GIANT CELL ARTERITIS PATIENTS TAKING PREDNISOLONE / 

K. Mankia* - M. Munir - D. Collins - E. Price - L. Williamson 

THU0454 QUESTIONNAIRE SURVEY FOR GOUT-RELATED KNOWLEDGE LEVEL IN 185 CHINESE PHYSICIANS / Q. H. Li - Z. X. Li 

- H. J. Liu - M. Lu - Y. H. Li - X. Ou-Yang - T. Li - C. J. Zou - H. R. Schumacher - L. Dai* 

THU0455 SURVEY OF PRIMARY CARE PHYSICIANS’ ATTITUDES TO CO-MANAGEMENT MEDICAL COLLABORATION IN TREAT- 

MENT OF RHEUMATOID ARTHRITIS: COMPARISON BETWEEN PHYSICIANS WITH AND WITHOUT RHEUMATOLOGY 

BOARD CERTIFICATION / S. Mizuki* - T. Murakami - K. Oryoji - K. Kamada - E.Yokota 

THU0456 A COMPARATVIE STUDY OF RHEUMATOLOGY TRAINING ACROSS THREE EUROPEAN COUNTRIES / S. Panchal* - 

S. Ramiro - A. Moorthy - F. Sivera 

THU0457 EVALUATION OF RHEUMATOLOGY ADMISSIONS IN A TEACHING HOSPITAL: A TRAINEE’S PERSPECTIVE / R. Khan - 

V. Kr Rao* - K. Chaudhuri 

THU0458 ASSESSMENT OF DIETARY CALCIUM INTAKE AMONG RHEUMATOLOGY PATIENTS / X. Grapton* - D. Leclere - P. Lemesle 

- L. Poulain - P. Renard 



71

Scientific Programme

Create successful ePaper yourself

Delete template?

Save as template?